P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.355e-17 | -38.84 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 28 | 16828 | 48 |
STXBP5L,CNTN5,ANK2,NRG1,RALYL,SLC35F3,CNTNAP2,NRG3,EBF1,FSTL5,TLL1,GRIA4,ZNF385B,RIMS1,GPC6,GRID2,CADPS2,NRXN3,LSAMP,SYT1,UNC5C,EPHA5,CHN2,CACNA2D1,SLC1A3,PTPRG,ST18,PCDH9 |
1.355e-17 | -38.84 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 28 | 16828 | 48 |
FSTL5,EBF1,TLL1,GRIA4,NRG3,CNTNAP2,SLC35F3,NRG1,RALYL,CNTN5,STXBP5L,ANK2,PCDH9,ST18,PTPRG,EPHA5,SLC1A3,CACNA2D1,CHN2,CADPS2,GRID2,SYT1,LSAMP,UNC5C,NRXN3,GPC6,RIMS1,ZNF385B |
1.442e-17 | -38.78 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 19 | 16828 | 48 |
FSTL5,PCDH9,GRIA4,TLL1,EPHA5,MYT1L,NRG3,CACNA2D1,TRPM3,GRID2,CNTNAP2,SLC35F3,LSAMP,RALYL,NRXN3,ZNF385D,ANK2,RIMS1,GPC6 |
5.017e-17 | -37.53 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 31 | 16828 | 48 |
RIMS1,GPC6,ZNF385B,RELN,SYT1,LSAMP,UNC5C,NRXN3,KIF21A,CADPS2,GRID2,SLC1A3,CACNA2D1,CHN2,NPAS3,EPHA5,PCDH9,PTPRG,ZNF385D,ANK2,KCNJ3,STXBP5L,CNTNAP2,SLC35F3,NRG1,RALYL,NRG3,TLL1,GRIA4,FSTL5,EBF1 |
5.017e-17 | -37.53 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 31 | 16828 | 48 |
ANK2,ZNF385D,KCNJ3,STXBP5L,CNTNAP2,SLC35F3,NRG1,RALYL,NRG3,TLL1,GRIA4,EBF1,FSTL5,RIMS1,GPC6,ZNF385B,RELN,SYT1,LSAMP,UNC5C,NRXN3,KIF21A,CADPS2,GRID2,SLC1A3,CACNA2D1,CHN2,NPAS3,EPHA5,PCDH9,PTPRG |
2.026e-16 | -36.14 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 34 | 16828 | 48 |
SLC1A3,CACNA2D1,CHN2,EPHA5,PCDH9,PTPRG,RIMS1,GPC6,ZNF385B,RELN,CNTN4,UNC5C,SYT1,LSAMP,NRXN3,CADPS2,GRID2,NRG3,MYT1L,TRPM3,RIMS2,GRIA4,TLL1,FSTL5,EBF1,ANK2,ZNF385D,KCNJ3,LRRTM4,STXBP5L,SLC35F3,CNTNAP2,RALYL,NRG1 |
2.530e-16 | -35.91 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 28 | 16828 | 48 |
EPHA5,CACNA2D1,SLC1A3,PCDH9,RELN,GPC6,RIMS1,CDH18,KIF21A,GRID2,LSAMP,NRXN3,DTNA,RIMS2,MYT1L,NRG3,TRPM3,EBF1,FSTL5,GRIA4,TLL1,GRIK2,ANK2,ZNF385D,KCNJ3,SLC35F3,CNTNAP2,RALYL |
6.812e-16 | -34.92 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 33 | 16828 | 48 |
NRG1,RALYL,CNTNAP2,SLC35F3,KCNJ3,ZNF385D,ANK2,STXBP5L,LRRTM4,TLL1,GRIA4,FSTL5,EBF1,MYT1L,NRG3,RIMS2,NRXN3,LSAMP,SYT1,UNC5C,GRID2,CADPS2,ZNF385B,RIMS1,GPC6,CNTN4,RELN,PTPRG,PCDH9,CHN2,CACNA2D1,SLC1A3,EPHA5 |
4.453e-14 | -30.74 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 17 | 16828 | 48 |
NRG3,CHN2,EPHA5,PCDH9,PTPRG,GRIA4,ST18,FSTL5,GPC6,RIMS1,ZNF385B,KCNJ3,SYT1,LSAMP,CNTNAP2,NRXN3,GRID2 |
7.773e-14 | -30.19 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 18 | 16828 | 48 |
ZNF385B,ANK2,ZNF385D,GPC6,GRID2,NRXN3,RALYL,NRG1,CNTNAP2,SLC35F3,NRXN1,EPHA5,NPAS3,CHN2,NRG3,MYT1L,GRIA4,PCDH9 |
7.979e-14 | -30.16 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 18 | 16828 | 48 |
PCDH9,GRIA4,NRG3,MYT1L,CHN2,EPHA5,NPAS3,NRXN1,CNTNAP2,SLC35F3,RALYL,NRXN3,NRG1,GRID2,ZNF385D,ANK2,GPC6,ZNF385B |
8.157e-14 | -30.14 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 19 | 16828 | 48 |
PCDH9,PTPRG,FSTL5,EBF1,NRG3,EPHA5,LSAMP,SYT1,UNC5C,SLC35F3,CNTNAP2,RALYL,CADPS2,GRID2,GPC6,RIMS1,ZNF385B,RELN,STXBP5L |
9.168e-14 | -30.02 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 19 | 16828 | 48 |
GRID2,NRXN3,RALYL,NRG1,SLC35F3,CNTNAP2,ZNF385B,ANK2,ZNF385D,GPC6,FSTL5,GRIA4,PCDH9,NRXN1,EPHA5,NPAS3,CHN2,MYT1L,NRG3 |
1.662e-13 | -29.43 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 28 | 16828 | 48 |
RELN,ZNF385B,GPC6,RIMS1,GRID2,CADPS2,KIF21A,NRXN3,UNC5C,LSAMP,EPHA5,SLC1A3,CACNA2D1,PTPRG,ST18,PCDH9,STXBP5L,ZNF385D,ANK2,RALYL,SLC35F3,CNTNAP2,RIMS2,NRG3,FSTL5,EBF1,GRIA4,TLL1 |
1.662e-13 | -29.43 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 28 | 16828 | 48 |
ANK2,ZNF385D,STXBP5L,RALYL,SLC35F3,CNTNAP2,NRG3,RIMS2,TLL1,GRIA4,FSTL5,EBF1,ZNF385B,GPC6,RIMS1,RELN,NRXN3,LSAMP,UNC5C,GRID2,KIF21A,CADPS2,SLC1A3,CACNA2D1,EPHA5,ST18,PTPRG,PCDH9 |
2.068e-13 | -29.21 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 28 | 16828 | 48 |
STXBP5L,ANK2,ZNF385D,SLC35F3,CNTNAP2,RALYL,RIMS2,NRG3,FSTL5,EBF1,TLL1,GRIA4,RELN,RIMS1,GPC6,ZNF385B,KIF21A,CADPS2,GRID2,LSAMP,UNC5C,NRXN3,EPHA5,CACNA2D1,SLC1A3,PCDH9,ST18,PTPRG |
2.581e-13 | -28.99 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 22 | 16828 | 48 |
NRG1,CNTNAP2,KCNJ3,ZNF385D,FSTL5,EBF1,GRIA4,RIMS2,NRG3,GRID2,NRXN3,LSAMP,SYT1,UNC5C,CNTN4,RELN,GPC6,PTPRG,PCDH9,EPHA5,CHN2,CACNA2D1 |
6.558e-13 | -28.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 23 | 16828 | 48 |
UNC5C,NRXN3,CADPS2,GRID2,GPC6,RIMS1,ZNF385B,RELN,ST18,PTPRG,CACNA2D1,CHN2,EPHA5,CNTNAP2,ANK2,ZNF385D,KCNJ3,STXBP5L,TLL1,FSTL5,EBF1,NRG3,TRPM3 |
1.088e-12 | -27.55 | synapse | cellular component | GO:0045202 | 1473 | 22 | 19108 | 48 |
SYT1,KCNJ3,NRG3,GPC6,UNC5C,CADPS2,APOE,RIMS1,NRXN3,GRIK2,DTNA,LRRTM4,CNTN4,CHN2,GRIA4,RIMS2,NRXN1,GRID2,CNTN5,CNTNAP2,SLC1A3,ANK2 |
1.843e-12 | -27.02 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 34 | 16828 | 48 |
CHN2,CACNA2D1,SLC1A3,NRXN1,EPHA5,PTPRG,NFIA,PCDH9,ZNF385B,RIMS1,GPC6,RELN,NRXN3,SYT1,LSAMP,UNC5C,GRID2,KIF21A,CADPS2,CDH18,NRG3,RIMS2,TLL1,GRIA4,FSTL5,EBF1,KCNJ3,ANK2,ZNF385D,CNTN5,LRRTM4,NRG1,SLC35F3,CNTNAP2 |
1.843e-12 | -27.02 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 34 | 16828 | 48 |
TLL1,GRIA4,EBF1,FSTL5,NRG3,RIMS2,SLC35F3,CNTNAP2,NRG1,ANK2,ZNF385D,KCNJ3,CNTN5,LRRTM4,PCDH9,PTPRG,NFIA,CACNA2D1,SLC1A3,CHN2,EPHA5,NRXN1,LSAMP,SYT1,UNC5C,NRXN3,KIF21A,CADPS2,CDH18,GRID2,GPC6,RIMS1,ZNF385B,RELN |
3.822e-12 | -26.29 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 23 | 16828 | 48 |
GPC6,RIMS1,ZNF385B,RELN,UNC5C,NRXN3,CADPS2,GRID2,CACNA2D1,CHN2,EPHA5,ST18,PTPRG,ANK2,ZNF385D,KCNJ3,STXBP5L,CNTNAP2,NRG3,TRPM3,TLL1,EBF1,FSTL5 |
6.831e-12 | -25.71 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 19 | 16828 | 48 |
CNTN4,KCNJ3,GPC6,ZNF385D,GRID2,NRG1,NRXN3,LSAMP,SYT1,CNTNAP2,UNC5C,EPHA5,CHN2,NRG3,CACNA2D1,FSTL5,PTPRG,GRIA4,PCDH9 |
8.237e-12 | -25.52 | cell junction | cellular component | GO:0030054 | 2224 | 25 | 19108 | 48 |
GRIA4,CHN2,CNTN4,RIMS2,LRRTM4,DTNA,CDH18,GRIK2,CNTN5,ANK2,SLC1A3,CNTNAP2,GRID2,PCDH9,NRXN1,GPC6,NRG3,UNC5C,KCNJ3,SYT1,NFIA,APOE,NRXN3,RIMS1,CADPS2 |
1.213e-11 | -25.13 | synaptic membrane | cellular component | GO:0097060 | 400 | 13 | 19108 | 48 |
GRIA4,RIMS2,LRRTM4,SYT1,GRIK2,KCNJ3,CNTN5,ANK2,NRXN3,CNTNAP2,RIMS1,NRXN1,GRID2 |
1.829e-11 | -24.72 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 30 | 16828 | 48 |
ANK2,KCNJ3,CNTN5,CNTNAP2,SLC35F3,NRG1,NRG3,TLL1,GRIA4,FSTL5,EBF1,RIMS1,GPC6,ZNF385B,RELN,LSAMP,SYT1,UNC5C,NRXN3,KIF21A,CDH18,CADPS2,GRID2,SLC1A3,CACNA2D1,CHN2,NPAS3,EPHA5,PCDH9,PTPRG |
3.380e-11 | -24.11 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 12 | 16828 | 48 |
FSTL5,GRIA4,ST18,EPHA5,CHN2,GRID2,CNTNAP2,NRXN3,GPC6,RIMS1,ZNF385B,KCNJ3 |
4.686e-11 | -23.78 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 27 | 16828 | 48 |
GRIA4,TLL1,FSTL5,EBF1,NRG3,CNTNAP2,SLC35F3,NRG1,ANK2,KCNJ3,PCDH9,PTPRG,SLC1A3,CACNA2D1,CHN2,EPHA5,UNC5C,SYT1,LSAMP,NRXN3,CADPS2,KIF21A,GRID2,RIMS1,GPC6,ZNF385B,RELN |
6.801e-11 | -23.41 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 31 | 16828 | 48 |
PCDH9,PTPRG,NPAS3,EPHA5,CACNA2D1,SLC1A3,CADPS2,CDH18,GRID2,LSAMP,SYT1,UNC5C,DTNA,NRXN3,RELN,CNTN4,GPC6,RIMS1,FSTL5,EBF1,TLL1,GRIA4,RIMS2,NRG3,MYT1L,TRPM3,SLC35F3,CNTNAP2,NRG1,RALYL,CNTN5 |
6.801e-11 | -23.41 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 31 | 16828 | 48 |
RALYL,NRG1,CNTNAP2,SLC35F3,CNTN5,EBF1,FSTL5,GRIA4,TLL1,RIMS2,TRPM3,MYT1L,NRG3,GRID2,CADPS2,CDH18,NRXN3,DTNA,UNC5C,SYT1,LSAMP,CNTN4,RELN,RIMS1,GPC6,PTPRG,PCDH9,EPHA5,NPAS3,SLC1A3,CACNA2D1 |
1.478e-10 | -22.63 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 33 | 16828 | 48 |
EPHA5,SLC1A3,CACNA2D1,CHN2,PCDH9,PTPRG,RELN,RIMS1,GPC6,ZNF385B,KIF21A,CADPS2,CDH18,GRID2,SYT1,LSAMP,UNC5C,DTNA,NRXN3,RIMS2,NRG3,EBF1,FSTL5,TLL1,GRIA4,STXBP5L,ANK2,ZNF385D,KCNJ3,SLC35F3,CNTNAP2,NRG1,RALYL |
1.526e-10 | -22.60 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 19 | 16828 | 48 |
FSTL5,EBF1,PTPRG,NFIA,EPHA5,NPAS3,NRG3,CADPS2,GRID2,UNC5C,CNTNAP2,LSAMP,RALYL,RUNX1T1,RELN,STXBP5L,RIMS1,GPC6,ZNF385B |
1.526e-10 | -22.60 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 19 | 16828 | 48 |
NRG3,NPAS3,EPHA5,PTPRG,NFIA,FSTL5,EBF1,RIMS1,GPC6,ZNF385B,RELN,STXBP5L,LSAMP,UNC5C,CNTNAP2,RUNX1T1,RALYL,CADPS2,GRID2 |
4.303e-10 | -21.57 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 23 | 16828 | 48 |
CNTNAP2,RUNX1T1,NRXN3,CDH18,GRID2,GPC6,RIMS1,GRIK2,ZNF385B,RELN,CNTN5,LRRTM4,CNTN4,STXBP5L,PCDH9,ST18,GRIA4,EBF1,FSTL5,NPAS3,RIMS2,EPHA5,NRXN1 |
4.393e-10 | -21.55 | larynx | COSMIC cancer mutations | larynx | 1948 | 23 | 16828 | 48 |
RIMS1,GPC6,ZNF385B,RELN,CNTN4,NRXN3,CDH18,GRID2,NPAS3,EPHA5,NRXN1,PCDH9,ST18,GRIK2,CNTN5,LRRTM4,STXBP5L,CNTNAP2,RUNX1T1,RIMS2,GRIA4,EBF1,FSTL5 |
1.057e-09 | -20.67 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 45 | 16828 | 48 |
GRID2,CADPS2,CDH18,KIF21A,SYT1,RELN,ZNF385B,APOE,RIMS1,NFIA,PCDH9,NRXN1,NPAS3,SLC1A3,RALYL,RUNX1T1,NRG1,SLC35F3,STXBP5L,LRRTM4,KCNJ3,ZNF385D,RIMS2,TRPM3,NRG3,NRXN3,DTNA,UNC5C,LSAMP,CNTN4,GPC6,PTPRG,GLCE,EPHA5,CACNA2D1,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2,FSTL5,EBF1,GRIA4,TLL1,MYT1L |
1.643e-09 | -20.23 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 39 | 16828 | 48 |
ST18,PTPRG,GLCE,PCDH9,CHN2,CACNA2D1,NRXN1,NPAS3,EPHA5,NRXN3,UNC5C,GRID2,KIF21A,CADPS2,CDH18,GPC6,RIMS1,CNTN4,RELN,TLL1,GRIA4,FSTL5,EBF1,TRPM3,MYT1L,NRG3,RIMS2,NRG1,RUNX1T1,RALYL,SLC35F3,CNTNAP2,LINGO2,KCNJ3,ANK2,GRIK2,ZNF385D,STXBP5L,CNTN5 |
1.780e-09 | -20.15 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 12 | 18204 | 45 |
APOE,GRIA4,SLC1A3,GRIK2,RELN,SYT1,CNTN4,NRG3,GRID2,NRXN1,RIMS1,RIMS2 |
1.821e-09 | -20.12 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 12 | 18204 | 45 |
APOE,GRIA4,SLC1A3,RELN,GRIK2,GRID2,SYT1,CNTN4,NRG3,NRXN1,RIMS2,RIMS1 |
2.146e-09 | -19.96 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 37 | 16828 | 48 |
TRPM3,NRG3,MYT1L,RIMS2,GRIA4,TLL1,FSTL5,EBF1,GRIK2,ANK2,ZNF385D,STXBP5L,LRRTM4,RALYL,NRG1,SLC35F3,CNTNAP2,CACNA2D1,SLC1A3,EPHA5,NPAS3,PTPRG,ST18,NFIA,PCDH9,ZNF385B,APOE,RIMS1,GPC6,RELN,NRXN3,UNC5C,LSAMP,GRID2,CDH18,CADPS2,KIF21A |
2.610e-09 | -19.76 | humerus | COSMIC cancer mutations | humerus | 546 | 13 | 16828 | 48 |
NRXN3,CNTNAP2,GRID2,CDH18,ZNF385B,KCNJ3,RIMS1,GPC6,GRIA4,ST18,FSTL5,CHN2,EPHA5 |
3.831e-09 | -19.38 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 11 | 18204 | 45 |
NRXN1,RIMS2,RIMS1,DTNA,GRID2,SYT1,SLC1A3,CADPS2,GRIK2,APOE,GRIA4 |
3.831e-09 | -19.38 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 11 | 18204 | 45 |
SLC1A3,NRXN1,GRIK2,RIMS1,RIMS2,CADPS2,DTNA,GRIA4,APOE,SYT1,GRID2 |
4.122e-09 | -19.31 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 32 | 16828 | 48 |
CNTN4,RELN,ZNF385B,RIMS1,GRID2,CADPS2,CDH18,KIF21A,NRXN3,DTNA,EPHA5,CHN2,SLC1A3,CACNA2D1,ST18,PTPRG,PCDH9,STXBP5L,CNTN5,KCNJ3,ANK2,NRG1,SLC35F3,CNTNAP2,RIMS2,TRPM3,NRG3,MYT1L,EBF1,FSTL5,GRIA4,TLL1 |
4.122e-09 | -19.31 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 32 | 16828 | 48 |
TLL1,GRIA4,EBF1,FSTL5,TRPM3,MYT1L,NRG3,RIMS2,NRG1,SLC35F3,CNTNAP2,KCNJ3,ANK2,STXBP5L,CNTN5,PTPRG,ST18,PCDH9,CHN2,CACNA2D1,SLC1A3,EPHA5,DTNA,NRXN3,GRID2,KIF21A,CADPS2,CDH18,ZNF385B,RIMS1,CNTN4,RELN |
4.964e-09 | -19.12 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 17 | 16828 | 48 |
FSTL5,PTPRG,ST18,TLL1,EPHA5,NRG3,CACNA2D1,GRID2,CDH18,NRXN3,UNC5C,CNTNAP2,SLC35F3,CNTN5,ZNF385D,ANK2,GPC6 |
5.391e-09 | -19.04 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 29 | 16828 | 48 |
STXBP5L,ANK2,ZNF385D,KCNJ3,SLC35F3,CNTNAP2,RALYL,NRG1,NRG3,EBF1,FSTL5,GRIA4,TLL1,RELN,GPC6,RIMS1,ZNF385B,CADPS2,KIF21A,GRID2,UNC5C,LSAMP,SYT1,NRXN3,EPHA5,CACNA2D1,CHN2,PCDH9,PTPRG |
5.676e-09 | -18.99 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 11 | 18204 | 45 |
SLC1A3,CADPS2,GRIK2,GRIA4,APOE,NRXN1,RIMS2,RIMS1,DTNA,GRID2,SYT1 |
5.934e-09 | -18.94 | cell-cell signaling | biological process | GO:0007267 | 822 | 14 | 18204 | 45 |
GRIA4,APOE,SLC1A3,GRIK2,CADPS2,KCNJ3,DTNA,SYT1,CACNA2D1,ANK2,GRID2,NRXN1,RIMS1,RIMS2 |
8.451e-09 | -18.59 | presynaptic membrane | cellular component | GO:0042734 | 168 | 8 | 19108 | 48 |
NRXN1,KCNJ3,GRIK2,SYT1,NRXN3,RIMS2,RIMS1,CNTN5 |
1.089e-08 | -18.34 | synaptic signaling | biological process | GO:0099536 | 459 | 11 | 18204 | 45 |
SLC1A3,NRXN1,GRIK2,RIMS1,CADPS2,RIMS2,APOE,DTNA,GRIA4,SYT1,GRID2 |
2.920e-08 | -17.35 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 10 | 10285 | 30 |
LRRTM4,GRIA4,NRXN3,CACNA2D1,NRXN1,RIMS1,KCNJ3,GRIK2,SLC1A3,SYT1 |
3.085e-08 | -17.29 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 25 | 16828 | 48 |
PCDH9,EPHA5,NPAS3,CACNA2D1,CDH18,GRID2,UNC5C,SYT1,NRXN3,RELN,CNTN4,ZNF385B,APOE,FSTL5,EBF1,GRIA4,RIMS2,MYT1L,TRPM3,LINGO2,CNTNAP2,RUNX1T1,NRG1,CNTN5,GRIK2 |
3.756e-08 | -17.10 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 46 | 16828 | 48 |
CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,MYT1L,EBF1,FSTL5,GRIA4,TLL1,CNTN4,GPC6,NRXN3,DTNA,UNC5C,LSAMP,EPHA5,CACNA2D1,PTPRG,GLCE,STXBP5L,LRRTM4,KCNJ3,ZNF385D,RALYL,NRG1,RUNX1T1,SLC35F3,RIMS2,TRPM3,NRG3,RELN,ZNF385B,APOE,RIMS1,GRID2,CDH18,CADPS2,KIF21A,NRXN1,NPAS3,CHN2,SLC1A3,ST18,NFIA,PCDH9 |
3.756e-08 | -17.10 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 46 | 16828 | 48 |
NRG1,RUNX1T1,RALYL,SLC35F3,KCNJ3,ZNF385D,STXBP5L,LRRTM4,TRPM3,NRG3,RIMS2,GRID2,KIF21A,CADPS2,CDH18,APOE,ZNF385B,RIMS1,RELN,NFIA,ST18,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,TLL1,GRIA4,EBF1,FSTL5,MYT1L,DTNA,NRXN3,LSAMP,UNC5C,GPC6,CNTN4,PTPRG,GLCE,CACNA2D1,EPHA5 |
4.010e-08 | -17.03 | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | COSMIC cancer mutations | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | 181 | 8 | 16828 | 48 |
GRID2,CDH18,SLC35F3,CNTNAP2,NPAS3,RELN,CNTN5,EPHA5 |
4.186e-08 | -16.99 | WNT_subtype | COSMIC cancer mutations | WNT_subtype | 182 | 8 | 16828 | 48 |
CDH18,GRID2,SLC35F3,CNTNAP2,NPAS3,RELN,CNTN5,EPHA5 |
5.405e-08 | -16.73 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 39 | 16828 | 48 |
KCNJ3,ZNF385D,ANK2,STXBP5L,CNTN5,NRG1,RALYL,SLC35F3,CNTNAP2,LINGO2,TRPM3,NRG3,RIMS2,TLL1,GRIA4,EBF1,FSTL5,ZNF385B,RIMS1,GPC6,CNTN4,RELN,NRXN3,LSAMP,SYT1,UNC5C,GRID2,KIF21A,CADPS2,CHN2,CACNA2D1,SLC1A3,NRXN1,NPAS3,EPHA5,PTPRG,NFIA,ST18,PCDH9 |
5.918e-08 | -16.64 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 39 | 16828 | 48 |
NRG3,MYT1L,TRPM3,RIMS2,GRIA4,TLL1,EBF1,GRIK2,ANK2,ZNF385D,KCNJ3,CST3,CNTN5,STXBP5L,CNTNAP2,RALYL,RUNX1T1,NRG1,CACNA2D1,CHN2,EPHA5,NPAS3,NRXN1,GLCE,PCDH9,PTPRG,NFIA,ST18,RIMS1,GPC6,ZNF385B,RELN,CNTN4,UNC5C,LSAMP,SYT1,NRXN3,CDH18,KIF21A |
5.918e-08 | -16.64 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 39 | 16828 | 48 |
RALYL,NRG1,RUNX1T1,CNTNAP2,KCNJ3,GRIK2,ZNF385D,ANK2,STXBP5L,CNTN5,CST3,GRIA4,TLL1,EBF1,TRPM3,MYT1L,NRG3,RIMS2,NRXN3,UNC5C,SYT1,LSAMP,CDH18,KIF21A,ZNF385B,GPC6,RIMS1,CNTN4,RELN,ST18,PTPRG,NFIA,PCDH9,GLCE,CHN2,CACNA2D1,NRXN1,EPHA5,NPAS3 |
7.510e-08 | -16.40 | neuron projection | cellular component | GO:0043005 | 1331 | 16 | 19108 | 48 |
DTNA,GRIK2,SYT1,CNTN4,GRIA4,UNC5C,GRID2,PCDH9,KIF21A,RELN,APOE,CNTN5,CNTNAP2,ANK2,EPHA5,SLC1A3 |
8.550e-08 | -16.27 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 39 | 16828 | 48 |
MYT1L,NRG3,GRIA4,TLL1,EBF1,FSTL5,ANK2,GRIK2,ZNF385D,KCNJ3,CNTN5,LRRTM4,STXBP5L,CNTNAP2,SLC35F3,RALYL,RUNX1T1,NRG1,LINGO2,CACNA2D1,SLC1A3,CHN2,EPHA5,PCDH9,GLCE,ST18,PTPRG,RIMS1,GPC6,ZNF385B,RELN,UNC5C,SYT1,LSAMP,NRXN3,CADPS2,CDH18,KIF21A,GRID2 |
8.619e-08 | -16.27 | mouth | COSMIC cancer mutations | mouth | 9004 | 43 | 16828 | 48 |
RUNX1T1,RALYL,SLC35F3,KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,TRPM3,NRG3,RIMS2,SYT1,GRID2,KIF21A,CDH18,APOE,ZNF385B,RIMS1,RELN,ST18,PCDH9,SLC1A3,NRXN1,NPAS3,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,TLL1,GRIA4,FSTL5,MYT1L,DTNA,NRXN3,LSAMP,UNC5C,GPC6,CNTN4,PTPRG,GLCE,CACNA2D1,EPHA5 |
9.202e-08 | -16.20 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 27 | 16828 | 48 |
RELN,RIMS1,GPC6,ZNF385B,CADPS2,CDH18,KIF21A,GRID2,UNC5C,NRXN3,EPHA5,PCDH9,ST18,CNTN5,LRRTM4,ZNF385D,ANK2,KCNJ3,LINGO2,CNTNAP2,RUNX1T1,RIMS2,NRG3,TRPM3,FSTL5,GRIA4,TLL1 |
9.316e-08 | -16.19 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 27 | 16828 | 48 |
EPHA5,ST18,PCDH9,ZNF385B,RIMS1,GPC6,RELN,NRXN3,UNC5C,GRID2,CADPS2,CDH18,KIF21A,TRPM3,NRG3,RIMS2,GRIA4,TLL1,FSTL5,KCNJ3,ZNF385D,ANK2,LRRTM4,CNTN5,RUNX1T1,CNTNAP2,LINGO2 |
9.955e-08 | -16.12 | femur | COSMIC cancer mutations | femur | 1197 | 16 | 16828 | 48 |
CNTNAP2,UNC5C,SYT1,NRXN3,CDH18,KIF21A,GRID2,ZNF385B,STXBP5L,CNTN4,PCDH9,PTPRG,ST18,GRIA4,TLL1,NRG3 |
1.070e-07 | -16.05 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 7 | 18204 | 45 |
SYT1,RIMS1,GRIK2,RIMS2,RELN,NRXN1,SLC1A3 |
1.291e-07 | -15.86 | modulation of excitatory postsynaptic potential | biological process | GO:0098815 | 49 | 5 | 18204 | 45 |
NRXN1,RELN,RIMS2,GRIK2,RIMS1 |
1.305e-07 | -15.85 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 36 | 16828 | 48 |
NRXN1,EPHA5,NPAS3,CACNA2D1,PTPRG,PCDH9,CNTN4,RELN,RIMS1,GPC6,GRID2,CADPS2,CDH18,KIF21A,NRXN3,UNC5C,RIMS2,TRPM3,NRG3,MYT1L,FSTL5,EBF1,GRIA4,TLL1,STXBP5L,CNTN5,LRRTM4,KCNJ3,GRIK2,ANK2,LINGO2,RALYL,RUNX1T1,NRG1,SLC35F3,CNTNAP2 |
1.477e-07 | -15.73 | regulation of membrane potential | biological process | GO:0042391 | 463 | 10 | 18204 | 45 |
CACNA2D1,ANK2,GRID2,GRIA4,KCNJ3,RIMS2,RELN,GRIK2,RIMS1,NRXN1 |
1.762e-07 | -15.55 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 34 | 16828 | 48 |
GRIK2,ANK2,KCNJ3,CNTN5,CST3,STXBP5L,SLC35F3,CNTNAP2,RUNX1T1,LINGO2,MYT1L,NRG3,TRPM3,RIMS2,GRIA4,TLL1,FSTL5,GPC6,RIMS1,RELN,UNC5C,LSAMP,NRXN3,DTNA,CDH18,CADPS2,KIF21A,GRID2,CACNA2D1,SLC1A3,EPHA5,NPAS3,ST18,PTPRG |
1.762e-07 | -15.55 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 34 | 16828 | 48 |
EPHA5,NPAS3,CACNA2D1,SLC1A3,PTPRG,ST18,RELN,RIMS1,GPC6,CADPS2,CDH18,KIF21A,GRID2,UNC5C,LSAMP,NRXN3,DTNA,RIMS2,NRG3,MYT1L,TRPM3,FSTL5,GRIA4,TLL1,CNTN5,CST3,STXBP5L,GRIK2,ANK2,KCNJ3,LINGO2,CNTNAP2,SLC35F3,RUNX1T1 |
2.255e-07 | -15.30 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 26 | 16828 | 48 |
NRXN1,EPHA5,PTPRG,ST18,PCDH9,CNTN4,RELN,ZNF385B,GRID2,CDH18,KIF21A,SYT1,RIMS2,TRPM3,NRG3,EBF1,FSTL5,TLL1,STXBP5L,CNTN5,ANK2,ZNF385D,GRIK2,RUNX1T1,CNTNAP2,SLC35F3 |
3.273e-07 | -14.93 | plasma membrane | cellular component | GO:0005886 | 5538 | 31 | 19108 | 48 |
LRRTM4,GRIK2,CDH18,DTNA,CST3,GRIA4,STXBP5L,CNTN4,RIMS2,NRXN1,PCDH9,LSAMP,GRID2,CNTN5,RELN,SLC1A3,CACNA2D1,EPHA5,ANK2,CNTNAP2,SYT1,KCNJ3,TRPM3,GPC6,NRG3,UNC5C,NRG1,APOE,PTPRG,NRXN3,RIMS1 |
4.332e-07 | -14.65 | cell projection | cellular component | GO:0042995 | 2398 | 20 | 19108 | 48 |
NRXN1,PCDH9,GRID2,KIF21A,RELN,CNTN5,APOE,CNTNAP2,RIMS1,SLC1A3,NRXN3,ANK2,EPHA5,GRIK2,SYT1,DTNA,CNTN4,GRIA4,RIMS2,UNC5C |
5.308e-07 | -14.45 | cell junction organization | biological process | GO:0034330 | 532 | 10 | 18204 | 45 |
NRG3,CNTN4,CNTN5,GRID2,ANK2,APOE,RELN,NRXN1,NFIA,CDH18 |
5.805e-07 | -14.36 | cell periphery | cellular component | GO:0071944 | 6020 | 32 | 19108 | 48 |
SLC1A3,EPHA5,CACNA2D1,ANK2,CNTNAP2,CNTN5,RELN,PCDH9,NRXN1,LSAMP,GRID2,RIMS2,STXBP5L,GRIA4,CNTN4,CST3,LRRTM4,GRIK2,DTNA,CDH18,PTPRG,NRXN3,RIMS1,APOE,NRG1,UNC5C,LINGO2,GPC6,NRG3,TRPM3,SYT1,KCNJ3 |
5.806e-07 | -14.36 | bone | COSMIC cancer mutations | bone | 8157 | 40 | 16828 | 48 |
ST18,PTPRG,GLCE,PCDH9,CHN2,CACNA2D1,SLC1A3,NRXN1,NPAS3,EPHA5,DTNA,NRXN3,LSAMP,SYT1,UNC5C,GRID2,KIF21A,CDH18,ZNF385B,GPC6,RIMS1,CNTN4,RELN,TLL1,GRIA4,FSTL5,TRPM3,NRG3,MYT1L,NRG1,RUNX1T1,CNTNAP2,LINGO2,KCNJ3,ANK2,GRIK2,STXBP5L,LRRTM4,CNTN5,CST3 |
6.422e-07 | -14.26 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 45 |
CNTN4,NFIA,NRXN1,NRXN3,EPHA5,CNTN5,CDH18,SLC1A3,CNTNAP2,UNC5C,RELN |
8.103e-07 | -14.03 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 7 | 16828 | 48 |
NRG3,GRID2,PCDH9,SYT1,CNTNAP2,PTPRG,GRIA4 |
8.676e-07 | -13.96 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 12 | 16828 | 48 |
KIF21A,CDH18,GRID2,CNTNAP2,DTNA,RELN,RIMS1,ANK2,EBF1,RIMS2,EPHA5,SLC1A3 |
1.020e-06 | -13.80 | regulation of synaptic plasticity | biological process | GO:0048167 | 219 | 7 | 18204 | 45 |
RIMS2,RELN,RIMS1,GRIK2,APOE,GRID2,CNTN4 |
1.114e-06 | -13.71 | positive regulation of excitatory postsynaptic potential | biological process | GO:2000463 | 32 | 4 | 18204 | 45 |
NRXN1,RELN,RIMS2,RIMS1 |
1.183e-06 | -13.65 | neurotransmitter transport | biological process | GO:0006836 | 140 | 6 | 18204 | 45 |
SYT1,RIMS1,RIMS2,CADPS2,NRXN1,SLC1A3 |
1.186e-06 | -13.64 | axon guidance | biological process | GO:0007411 | 224 | 7 | 18204 | 45 |
EPHA5,NRXN3,RELN,UNC5C,NRXN1,CNTN5,CNTN4 |
1.186e-06 | -13.64 | neuron projection guidance | biological process | GO:0097485 | 224 | 7 | 18204 | 45 |
NRXN1,UNC5C,RELN,EPHA5,NRXN3,CNTN4,CNTN5 |
1.243e-06 | -13.60 | I-set | pfam domains | PF07679 | 132 | 6 | 17795 | 47 |
UNC5C,CNTN4,LINGO2,LSAMP,NRG1,CNTN5 |
1.255e-06 | -13.59 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 28 | 16828 | 48 |
EPHA5,PCDH9,NFIA,RELN,RIMS1,GPC6,KIF21A,CDH18,CADPS2,UNC5C,NRXN3,RIMS2,NRG3,MYT1L,TRPM3,EBF1,FSTL5,TLL1,GRIA4,LRRTM4,CNTN5,STXBP5L,GRIK2,ANK2,KCNJ3,LINGO2,CNTNAP2,RUNX1T1 |
1.271e-06 | -13.58 | Ig_I-set | interpro domains | IPR013098 | 132 | 6 | 18521 | 49 |
LSAMP,NRG1,UNC5C,LINGO2,CNTN5,CNTN4 |
1.305e-06 | -13.55 | neuron differentiation | biological process | GO:0030182 | 1081 | 13 | 18204 | 45 |
UNC5C,CNTNAP2,SLC1A3,RELN,APOE,CNTN5,NRXN1,NFIA,EPHA5,NRXN3,CNTN4,MYT1L,GRID2 |
1.330e-06 | -13.53 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 39 | 16828 | 48 |
RIMS1,GPC6,ZNF385B,RELN,CNTN4,UNC5C,NRXN3,CADPS2,CDH18,KIF21A,GRID2,CACNA2D1,CHN2,EPHA5,NPAS3,NRXN1,PCDH9,PTPRG,ST18,ANK2,GRIK2,KCNJ3,CNTN5,LRRTM4,STXBP5L,CNTNAP2,SLC35F3,RALYL,RUNX1T1,NRG1,LINGO2,MYT1L,NRG3,TRPM3,RIMS2,GRIA4,TLL1,EBF1,FSTL5 |
1.342e-06 | -13.52 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 45 | 16828 | 48 |
RIMS2,NRG3,TRPM3,LRRTM4,CST3,STXBP5L,ZNF385D,KCNJ3,SLC35F3,RALYL,NRG1,RUNX1T1,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,ST18,RELN,RIMS1,ZNF385B,CADPS2,CDH18,KIF21A,GRID2,SYT1,MYT1L,EBF1,FSTL5,GRIA4,TLL1,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,EPHA5,CACNA2D1,GLCE,PTPRG,CNTN4,UNC5C,LSAMP,NRXN3,DTNA |
1.378e-06 | -13.49 | synapse organization | biological process | GO:0050808 | 333 | 8 | 18204 | 45 |
RELN,NRXN1,NFIA,CNTN5,NRG3,CNTN4,GRID2,APOE |
1.562e-06 | -13.37 | pleura-pulmonary_blastoma | COSMIC cancer mutations | pleura-pulmonary_blastoma | 648 | 11 | 16828 | 48 |
PTPRG,ST18,EPHA5,RIMS2,KIF21A,LINGO2,CDH18,CADPS2,CNTNAP2,RUNX1T1,RIMS1 |
1.562e-06 | -13.37 | pulmonary_blastoma | COSMIC cancer mutations | pulmonary_blastoma | 648 | 11 | 16828 | 48 |
RIMS1,CNTNAP2,RUNX1T1,KIF21A,LINGO2,CADPS2,CDH18,EPHA5,RIMS2,PTPRG,ST18 |
1.675e-06 | -13.30 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 25 | 16828 | 48 |
RIMS2,MYT1L,TRPM3,FSTL5,LRRTM4,GRIK2,LINGO2,CNTNAP2,NRG1,RUNX1T1,EPHA5,NPAS3,CHN2,PCDH9,ST18,PTPRG,RELN,RIMS1,ZNF385B,CADPS2,CDH18,KIF21A,GRID2,UNC5C,NRXN3 |
1.725e-06 | -13.27 | nervous system development | biological process | GO:0007399 | 2185 | 18 | 18204 | 45 |
RELN,SLC1A3,LSAMP,CNTNAP2,UNC5C,CNTN5,APOE,NRG1,PCDH9,EPHA5,NRXN3,NRXN1,NFIA,ANK2,GRID2,MYT1L,NRG3,CNTN4 |
1.755e-06 | -13.25 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 18 | 16828 | 48 |
NRXN3,SYT1,CNTNAP2,UNC5C,GRID2,CDH18,ZNF385B,RIMS1,ANK2,RELN,CNTN5,TLL1,PTPRG,ST18,PCDH9,MYT1L,CACNA2D1,EPHA5 |
1.768e-06 | -13.25 | extremity | COSMIC cancer mutations | extremity | 1876 | 18 | 16828 | 48 |
ST18,PTPRG,TLL1,PCDH9,EPHA5,MYT1L,CACNA2D1,GRID2,CDH18,NRXN3,UNC5C,CNTNAP2,SYT1,CNTN5,RELN,ZNF385B,ANK2,RIMS1 |
1.816e-06 | -13.22 | Protein-protein interactions at synapses | REACTOME pathways | R-HSA-6794362 | 72 | 5 | 10285 | 30 |
NRXN3,LRRTM4,GRIA4,SYT1,NRXN1 |
1.868e-06 | -13.19 | plasma membrane region | cellular component | GO:0098590 | 1278 | 14 | 19108 | 48 |
LRRTM4,GRIK2,SYT1,KCNJ3,RIMS2,GRIA4,NRXN1,GRID2,SLC1A3,NRXN3,ANK2,CNTNAP2,RIMS1,CNTN5 |
2.276e-06 | -12.99 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 7 | 10285 | 30 |
KCNJ3,CACNA2D1,GRIA4,GRIK2,SLC1A3,SYT1,RIMS1 |
2.427e-06 | -12.93 | EGF-like_dom | interpro domains | IPR000742 | 232 | 7 | 18521 | 49 |
NRG1,NRXN3,TLL1,RELN,NRXN1,CNTNAP2,NRG3 |
2.469e-06 | -12.91 | neurotransmitter secretion | biological process | GO:0007269 | 88 | 5 | 18204 | 45 |
NRXN1,SYT1,RIMS1,CADPS2,RIMS2 |
2.469e-06 | -12.91 | signal release from synapse | biological process | GO:0099643 | 88 | 5 | 18204 | 45 |
RIMS1,SYT1,RIMS2,CADPS2,NRXN1 |
2.603e-06 | -12.86 | primary_central_nervous_system_lymphoma | COSMIC cancer mutations | primary_central_nervous_system_lymphoma | 683 | 11 | 16828 | 48 |
NRXN1,EPHA5,NRG3,CACNA2D1,EBF1,GRIA4,PTPRG,STXBP5L,GPC6,GRIK2,CNTNAP2 |
2.603e-06 | -12.86 | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | 683 | 11 | 16828 | 48 |
EPHA5,NRXN1,NRG3,CACNA2D1,EBF1,PTPRG,GRIA4,STXBP5L,GPC6,GRIK2,CNTNAP2 |
2.811e-06 | -12.78 | generation of neurons | biological process | GO:0048699 | 1158 | 13 | 18204 | 45 |
RELN,SLC1A3,CNTNAP2,UNC5C,CNTN5,APOE,NRXN3,EPHA5,NRXN1,NFIA,GRID2,MYT1L,CNTN4 |
2.955e-06 | -12.73 | Ig_sub2 | interpro domains | IPR003598 | 239 | 7 | 18521 | 49 |
LSAMP,NRG1,UNC5C,LINGO2,CNTN5,FSTL5,CNTN4 |
2.975e-06 | -12.73 | EGF_3 | prosite domains | PS50026 | 196 | 7 | 12186 | 40 |
NRXN1,NRG1,CNTNAP2,NRG3,NRXN3,TLL1,RELN |
3.057e-06 | -12.70 | auditory behavior | biological process | GO:0031223 | 12 | 3 | 18204 | 45 |
CNTNAP2,NRXN1,SLC1A3 |
3.468e-06 | -12.57 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 15 | 16828 | 48 |
TRPM3,CACNA2D1,MYT1L,EPHA5,TLL1,PTPRG,PCDH9,KCNJ3,ANK2,GRIK2,STXBP5L,CNTN5,NRXN3,CNTNAP2,KIF21A |
3.725e-06 | -12.50 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 45 | 16828 | 48 |
SLC1A3,CHN2,NPAS3,NRXN1,PCDH9,ST18,RIMS1,ZNF385B,RELN,SYT1,KIF21A,CDH18,CADPS2,GRID2,NRG3,TRPM3,RIMS2,ZNF385D,KCNJ3,LRRTM4,CST3,STXBP5L,SLC35F3,NRG1,RUNX1T1,RALYL,CACNA2D1,EPHA5,GLCE,PTPRG,CNTN4,LSAMP,UNC5C,DTNA,NRXN3,MYT1L,TLL1,GRIA4,FSTL5,EBF1,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2 |
3.934e-06 | -12.45 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 15 | 16828 | 48 |
CNTNAP2,NRXN3,KIF21A,ANK2,GRIK2,KCNJ3,CNTN5,STXBP5L,PCDH9,PTPRG,TLL1,MYT1L,CACNA2D1,TRPM3,EPHA5 |
3.936e-06 | -12.45 | axon | cellular component | GO:0030424 | 650 | 10 | 19108 | 48 |
UNC5C,EPHA5,CNTNAP2,CNTN5,CNTN4,KIF21A,PCDH9,DTNA,SYT1,GRIK2 |
4.755e-06 | -12.26 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 18 | 16828 | 48 |
NRG3,FSTL5,EBF1,PCDH9,TLL1,ST18,RELN,CNTN4,GPC6,ZNF385D,GRIK2,ANK2,CDH18,GRID2,SYT1,UNC5C,CNTNAP2,NRG1 |
4.755e-06 | -12.26 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 18 | 16828 | 48 |
SYT1,CNTNAP2,UNC5C,NRG1,CDH18,GRID2,GPC6,GRIK2,ZNF385D,ANK2,RELN,CNTN4,PCDH9,TLL1,ST18,EBF1,FSTL5,NRG3 |
4.928e-06 | -12.22 | receptor clustering | biological process | GO:0043113 | 46 | 4 | 18204 | 45 |
RELN,GRIK2,APOE,NRXN1 |
4.968e-06 | -12.21 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 48 |
RELN,GPC6,RIMS1,ANK2,ZNF385B,LINGO2,CDH18,UNC5C,CNTNAP2,DTNA,NRXN3,NPAS3,MYT1L,NRG3,EBF1,GLCE,PCDH9,TLL1,PTPRG,ST18,NFIA |
5.041e-06 | -12.20 | mechanosensory behavior | biological process | GO:0007638 | 14 | 3 | 18204 | 45 |
SLC1A3,NRXN1,CNTNAP2 |
5.627e-06 | -12.09 | neuron development | biological process | GO:0048666 | 859 | 11 | 18204 | 45 |
APOE,MYT1L,CNTN4,CNTN5,SLC1A3,NRXN1,CNTNAP2,UNC5C,RELN,EPHA5,NRXN3 |
5.766e-06 | -12.06 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 11 | 19108 | 48 |
RELN,APOE,GRIA4,CNTNAP2,EPHA5,UNC5C,SLC1A3,GRIK2,GRID2,NRXN1,KIF21A |
5.855e-06 | -12.05 | calcium-ion regulated exocytosis | biological process | GO:0017156 | 48 | 4 | 18204 | 45 |
RIMS2,CADPS2,RIMS1,SYT1 |
6.102e-06 | -12.01 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 7 | 16828 | 48 |
NRG3,NPAS3,CNTNAP2,SYT1,PCDH9,NFIA,CADPS2 |
6.102e-06 | -12.01 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 7 | 16828 | 48 |
CADPS2,CNTNAP2,PCDH9,SYT1,NFIA,NPAS3,NRG3 |
6.206e-06 | -11.99 | Neurexin-like | interpro domains | IPR003585 | 14 | 3 | 18521 | 49 |
CNTNAP2,NRXN3,NRXN1 |
7.729e-06 | -11.77 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 3 | 18204 | 45 |
CNTN4,NRXN3,NRXN1 |
8.691e-06 | -11.65 | trunk | COSMIC cancer mutations | trunk | 3554 | 24 | 16828 | 48 |
ST18,PTPRG,PCDH9,NRXN1,NPAS3,CACNA2D1,SLC1A3,GRID2,KIF21A,NRXN3,LSAMP,CNTN4,RELN,EBF1,GRIA4,TLL1,RIMS2,MYT1L,NRG3,SLC35F3,STXBP5L,CNTN5,ANK2,GRIK2 |
8.918e-06 | -11.63 | regulation of system process | biological process | GO:0044057 | 571 | 9 | 18204 | 45 |
ANK2,CACNA2D1,APOE,KCNJ3,RELN,RIMS2,RIMS1,GRIK2,NRXN1 |
8.945e-06 | -11.62 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 35 | 16828 | 48 |
ANK2,ZNF385D,GRIK2,KCNJ3,LRRTM4,CNTN5,CST3,STXBP5L,SLC35F3,CNTNAP2,RUNX1T1,LINGO2,NRG3,MYT1L,TRPM3,RIMS2,GRIA4,FSTL5,RIMS1,GPC6,ZNF385B,RELN,CNTN4,LSAMP,DTNA,NRXN3,CDH18,GRID2,CACNA2D1,EPHA5,NRXN1,PCDH9,GLCE,ST18,PTPRG |
9.832e-06 | -11.53 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 26 | 16828 | 48 |
EBF1,GRIA4,RIMS2,TRPM3,MYT1L,LINGO2,RUNX1T1,RALYL,STXBP5L,LRRTM4,ANK2,ZNF385D,GRIK2,ST18,NFIA,PCDH9,GLCE,NRXN1,GRID2,DTNA,NRXN3,LSAMP,SYT1,RELN,GPC6,RIMS1 |
1.028e-05 | -11.49 | presynapse | cellular component | GO:0098793 | 569 | 9 | 19108 | 48 |
NRXN1,CADPS2,SYT1,GRIK2,KCNJ3,RIMS1,RIMS2,NRXN3,CNTN5 |
1.069e-05 | -11.45 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 14 | 16828 | 48 |
TRPM3,NPAS3,TLL1,GRIA4,ZNF385B,ZNF385D,GRIK2,ANK2,RUNX1T1,NRXN3,SYT1,GRID2,LINGO2,CDH18 |
1.122e-05 | -11.40 | calcium ion-regulated exocytosis of neurotransmitter | biological process | GO:0048791 | 18 | 3 | 18204 | 45 |
RIMS2,SYT1,RIMS1 |
1.129e-05 | -11.39 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 8 | 18204 | 45 |
CNTN4,CNTN5,EPHA5,NRXN3,RELN,UNC5C,NRXN1,SLC1A3 |
1.133e-05 | -11.39 | regulation of nervous system process | biological process | GO:0031644 | 120 | 5 | 18204 | 45 |
NRXN1,RIMS1,GRIK2,RELN,RIMS2 |
1.245e-05 | -11.29 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 20 | 16828 | 48 |
PCDH9,GLCE,TLL1,ST18,PTPRG,NRG3,CACNA2D1,SLC1A3,TRPM3,NRXN1,CNTNAP2,RUNX1T1,NRXN3,LINGO2,CDH18,GRID2,GPC6,GRIK2,RELN,CNTN4 |
1.304e-05 | -11.25 | arm | COSMIC cancer mutations | arm | 1331 | 14 | 16828 | 48 |
SYT1,NRXN3,RUNX1T1,CDH18,LINGO2,GRID2,GRIK2,ANK2,ZNF385D,ZNF385B,GRIA4,TLL1,TRPM3,NPAS3 |
1.318e-05 | -11.24 | neurogenesis | biological process | GO:0022008 | 1334 | 13 | 18204 | 45 |
GRID2,CNTN4,MYT1L,EPHA5,NRXN3,NFIA,NRXN1,CNTN5,APOE,RELN,SLC1A3,UNC5C,CNTNAP2 |
1.330e-05 | -11.23 | vocalization behavior | biological process | GO:0071625 | 19 | 3 | 18204 | 45 |
NRXN1,CNTNAP2,NRXN3 |
1.370e-05 | -11.20 | Lig_chan | pfam domains | PF00060 | 18 | 3 | 17795 | 47 |
GRID2,GRIA4,GRIK2 |
1.370e-05 | -11.20 | Lig_chan-Glu_bd | pfam domains | PF10613 | 18 | 3 | 17795 | 47 |
GRIK2,GRIA4,GRID2 |
1.381e-05 | -11.19 | Ionotropic_Glu_rcpt | interpro domains | IPR015683 | 18 | 3 | 18521 | 49 |
GRIK2,GRIA4,GRID2 |
1.381e-05 | -11.19 | Glu/Gly-bd | interpro domains | IPR019594 | 18 | 3 | 18521 | 49 |
GRIK2,GRID2,GRIA4 |
1.381e-05 | -11.19 | Iono_Glu_rcpt_met | interpro domains | IPR001508 | 18 | 3 | 18521 | 49 |
GRID2,GRIA4,GRIK2 |
1.381e-05 | -11.19 | Iontro_rcpt_C | interpro domains | IPR001320 | 18 | 3 | 18521 | 49 |
GRIK2,GRIA4,GRID2 |
1.414e-05 | -11.17 | LRRTM3 (leucine rich repeat transmembrane neuronal 3) | protein interactions | 347731 | 19 | 3 | 19454 | 49 |
NRXN3,LRRTM4,GPC6 |
1.525e-05 | -11.09 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 20 | 16828 | 48 |
ST18,GRIA4,PTPRG,PCDH9,NRXN1,RIMS2,SLC1A3,MYT1L,NRG3,CACNA2D1,GRID2,NRXN3,LSAMP,SLC35F3,CNTN4,STXBP5L,RELN,CNTN5,ANK2,GRIK2 |
1.558e-05 | -11.07 | Ig-like_fold | interpro domains | IPR013783 | 721 | 10 | 18521 | 49 |
CNTN4,PTPRG,UNC5C,NRG1,LSAMP,CNTN5,FSTL5,LINGO2,EPHA5,EBF1 |
1.745e-05 | -10.96 | synaptic vesicle exocytosis | biological process | GO:0016079 | 63 | 4 | 18204 | 45 |
SYT1,RIMS1,CADPS2,RIMS2 |
1.811e-05 | -10.92 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 43 | 16828 | 48 |
SLC35F3,CNTNAP2,RALYL,NRG1,RUNX1T1,LINGO2,ANK2,GRIK2,ZNF385D,LRRTM4,CNTN5,STXBP5L,GRIA4,TLL1,EBF1,FSTL5,MYT1L,NRG3,TRPM3,RIMS2,UNC5C,LSAMP,SYT1,NRXN3,CDH18,CADPS2,KIF21A,GRID2,RIMS1,GPC6,ZNF385B,RELN,CNTN4,PCDH9,NFIA,ST18,PTPRG,CACNA2D1,SLC1A3,CHN2,EPHA5,NPAS3,NRXN1 |
1.811e-05 | -10.92 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 43 | 16828 | 48 |
NRXN1,NPAS3,EPHA5,CHN2,CACNA2D1,SLC1A3,ST18,PTPRG,NFIA,PCDH9,CNTN4,RELN,ZNF385B,RIMS1,GPC6,GRID2,KIF21A,CDH18,CADPS2,NRXN3,SYT1,LSAMP,UNC5C,RIMS2,TRPM3,MYT1L,NRG3,FSTL5,EBF1,TLL1,GRIA4,STXBP5L,CNTN5,LRRTM4,ANK2,ZNF385D,GRIK2,LINGO2,NRG1,RUNX1T1,RALYL,CNTNAP2,SLC35F3 |
1.950e-05 | -10.85 | 4.1m | smart domains | SM00294 | 14 | 3 | 9717 | 38 |
NRXN1,CNTNAP2,NRXN3 |
2.034e-05 | -10.80 | dendrite | cellular component | GO:0030425 | 620 | 9 | 19108 | 48 |
GRID2,CNTNAP2,EPHA5,UNC5C,KIF21A,RELN,GRIK2,APOE,GRIA4 |
2.045e-05 | -10.80 | MYT1 | pfam domains | PF08474 | 3 | 2 | 17795 | 47 |
MYT1L,ST18 |
2.054e-05 | -10.79 | Myelin_TF | interpro domains | IPR013681 | 3 | 2 | 18521 | 49 |
ST18,MYT1L |
2.054e-05 | -10.79 | Neuregulin | interpro domains | IPR040180 | 3 | 2 | 18521 | 49 |
NRG3,NRG1 |
2.087e-05 | -10.78 | dendritic tree | cellular component | GO:0097447 | 622 | 9 | 19108 | 48 |
GRID2,KIF21A,GRIK2,CNTNAP2,UNC5C,EPHA5,RELN,GRIA4,APOE |
2.203e-05 | -10.72 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 45 |
CNTN5,CNTN4,RELN,NRXN3,EPHA5,NRXN1,UNC5C,CNTNAP2 |
2.237e-05 | -10.71 | Interactions of neurexins and neuroligins at synapses | REACTOME pathways | R-HSA-6794361 | 58 | 4 | 10285 | 30 |
NRXN1,SYT1,LRRTM4,NRXN3 |
2.256e-05 | -10.70 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 15 | 16828 | 48 |
NRXN1,EPHA5,RIMS2,ST18,STXBP5L,CNTN4,RELN,KCNJ3,GRIK2,ANK2,NRXN3,NRG1,UNC5C,SYT1,LSAMP |
2.370e-05 | -10.65 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 45 |
CNTN4,CNTN5,CNTNAP2,UNC5C,NRXN1,EPHA5,NRXN3,RELN |
2.501e-05 | -10.60 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 17 | 16828 | 48 |
KIF21A,CDH18,LSAMP,CNTNAP2,RELN,CNTN4,STXBP5L,GPC6,ZNF385D,ANK2,ZNF385B,PCDH9,ST18,EPHA5,NRG3,CACNA2D1,TRPM3 |
2.549e-05 | -10.58 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 45 |
CNTN5,CNTN4,NRXN3,EPHA5,RELN,UNC5C,CNTNAP2,NRXN1 |
2.641e-05 | -10.54 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-follicular_lymphoma | 208 | 6 | 16828 | 48 |
RELN,RIMS2,GRID2,PCDH9,CNTNAP2,KCNJ3 |
2.666e-05 | -10.53 | neuronal cell body | cellular component | GO:0043025 | 489 | 8 | 19108 | 48 |
NRXN1,GRIK2,CNTNAP2,UNC5C,EPHA5,SLC1A3,APOE,GRIA4 |
2.673e-05 | -10.53 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 15 | 16828 | 48 |
TLL1,FSTL5,RIMS2,RUNX1T1,DTNA,NRXN3,GRID2,CDH18,RIMS1,GRIK2,ZNF385D,ANK2,CNTN4,RELN,CNTN5 |
2.673e-05 | -10.53 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 15 | 16828 | 48 |
RIMS2,TLL1,FSTL5,GRIK2,ANK2,ZNF385D,RIMS1,CNTN4,CNTN5,RELN,NRXN3,DTNA,RUNX1T1,GRID2,CDH18 |
2.755e-05 | -10.50 | positive regulation of dendrite extension | biological process | GO:1903861 | 24 | 3 | 18204 | 45 |
RIMS2,SYT1,RIMS1 |
2.947e-05 | -10.43 | axonogenesis | biological process | GO:0007409 | 366 | 7 | 18204 | 45 |
NRXN1,UNC5C,RELN,EPHA5,NRXN3,CNTN4,CNTN5 |
3.211e-05 | -10.35 | NMDARECEPTOR | prints domains | PR00177 | 18 | 3 | 5227 | 19 |
GRID2,GRIK2,GRIA4 |
3.227e-05 | -10.34 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 44 | 16828 | 48 |
EPHA5,CACNA2D1,PTPRG,CNTN4,GPC6,DTNA,NRXN3,LSAMP,UNC5C,MYT1L,EBF1,FSTL5,TLL1,GRIA4,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,NRXN1,NPAS3,CHN2,SLC1A3,NFIA,ST18,PCDH9,RELN,ZNF385B,RIMS1,GRID2,KIF21A,CADPS2,CDH18,SYT1,RIMS2,TRPM3,NRG3,STXBP5L,LRRTM4,ZNF385D,RUNX1T1,NRG1,RALYL,SLC35F3 |
3.283e-05 | -10.32 | IGc2 | smart domains | SM00408 | 239 | 7 | 9717 | 38 |
FSTL5,CNTN5,LINGO2,CNTN4,UNC5C,LSAMP,NRG1 |
3.574e-05 | -10.24 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 2 | 18204 | 45 |
RELN,APOE |
3.591e-05 | -10.23 | glutamate receptor activity | molecular function | GO:0008066 | 26 | 3 | 18094 | 45 |
GRIA4,GRID2,GRIK2 |
3.617e-05 | -10.23 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 2 | 18094 | 45 |
RELN,APOE |
3.632e-05 | -10.22 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 13 | 16828 | 48 |
FSTL5,ST18,PTPRG,RIMS2,NRG3,LINGO2,CDH18,CNTNAP2,RELN,CNTN5,GPC6,GRIK2,ANK2 |
3.632e-05 | -10.22 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 13 | 16828 | 48 |
NRG3,RIMS2,ST18,PTPRG,FSTL5,ANK2,GRIK2,GPC6,CNTN5,RELN,CNTNAP2,CDH18,LINGO2 |
3.865e-05 | -10.16 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 4 | 18204 | 45 |
NRXN1,SYT1,GRIK2,RELN |
3.935e-05 | -10.14 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 46 | 16828 | 48 |
PTPRG,GLCE,CACNA2D1,EPHA5,DTNA,NRXN3,LSAMP,UNC5C,GPC6,CNTN4,TLL1,GRIA4,FSTL5,EBF1,MYT1L,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,NFIA,ST18,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,SYT1,GRID2,KIF21A,CDH18,CADPS2,ZNF385B,RIMS1,RELN,TRPM3,NRG3,RIMS2,RUNX1T1,NRG1,RALYL,SLC35F3,KCNJ3,ZNF385D,STXBP5L,LRRTM4 |
3.961e-05 | -10.14 | regulation of dendrite extension | biological process | GO:1903859 | 27 | 3 | 18204 | 45 |
RIMS1,SYT1,RIMS2 |
3.961e-05 | -10.14 | cell-cell signaling involved in cardiac conduction | biological process | GO:0086019 | 27 | 3 | 18204 | 45 |
KCNJ3,ANK2,CACNA2D1 |
3.969e-05 | -10.13 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 20 | 16828 | 48 |
CDH18,GRID2,CNTNAP2,UNC5C,NRG1,RELN,CNTN5,CNTN4,RIMS1,ANK2,GRIK2,ZNF385B,EBF1,PCDH9,TLL1,PTPRG,ST18,NRG3,CACNA2D1,TRPM3 |
3.969e-05 | -10.13 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 20 | 16828 | 48 |
EBF1,PCDH9,ST18,PTPRG,TLL1,CACNA2D1,NRG3,TRPM3,CDH18,GRID2,UNC5C,CNTNAP2,NRG1,CNTN5,RELN,CNTN4,GRIK2,ANK2,RIMS1,ZNF385B |
3.986e-05 | -10.13 | scalp | COSMIC cancer mutations | scalp | 2110 | 17 | 16828 | 48 |
GRID2,LSAMP,SYT1,UNC5C,NRG1,NRXN3,RELN,CNTN4,STXBP5L,GRIK2,ANK2,KCNJ3,NFIA,ST18,RIMS2,EPHA5,NRXN1 |
4.100e-05 | -10.10 | Rim-like | interpro domains | IPR039032 | 4 | 2 | 18521 | 49 |
RIMS2,RIMS1 |
4.129e-05 | -10.09 | neuron projection development | biological process | GO:0031175 | 693 | 9 | 18204 | 45 |
CNTN4,CNTN5,APOE,RELN,EPHA5,NRXN3,NRXN1,UNC5C,CNTNAP2 |
4.286e-05 | -10.06 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 36 | 16828 | 48 |
FSTL5,EBF1,GRIA4,TLL1,TRPM3,NRG3,LINGO2,RALYL,NRG1,RUNX1T1,CNTNAP2,SLC35F3,STXBP5L,LRRTM4,KCNJ3,ZNF385D,ANK2,PTPRG,ST18,PCDH9,EPHA5,CHN2,CACNA2D1,SLC1A3,GRID2,CADPS2,KIF21A,NRXN3,UNC5C,LSAMP,SYT1,RELN,ZNF385B,APOE,GPC6,RIMS1 |
4.324e-05 | -10.05 | Lig_chan-Glu_bd | smart domains | SM00918 | 18 | 3 | 9717 | 38 |
GRID2,GRIK2,GRIA4 |
4.324e-05 | -10.05 | PBPe | smart domains | SM00079 | 18 | 3 | 9717 | 38 |
GRIA4,GRID2,GRIK2 |
4.349e-05 | -10.04 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 3 | 10285 | 30 |
SYT1,RIMS1,SLC1A3 |
4.453e-05 | -10.02 | Periplasmic binding protein-like II | gene3d domains | 3.40.190.10 | 23 | 3 | 14470 | 44 |
GRIK2,GRIA4,GRID2 |
4.636e-05 | -9.98 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 16 | 18204 | 45 |
ANK2,GRID2,NRG3,CNTN4,NRXN1,NFIA,NRXN3,EPHA5,APOE,NRG1,CNTN5,CDH18,SLC1A3,CNTNAP2,UNC5C,RELN |
4.702e-05 | -9.96 | Immunoglobulins | gene3d domains | 2.60.40.10 | 721 | 10 | 14470 | 44 |
NRG1,PTPRG,CNTN4,FSTL5,EPHA5,LINGO2,LSAMP,UNC5C,CNTN5,EBF1 |
4.755e-05 | -9.95 | face | COSMIC cancer mutations | face | 2139 | 17 | 16828 | 48 |
KIF21A,CDH18,LSAMP,CNTNAP2,STXBP5L,CNTN4,RELN,ZNF385B,GPC6,ZNF385D,ANK2,ST18,PCDH9,EPHA5,TRPM3,CACNA2D1,NRG3 |
4.931e-05 | -9.92 | regulation of presynaptic membrane potential | biological process | GO:0099505 | 29 | 3 | 18204 | 45 |
GRIK2,KCNJ3,GRIA4 |
4.931e-05 | -9.92 | postsynaptic membrane organization | biological process | GO:0001941 | 29 | 3 | 18204 | 45 |
NRXN1,APOE,RELN |
5.020e-05 | -9.90 | lipoprotein particle receptor binding | molecular function | GO:0070325 | 29 | 3 | 18094 | 45 |
SYT1,APOE,RELN |
5.799e-05 | -9.76 | brain development | biological process | GO:0007420 | 724 | 9 | 18204 | 45 |
PCDH9,CNTN5,NRG3,CNTN4,GRID2,CNTNAP2,UNC5C,EPHA5,RELN |
5.839e-05 | -9.75 | Laminin | gene3d domains | 2.10.25.10 | 226 | 6 | 14470 | 44 |
NRG1,TLL1,NRG3,CNTNAP2,NRXN3,NRXN1 |
6.019e-05 | -9.72 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 2 | 18094 | 45 |
NRXN1,NRXN3 |
6.609e-05 | -9.62 | cell body | cellular component | GO:0044297 | 556 | 8 | 19108 | 48 |
CNTNAP2,SLC1A3,EPHA5,UNC5C,GRIA4,APOE,NRXN1,GRIK2 |
6.794e-05 | -9.60 | cell communication | biological process | GO:0007154 | 5010 | 25 | 18204 | 45 |
RIMS2,EPHA5,NRXN1,GRID2,SYT1,DTNA,KCNJ3,RELN,SLC1A3,CNTNAP2,NRG1,GRIA4,APOE,RIMS1,ZNF385B,NFIA,CHN2,CACNA2D1,ANK2,NRG3,CADPS2,GRIK2,PTPRG,UNC5C,ST18 |
6.812e-05 | -9.59 | cell junction assembly | biological process | GO:0034329 | 285 | 6 | 18204 | 45 |
ANK2,GRID2,CNTN5,NRG3,CDH18,NRXN1 |
6.822e-05 | -9.59 | Znf_C2H2C_sf | interpro domains | IPR036060 | 5 | 2 | 18521 | 49 |
ST18,MYT1L |
7.045e-05 | -9.56 | axon development | biological process | GO:0061564 | 420 | 7 | 18204 | 45 |
EPHA5,NRXN3,RELN,UNC5C,NRXN1,CNTN4,CNTN5 |
7.070e-05 | -9.56 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 7 | 19108 | 48 |
CADPS2,GRID2,APOE,GRIK2,SYT1,GPC6,NRG3 |
7.087e-05 | -9.55 | EGF | smart domains | SM00181 | 184 | 6 | 9717 | 38 |
NRXN1,RELN,NRG1,NRXN3,CNTNAP2,TLL1 |
7.312e-05 | -9.52 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 45 |
NRXN1,SLC1A3,CNTNAP2 |
7.433e-05 | -9.51 | Ig_sub | interpro domains | IPR003599 | 394 | 7 | 18521 | 49 |
CNTN4,NRG1,LSAMP,UNC5C,CNTN5,FSTL5,LINGO2 |
7.769e-05 | -9.46 | VLDLR (very low density lipoprotein receptor) | protein interactions | 7436 | 33 | 3 | 19454 | 49 |
APOE,SYT1,RELN |
7.998e-05 | -9.43 | cell adhesion | biological process | GO:0007155 | 942 | 10 | 18204 | 45 |
GRID2,CNTN5,CNTN4,PCDH9,RELN,NRXN3,CDH18,LSAMP,NRXN1,CNTNAP2 |
8.698e-05 | -9.35 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 16 | 19108 | 48 |
DTNA,GRIK2,SYT1,GRIA4,CNTN4,UNC5C,KIF21A,GRID2,PCDH9,APOE,CNTN5,RELN,ANK2,EPHA5,SLC1A3,CNTNAP2 |
8.821e-05 | -9.34 | chondrosarcoma | COSMIC cancer mutations | chondrosarcoma | 1181 | 12 | 16828 | 48 |
CHN2,ST18,RIMS1,ZNF385B,LRRTM4,STXBP5L,CNTN4,LSAMP,UNC5C,CNTNAP2,CDH18,GRID2 |
8.907e-05 | -9.33 | positive regulation of inhibitory postsynaptic potential | biological process | GO:0097151 | 6 | 2 | 18204 | 45 |
RIMS1,RIMS2 |
8.907e-05 | -9.33 | vocal learning | biological process | GO:0042297 | 6 | 2 | 18204 | 45 |
CNTNAP2,NRXN1 |
8.907e-05 | -9.33 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 2 | 18204 | 45 |
RELN,NRXN1 |
8.907e-05 | -9.33 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 2 | 18204 | 45 |
NRG1,NRG3 |
8.907e-05 | -9.33 | imitative learning | biological process | GO:0098596 | 6 | 2 | 18204 | 45 |
NRXN1,CNTNAP2 |
9.194e-05 | -9.29 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 34 | 16828 | 48 |
RELN,RIMS1,GPC6,ZNF385B,APOE,CADPS2,KIF21A,GRID2,UNC5C,LSAMP,SYT1,NRXN3,EPHA5,SLC1A3,CACNA2D1,CHN2,PCDH9,PTPRG,ST18,LRRTM4,STXBP5L,ZNF385D,ANK2,KCNJ3,CNTNAP2,SLC35F3,RALYL,RUNX1T1,NRG1,NRG3,EBF1,FSTL5,GRIA4,TLL1 |
9.363e-05 | -9.28 | functioning | COSMIC cancer mutations | functioning | 1803 | 15 | 16828 | 48 |
KCNJ3,RIMS1,GRIK2,ANK2,STXBP5L,RUNX1T1,NRXN3,UNC5C,CADPS2,CDH18,TRPM3,NRG3,MYT1L,PTPRG,PCDH9 |
9.363e-05 | -9.28 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 15 | 16828 | 48 |
NRG3,MYT1L,TRPM3,PCDH9,PTPRG,STXBP5L,ANK2,GRIK2,RIMS1,KCNJ3,CDH18,CADPS2,UNC5C,NRXN3,RUNX1T1 |
9.688e-05 | -9.24 | head development | biological process | GO:0060322 | 774 | 9 | 18204 | 45 |
RELN,EPHA5,UNC5C,CNTNAP2,GRID2,CNTN5,NRG3,CNTN4,PCDH9 |
9.734e-05 | -9.24 | signal release | biological process | GO:0023061 | 188 | 5 | 18204 | 45 |
NRXN1,CADPS2,RIMS2,SYT1,RIMS1 |
1.017e-04 | -9.19 | Syndecan | pfam domains | PF01034 | 6 | 2 | 17795 | 47 |
NRXN1,NRXN3 |
1.017e-04 | -9.19 | zf-C2HC | pfam domains | PF01530 | 6 | 2 | 17795 | 47 |
ST18,MYT1L |
1.022e-04 | -9.19 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 2 | 18521 | 49 |
NRXN3,NRXN1 |
1.037e-04 | -9.17 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 6 | 16828 | 48 |
FSTL5,CNTN5,RUNX1T1,APOE,GRIA4,CNTNAP2 |
1.078e-04 | -9.14 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 4 | 19454 | 49 |
SYT1,LSAMP,ANK2,CACNA2D1 |
1.138e-04 | -9.08 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 47 | 16828 | 48 |
PCDH9,ST18,NFIA,NPAS3,NRXN1,SLC1A3,CHN2,CDH18,CADPS2,KIF21A,GRID2,SYT1,RELN,RIMS1,ZNF385B,APOE,RIMS2,NRG3,TRPM3,SLC35F3,RALYL,RUNX1T1,CST3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,GLCE,PTPRG,EPHA5,CACNA2D1,UNC5C,LSAMP,NRXN3,DTNA,CNTN4,GPC6,FSTL5,EBF1,GRIA4,TLL1,MYT1L,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2 |
1.160e-04 | -9.06 | Laminin_G_2 | pfam domains | PF02210 | 36 | 3 | 17795 | 47 |
NRXN3,NRXN1,CNTNAP2 |
1.245e-04 | -8.99 | observational learning | biological process | GO:0098597 | 7 | 2 | 18204 | 45 |
NRXN1,CNTNAP2 |
1.245e-04 | -8.99 | modulation of inhibitory postsynaptic potential | biological process | GO:0098828 | 7 | 2 | 18204 | 45 |
RIMS2,RIMS1 |
1.245e-04 | -8.99 | spontaneous neurotransmitter secretion | biological process | GO:0061669 | 7 | 2 | 18204 | 45 |
SYT1,RIMS2 |
1.260e-04 | -8.98 | ANF_receptor | pfam domains | PF01094 | 37 | 3 | 17795 | 47 |
GRIK2,GRID2,GRIA4 |
1.269e-04 | -8.97 | ANF_lig-bd_rcpt | interpro domains | IPR001828 | 37 | 3 | 18521 | 49 |
GRID2,GRIA4,GRIK2 |
1.308e-04 | -8.94 | regulation of heart rate by cardiac conduction | biological process | GO:0086091 | 40 | 3 | 18204 | 45 |
ANK2,CACNA2D1,KCNJ3 |
1.319e-04 | -8.93 | Ig-like_dom | interpro domains | IPR007110 | 432 | 7 | 18521 | 49 |
UNC5C,LSAMP,NRG1,CNTN4,LINGO2,FSTL5,CNTN5 |
1.345e-04 | -8.91 | - | gene3d domains | 4.10.320.30 | 6 | 2 | 14470 | 44 |
MYT1L,ST18 |
1.420e-04 | -8.86 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 13 | 16828 | 48 |
GRIA4,EPHA5,NRXN1,MYT1L,CHN2,TRPM3,KIF21A,CNTNAP2,LSAMP,RELN,STXBP5L,GRIK2,RIMS1 |
1.428e-04 | -8.85 | Znf_C2H2C | interpro domains | IPR002515 | 7 | 2 | 18521 | 49 |
MYT1L,ST18 |
1.438e-04 | -8.85 | membrane | cellular component | GO:0016020 | 9220 | 36 | 19108 | 48 |
CST3,DTNA,CDH18,GRIK2,LRRTM4,RIMS2,CHN2,CNTN4,STXBP5L,GRIA4,GRID2,PCDH9,NRXN1,LSAMP,CNTNAP2,CACNA2D1,EPHA5,ANK2,SLC1A3,RELN,CNTN5,TRPM3,KCNJ3,SYT1,NRG1,LINGO2,UNC5C,GPC6,NRG3,CADPS2,GLCE,SLC35F3,RIMS1,NRXN3,PTPRG,APOE |
1.483e-04 | -8.82 | ionotropic glutamate receptor complex | cellular component | GO:0008328 | 41 | 3 | 19108 | 48 |
GRIK2,GRIA4,GRID2 |
1.487e-04 | -8.81 | Peripla_BP_I | interpro domains | IPR028082 | 39 | 3 | 18521 | 49 |
GRIA4,GRID2,GRIK2 |
1.520e-04 | -8.79 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 31 | 16828 | 48 |
TRPM3,NRG3,MYT1L,FSTL5,TLL1,GRIA4,STXBP5L,LRRTM4,CNTN5,KCNJ3,ANK2,LINGO2,NRG1,CNTNAP2,NRXN1,EPHA5,CHN2,CACNA2D1,NFIA,PTPRG,ST18,GLCE,RELN,ZNF385B,GPC6,RIMS1,GRID2,KIF21A,CADPS2,CDH18,NRXN3 |
1.520e-04 | -8.79 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 31 | 16828 | 48 |
CADPS2,CDH18,KIF21A,GRID2,NRXN3,RELN,GPC6,RIMS1,ZNF385B,GLCE,ST18,PTPRG,NFIA,EPHA5,NRXN1,CACNA2D1,CHN2,LINGO2,CNTNAP2,NRG1,CNTN5,LRRTM4,STXBP5L,ANK2,KCNJ3,FSTL5,GRIA4,TLL1,MYT1L,NRG3,TRPM3 |
1.554e-04 | -8.77 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 4 | 18204 | 45 |
CNTNAP2,NRXN1,LINGO2,GRID2 |
1.582e-04 | -8.75 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 5 | 19454 | 49 |
NRXN1,NRXN3,CNTNAP2,DTNA,GRIK2 |
1.626e-04 | -8.72 | regulation of synaptic vesicle exocytosis | biological process | GO:2000300 | 43 | 3 | 18204 | 45 |
RIMS2,SYT1,RIMS1 |
1.657e-04 | -8.71 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 2 | 18204 | 45 |
NRG1,NRG3 |
1.683e-04 | -8.69 | metal ion binding | molecular function | GO:0046872 | 4239 | 22 | 18094 | 45 |
NRXN1,CACNA2D1,RUNX1T1,APOE,FSTL5,DTNA,RIMS2,PCDH9,RELN,SLC1A3,ZNF385D,ZNF385B,EBF1,RIMS1,CHN2,MYT1L,GLCE,TLL1,NRXN3,CADPS2,ST18,SYT1 |
1.714e-04 | -8.67 | cytoskeleton of presynaptic active zone | cellular component | GO:0048788 | 8 | 2 | 19108 | 48 |
RIMS2,RIMS1 |
1.728e-04 | -8.66 | Laminin_G | interpro domains | IPR001791 | 41 | 3 | 18521 | 49 |
CNTNAP2,NRXN3,NRXN1 |
1.742e-04 | -8.66 | synaptic transmission, glutamatergic | biological process | GO:0035249 | 44 | 3 | 18204 | 45 |
GRIA4,GRID2,GRIK2 |
1.758e-04 | -8.65 | cell differentiation | biological process | GO:0030154 | 3645 | 20 | 18204 | 45 |
CNTNAP2,TLL1,UNC5C,SLC1A3,RELN,APOE,NRG1,CNTN5,NRXN1,NFIA,RIMS1,NRXN3,EPHA5,RIMS2,FSTL5,MYT1L,SYT1,CNTN4,GRID2,ANK2 |
1.760e-04 | -8.65 | multicellular organism development | biological process | GO:0007275 | 3957 | 21 | 18204 | 45 |
CNTN5,PCDH9,APOE,NRG1,RELN,CNTNAP2,UNC5C,TLL1,CDH18,SLC1A3,LSAMP,FSTL5,MYT1L,CNTN4,NRG3,ANK2,GRID2,NRXN3,EPHA5,NFIA,NRXN1 |
1.779e-04 | -8.63 | cellular developmental process | biological process | GO:0048869 | 3648 | 20 | 18204 | 45 |
CNTN5,NRG1,APOE,RELN,UNC5C,TLL1,CNTNAP2,SLC1A3,CNTN4,SYT1,FSTL5,MYT1L,GRID2,ANK2,RIMS1,EPHA5,NRXN3,RIMS2,NFIA,NRXN1 |
1.831e-04 | -8.61 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 3 | 5310 | 12 |
SLC1A3,SYT1,RIMS1 |
1.863e-04 | -8.59 | cardiac muscle cell action potential involved in contraction | biological process | GO:0086002 | 45 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
1.863e-04 | -8.59 | cell communication involved in cardiac conduction | biological process | GO:0086065 | 45 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
1.863e-04 | -8.59 | glutamate receptor signaling pathway | biological process | GO:0007215 | 45 | 3 | 18204 | 45 |
GRID2,GRIK2,GRIA4 |
1.907e-04 | -8.56 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 13 | 16828 | 48 |
ST18,TLL1,PCDH9,GLCE,NPAS3,NRG3,LINGO2,NRXN3,DTNA,CNTNAP2,ZNF385B,ANK2,GPC6 |
1.924e-04 | -8.56 | signaling | biological process | GO:0023052 | 4968 | 24 | 18204 | 45 |
ST18,GRIK2,CADPS2,UNC5C,PTPRG,NRG3,ANK2,CACNA2D1,RIMS1,NFIA,CHN2,ZNF385B,APOE,NRG1,GRIA4,RELN,SLC1A3,SYT1,GRID2,KCNJ3,DTNA,EPHA5,RIMS2,NRXN1 |
1.989e-04 | -8.52 | negative chemotaxis | biological process | GO:0050919 | 46 | 3 | 18204 | 45 |
NRG3,NRG1,UNC5C |
1.994e-04 | -8.52 | LAM_G_DOMAIN | prosite domains | PS50025 | 35 | 3 | 12186 | 40 |
NRXN3,NRXN1,CNTNAP2 |
2.036e-04 | -8.50 | synapse assembly | biological process | GO:0007416 | 118 | 4 | 18204 | 45 |
GRID2,CNTN5,NRG3,NRXN1 |
2.053e-04 | -8.49 | large_intestine-colon | COSMIC cancer mutations | large_intestine-colon | 1291 | 12 | 16828 | 48 |
PTPRG,MYT1L,EPHA5,RIMS2,NRXN3,CNTNAP2,KIF21A,RIMS1,ZNF385D,CNTN4,RELN,CNTN5 |
2.093e-04 | -8.47 | neurotransmitter receptor complex | cellular component | GO:0098878 | 46 | 3 | 19108 | 48 |
GRID2,GRIA4,GRIK2 |
2.114e-04 | -8.46 | monoatomic ion channel complex | cellular component | GO:0034702 | 344 | 6 | 19108 | 48 |
GRIA4,KCNJ3,GRIK2,CACNA2D1,GRID2,CNTNAP2 |
2.121e-04 | -8.46 | regulation of neuron migration | biological process | GO:2001222 | 47 | 3 | 18204 | 45 |
RELN,NRG3,UNC5C |
2.127e-04 | -8.46 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 2 | 18204 | 45 |
RELN,NRXN1 |
2.127e-04 | -8.46 | spontaneous synaptic transmission | biological process | GO:0098814 | 9 | 2 | 18204 | 45 |
RIMS2,SYT1 |
2.171e-04 | -8.43 | striated muscle contraction | biological process | GO:0006941 | 120 | 4 | 18204 | 45 |
KCNJ3,DTNA,ANK2,CACNA2D1 |
2.183e-04 | -8.43 | ZF_CCHHC | prosite domains | PS51802 | 7 | 2 | 12186 | 40 |
ST18,MYT1L |
2.252e-04 | -8.40 | GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) | protein interactions | 2890 | 47 | 3 | 19454 | 49 |
GRIK2,GRID2,GRIA4 |
2.378e-04 | -8.34 | system process | biological process | GO:0003008 | 2015 | 14 | 18204 | 45 |
APOE,CNTN5,SLC1A3,CNTNAP2,RELN,GRIK2,DTNA,KCNJ3,CACNA2D1,ANK2,GRID2,NRXN1,RIMS1,NRXN3 |
2.430e-04 | -8.32 | cation binding | molecular function | GO:0043169 | 4341 | 22 | 18094 | 45 |
GLCE,MYT1L,SYT1,ST18,CADPS2,TLL1,NRXN3,SLC1A3,ZNF385B,ZNF385D,RELN,CHN2,RIMS1,EBF1,RIMS2,FSTL5,APOE,DTNA,PCDH9,NRXN1,CACNA2D1,RUNX1T1 |
2.462e-04 | -8.31 | action potential | biological process | GO:0001508 | 124 | 4 | 18204 | 45 |
KCNJ3,GRIK2,ANK2,CACNA2D1 |
2.596e-04 | -8.26 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 40 | 16828 | 48 |
EBF1,FSTL5,GRIA4,TLL1,RIMS2,MYT1L,NRG3,TRPM3,LINGO2,CNTNAP2,SLC35F3,NRG1,RUNX1T1,LRRTM4,CST3,CNTN5,STXBP5L,ANK2,GRIK2,KCNJ3,PCDH9,PTPRG,NFIA,ST18,EPHA5,NPAS3,NRXN1,CACNA2D1,CHN2,CDH18,CADPS2,KIF21A,GRID2,SYT1,NRXN3,DTNA,RELN,CNTN4,RIMS1,ZNF385B |
2.614e-04 | -8.25 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 7 | 18521 | 49 |
CNTN4,CNTN5,FSTL5,LINGO2,UNC5C,NRG1,LSAMP |
2.635e-04 | -8.24 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 40 | 16828 | 48 |
GRID2,CADPS2,CDH18,KIF21A,NRXN3,DTNA,SYT1,CNTN4,RELN,ZNF385B,RIMS1,ST18,PTPRG,NFIA,PCDH9,NRXN1,EPHA5,NPAS3,CHN2,CACNA2D1,LINGO2,RUNX1T1,NRG1,SLC35F3,CNTNAP2,STXBP5L,CST3,LRRTM4,CNTN5,KCNJ3,ANK2,GRIK2,FSTL5,EBF1,GRIA4,TLL1,RIMS2,TRPM3,NRG3,MYT1L |
2.655e-04 | -8.23 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 2 | 18204 | 45 |
NRXN1,CNTNAP2 |
2.705e-04 | -8.22 | cardiac muscle cell contraction | biological process | GO:0086003 | 51 | 3 | 18204 | 45 |
ANK2,CACNA2D1,KCNJ3 |
2.906e-04 | -8.14 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 10 | 16828 | 48 |
EPHA5,RIMS2,ANK2,CACNA2D1,MYT1L,TRPM3,CADPS2,NRXN3,GRIA4,RUNX1T1 |
2.906e-04 | -8.14 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 10 | 16828 | 48 |
CADPS2,RUNX1T1,NRXN3,GRIA4,EPHA5,RIMS2,TRPM3,MYT1L,CACNA2D1,ANK2 |
3.015e-04 | -8.11 | T-tubule | cellular component | GO:0030315 | 52 | 3 | 19108 | 48 |
CACNA2D1,ANK2,KCNJ3 |
3.033e-04 | -8.10 | biological process involved in intraspecies interaction between organisms | biological process | GO:0051703 | 53 | 3 | 18204 | 45 |
NRXN3,NRXN1,CNTNAP2 |
3.033e-04 | -8.10 | social behavior | biological process | GO:0035176 | 53 | 3 | 18204 | 45 |
NRXN3,NRXN1,CNTNAP2 |
3.087e-04 | -8.08 | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | GO:1904315 | 53 | 3 | 18094 | 45 |
GRIA4,GRID2,GRIK2 |
3.095e-04 | -8.08 | exocytosis | biological process | GO:0006887 | 241 | 5 | 18204 | 45 |
RIMS2,STXBP5L,CADPS2,RIMS1,SYT1 |
3.219e-04 | -8.04 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 48 |
CACNA2D1,EPHA5,PTPRG,GLCE,GPC6,CNTN4,DTNA,NRXN3,LSAMP,UNC5C,MYT1L,TLL1,GRIA4,EBF1,FSTL5,ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,CHN2,SLC1A3,NRXN1,NPAS3,ST18,NFIA,PCDH9,APOE,ZNF385B,RIMS1,RELN,SYT1,GRID2,KIF21A,CADPS2,CDH18,TRPM3,NRG3,RIMS2,KCNJ3,ZNF385D,STXBP5L,LRRTM4,CST3,RUNX1T1,NRG1,RALYL,SLC35F3 |
3.342e-04 | -8.00 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 16 | 16828 | 48 |
MYT1L,NRG3,TRPM3,PCDH9,PTPRG,GRIK2,ANK2,RIMS1,ZNF385B,KCNJ3,STXBP5L,UNC5C,NRXN3,RUNX1T1,CADPS2,CDH18 |
3.350e-04 | -8.00 | presynaptic cytoskeleton | cellular component | GO:0099569 | 11 | 2 | 19108 | 48 |
RIMS2,RIMS1 |
3.352e-04 | -8.00 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 48 |
RIMS2,TRPM3,NRG3,RUNX1T1,NRG1,RALYL,SLC35F3,STXBP5L,CST3,LRRTM4,KCNJ3,ZNF385D,ST18,NFIA,PCDH9,NRXN1,NPAS3,CHN2,SLC1A3,GRID2,KIF21A,CDH18,CADPS2,SYT1,RELN,APOE,ZNF385B,RIMS1,FSTL5,EBF1,TLL1,GRIA4,MYT1L,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2,PTPRG,GLCE,EPHA5,CACNA2D1,DTNA,NRXN3,LSAMP,UNC5C,CNTN4,GPC6 |
3.369e-04 | -8.00 | RIMS3 (regulating synaptic membrane exocytosis 3) | protein interactions | 9783 | 11 | 2 | 19454 | 49 |
RIMS1,RIMS2 |
3.401e-04 | -7.99 | regulation of synapse organization | biological process | GO:0050807 | 246 | 5 | 18204 | 45 |
LINGO2,RELN,GRID2,NRXN1,APOE |
3.445e-04 | -7.97 | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | molecular function | GO:0099529 | 55 | 3 | 18094 | 45 |
GRIK2,GRID2,GRIA4 |
3.545e-04 | -7.94 | cell-cell adhesion | biological process | GO:0098609 | 546 | 7 | 18204 | 45 |
NRXN3,CNTN5,CNTN4,GRID2,PCDH9,NRXN1,CDH18 |
3.570e-04 | -7.94 | cardiac muscle cell action potential | biological process | GO:0086001 | 56 | 3 | 18204 | 45 |
KCNJ3,ANK2,CACNA2D1 |
3.571e-04 | -7.94 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 4 | 7161 | 22 |
GRIK2,KCNJ3,GRIA4,SLC1A3 |
3.571e-04 | -7.94 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 4 | 7161 | 22 |
GRIK2,KCNJ3,SLC1A3,GRIA4 |
3.582e-04 | -7.93 | transmembrane transporter binding | molecular function | GO:0044325 | 136 | 4 | 18094 | 45 |
ANK2,RIMS1,RIMS2,CNTNAP2 |
3.648e-04 | -7.92 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 2 | 10285 | 30 |
NRG1,NRG3 |
3.699e-04 | -7.90 | ZU5 | pfam domains | PF00791 | 11 | 2 | 17795 | 47 |
ANK2,UNC5C |
3.724e-04 | -7.90 | system development | biological process | GO:0048731 | 3533 | 19 | 18204 | 45 |
MYT1L,CNTN4,NRG3,ANK2,GRID2,EPHA5,NRXN3,NFIA,NRXN1,CNTN5,PCDH9,APOE,NRG1,RELN,CNTNAP2,TLL1,UNC5C,LSAMP,SLC1A3 |
3.798e-04 | -7.88 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 5 | 18204 | 45 |
GRID2,RELN,LINGO2,APOE,NRXN1 |
3.837e-04 | -7.87 | regulation of cell communication | biological process | GO:0010646 | 3541 | 19 | 18204 | 45 |
GRIK2,RELN,SLC1A3,GLCE,GPC6,APOE,NRG1,GRIA4,EPHA5,RIMS1,RIMS2,CHN2,NRXN1,SYT1,FSTL5,CNTN4,NRG3,ANK2,GRID2 |
3.882e-04 | -7.85 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 2 | 18204 | 45 |
RELN,APOE |
3.957e-04 | -7.83 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 23 | 16828 | 48 |
NFIA,PTPRG,ST18,NPAS3,SLC1A3,GRID2,KIF21A,CADPS2,CDH18,RELN,APOE,RIMS1,EBF1,TLL1,RIMS2,TRPM3,MYT1L,NRG1,CNTNAP2,STXBP5L,LRRTM4,GRIK2,ANK2 |
4.019e-04 | -7.82 | Effects of Botulinum toxin | Pathway Interaction DB | botulinumtoxinpathway | 9 | 2 | 2226 | 8 |
SYT1,RIMS1 |
4.239e-04 | -7.77 | transmitter-gated monoatomic ion channel activity | molecular function | GO:0022824 | 59 | 3 | 18094 | 45 |
GRID2,GRIA4,GRIK2 |
4.239e-04 | -7.77 | transmitter-gated channel activity | molecular function | GO:0022835 | 59 | 3 | 18094 | 45 |
GRIK2,GRIA4,GRID2 |
4.244e-04 | -7.76 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 3 | 10285 | 30 |
SYT1,RIMS1,SLC1A3 |
4.349e-04 | -7.74 | synaptic vesicle cycle | biological process | GO:0099504 | 144 | 4 | 18204 | 45 |
CADPS2,RIMS2,SYT1,RIMS1 |
4.349e-04 | -7.74 | regulated exocytosis | biological process | GO:0045055 | 144 | 4 | 18204 | 45 |
SYT1,RIMS1,CADPS2,RIMS2 |
4.407e-04 | -7.73 | IG_LIKE | prosite domains | PS50835 | 430 | 7 | 12186 | 40 |
NRG1,CNTN4,UNC5C,LINGO2,CNTN5,LSAMP,FSTL5 |
4.413e-04 | -7.73 | sarcolemma | cellular component | GO:0042383 | 142 | 4 | 19108 | 48 |
KCNJ3,DTNA,CACNA2D1,ANK2 |
4.450e-04 | -7.72 | Rab_BD | interpro domains | IPR010911 | 12 | 2 | 18521 | 49 |
RIMS1,RIMS2 |
4.512e-04 | -7.70 | fn3 | pfam domains | PF00041 | 136 | 4 | 17795 | 47 |
EPHA5,CNTN5,PTPRG,CNTN4 |
4.581e-04 | -7.69 | prepulse inhibition | biological process | GO:0060134 | 13 | 2 | 18204 | 45 |
CNTNAP2,GRID2 |
4.653e-04 | -7.67 | - | gene3d domains | 3.40.50.2300 | 50 | 3 | 14470 | 44 |
GRIK2,GRID2,GRIA4 |
4.934e-04 | -7.61 | LamG | smart domains | SM00282 | 40 | 3 | 9717 | 38 |
NRXN1,CNTNAP2,NRXN3 |
4.948e-04 | -7.61 | neuromuscular process | biological process | GO:0050905 | 149 | 4 | 18204 | 45 |
CNTNAP2,SLC1A3,NRXN1,GRID2 |
5.172e-04 | -7.57 | Ig_3 | pfam domains | PF13927 | 141 | 4 | 17795 | 47 |
LSAMP,CNTN5,FSTL5,CNTN4 |
5.250e-04 | -7.55 | ZU5_dom | interpro domains | IPR000906 | 13 | 2 | 18521 | 49 |
ANK2,UNC5C |
5.269e-04 | -7.55 | ZU5 | smart domains | SM00218 | 9 | 2 | 9717 | 38 |
ANK2,UNC5C |
5.271e-04 | -7.55 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 23 | 16828 | 48 |
RELN,RIMS1,APOE,CDH18,CADPS2,KIF21A,GRID2,NPAS3,SLC1A3,ST18,PTPRG,NFIA,LRRTM4,STXBP5L,ANK2,GRIK2,CNTNAP2,NRG1,RIMS2,MYT1L,TRPM3,EBF1,TLL1 |
5.336e-04 | -7.54 | atrial cardiac muscle cell to AV node cell signaling | biological process | GO:0086026 | 14 | 2 | 18204 | 45 |
KCNJ3,ANK2 |
5.336e-04 | -7.54 | atrial cardiac muscle cell action potential | biological process | GO:0086014 | 14 | 2 | 18204 | 45 |
ANK2,KCNJ3 |
5.434e-04 | -7.52 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 15 | 18204 | 45 |
GLCE,APOE,NRG1,RELN,PTPRG,CNTNAP2,GRID2,CST3,SYT1,NRG3,RIMS2,EPHA5,LINGO2,RIMS1,NRXN1 |
5.450e-04 | -7.51 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 30 | 16828 | 48 |
GRID2,CDH18,KIF21A,UNC5C,SYT1,RELN,ZNF385B,APOE,RIMS1,PTPRG,GLCE,EPHA5,NPAS3,SLC1A3,LINGO2,RALYL,RUNX1T1,CNTNAP2,STXBP5L,LRRTM4,CNTN5,GRIK2,ANK2,ZNF385D,FSTL5,GRIA4,TLL1,TRPM3,MYT1L,NRG3 |
5.513e-04 | -7.50 | C2_dom | interpro domains | IPR000008 | 143 | 4 | 18521 | 49 |
RIMS1,CADPS2,SYT1,RIMS2 |
5.535e-04 | -7.50 | secretion by cell | biological process | GO:0032940 | 420 | 6 | 18204 | 45 |
NRXN1,RIMS2,CADPS2,STXBP5L,RIMS1,SYT1 |
5.539e-04 | -7.50 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 3 | 18204 | 45 |
NRXN1,LINGO2,GRID2 |
5.547e-04 | -7.50 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 2 | 19454 | 49 |
SYT1,NRXN1 |
5.603e-04 | -7.49 | learning | biological process | GO:0007612 | 154 | 4 | 18204 | 45 |
CNTNAP2,NRXN1,NRXN3,RELN |
5.603e-04 | -7.49 | vesicle-mediated transport in synapse | biological process | GO:0099003 | 154 | 4 | 18204 | 45 |
RIMS1,SYT1,RIMS2,CADPS2 |
5.749e-04 | -7.46 | learning or memory | biological process | GO:0007611 | 276 | 5 | 18204 | 45 |
APOE,NRXN1,CNTNAP2,RELN,NRXN3 |
5.817e-04 | -7.45 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 9 | 16828 | 48 |
CACNA2D1,ANK2,RELN,RIMS2,STXBP5L,PCDH9,ST18,NFIA,GRID2 |
5.825e-04 | -7.45 | excitatory synapse | cellular component | GO:0060076 | 65 | 3 | 19108 | 48 |
KCNJ3,SYT1,GRID2 |
5.887e-04 | -7.44 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 22 | 16828 | 48 |
STXBP5L,RELN,CNTN5,LRRTM4,RIMS1,GRIK2,GRID2,KIF21A,LINGO2,CDH18,CADPS2,CNTNAP2,SLC35F3,NPAS3,EPHA5,RIMS2,CHN2,MYT1L,ST18,NFIA,PTPRG,PCDH9 |
5.909e-04 | -7.43 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 22 | 16828 | 48 |
STXBP5L,LRRTM4,CNTN5,GRIK2,LINGO2,SLC35F3,CNTNAP2,RIMS2,MYT1L,RELN,RIMS1,GRID2,KIF21A,CADPS2,CDH18,NPAS3,EPHA5,CHN2,PTPRG,ST18,NFIA,PCDH9 |
6.084e-04 | -7.40 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 17 | 16828 | 48 |
NRXN3,RUNX1T1,UNC5C,CADPS2,CDH18,KCNJ3,ZNF385B,GRIK2,ANK2,RIMS1,STXBP5L,CNTN5,PTPRG,PCDH9,TRPM3,MYT1L,NRG3 |
6.147e-04 | -7.39 | atrial cardiac muscle cell to AV node cell communication | biological process | GO:0086066 | 15 | 2 | 18204 | 45 |
KCNJ3,ANK2 |
6.225e-04 | -7.38 | EGF_2 | prosite domains | PS01186 | 213 | 5 | 12186 | 40 |
NRG3,RELN,TLL1,EPHA5,NRG1 |
6.267e-04 | -7.38 | central nervous system development | biological process | GO:0007417 | 995 | 9 | 18204 | 45 |
PCDH9,GRID2,CNTN4,CNTN5,NRG3,UNC5C,CNTNAP2,RELN,EPHA5 |
6.289e-04 | -7.37 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 2 | 10285 | 30 |
NRG3,NRG1 |
6.544e-04 | -7.33 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 4 | 16828 | 48 |
FSTL5,NRG3,CNTNAP2,NRG1 |
6.545e-04 | -7.33 | regulation of secretion | biological process | GO:0051046 | 605 | 7 | 18204 | 45 |
RIMS2,CADPS2,EPHA5,RIMS1,SYT1,NRG1,APOE |
6.669e-04 | -7.31 | postsynaptic membrane | cellular component | GO:0045211 | 280 | 5 | 19108 | 48 |
GRIK2,GRIA4,LRRTM4,GRID2,ANK2 |
6.693e-04 | -7.31 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 22 | 16828 | 48 |
RELN,RIMS1,CADPS2,CDH18,KIF21A,GRID2,EPHA5,NPAS3,CHN2,PCDH9,ST18,PTPRG,NFIA,LRRTM4,CNTN5,STXBP5L,GRIK2,LINGO2,SLC35F3,CNTNAP2,RIMS2,MYT1L |
6.791e-04 | -7.29 | RABBD | prosite domains | PS50916 | 12 | 2 | 12186 | 40 |
RIMS1,RIMS2 |
6.882e-04 | -7.28 | cardiac conduction | biological process | GO:0061337 | 70 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
6.900e-04 | -7.28 | - | gene3d domains | 2.60.220.30 | 13 | 2 | 14470 | 44 |
ANK2,UNC5C |
6.985e-04 | -7.27 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 17 | 16828 | 48 |
CNTNAP2,NRG1,CDH18,CADPS2,KIF21A,ANK2,RIMS1,APOE,LRRTM4,RELN,STXBP5L,NFIA,EBF1,MYT1L,TRPM3,RIMS2,NPAS3 |
6.985e-04 | -7.27 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 17 | 16828 | 48 |
RIMS1,ANK2,APOE,RELN,LRRTM4,STXBP5L,CNTNAP2,NRG1,KIF21A,CDH18,CADPS2,MYT1L,TRPM3,NPAS3,RIMS2,NFIA,EBF1 |
6.993e-04 | -7.27 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 7 | 19108 | 48 |
GRID2,CNTNAP2,CACNA2D1,KCNJ3,CDH18,GRIK2,GRIA4 |
7.004e-04 | -7.26 | postsynaptic neurotransmitter receptor activity | molecular function | GO:0098960 | 70 | 3 | 18094 | 45 |
GRIK2,GRIA4,GRID2 |
7.014e-04 | -7.26 | positive regulation of CREB transcription factor activity | biological process | GO:0032793 | 16 | 2 | 18204 | 45 |
EPHA5,RELN |
7.099e-04 | -7.25 | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099507 | 16 | 2 | 18094 | 45 |
GRIA4,GRIK2 |
7.099e-04 | -7.25 | glutamate-gated receptor activity | molecular function | GO:0004970 | 16 | 2 | 18094 | 45 |
GRIK2,GRIA4 |
7.251e-04 | -7.23 | IG | smart domains | SM00409 | 394 | 7 | 9717 | 38 |
FSTL5,CNTN5,UNC5C,NRG1,LSAMP,CNTN4,LINGO2 |
7.259e-04 | -7.23 | transmembrane transporter complex | cellular component | GO:1902495 | 434 | 6 | 19108 | 48 |
GRIA4,GRIK2,KCNJ3,CACNA2D1,CNTNAP2,GRID2 |
7.292e-04 | -7.22 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 2 | 19454 | 49 |
NRXN1,SYT1 |
7.324e-04 | -7.22 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 2 | 10285 | 30 |
NRG1,NRG3 |
7.377e-04 | -7.21 | monoatomic ion channel activity | molecular function | GO:0005216 | 441 | 6 | 18094 | 45 |
GRID2,CACNA2D1,TRPM3,GRIK2,GRIA4,KCNJ3 |
7.465e-04 | -7.20 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 9 | 16828 | 48 |
CACNA2D1,ANK2,RELN,RIMS2,STXBP5L,PCDH9,ST18,NFIA,GRID2 |
7.492e-04 | -7.20 | behavior | biological process | GO:0007610 | 619 | 7 | 18204 | 45 |
APOE,RELN,GRIK2,NRXN3,SLC1A3,NRXN1,CNTNAP2 |
7.504e-04 | -7.19 | DLG4 (discs large MAGUK scaffold protein 4) | protein interactions | 1742 | 163 | 4 | 19454 | 49 |
GRIK2,PTPRG,NRG1,CNTNAP2 |
7.604e-04 | -7.18 | extracellular ligand-gated monoatomic ion channel activity | molecular function | GO:0005230 | 72 | 3 | 18094 | 45 |
GRID2,GRIA4,GRIK2 |
7.937e-04 | -7.14 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
8.009e-04 | -7.13 | ZU5 | prosite domains | PS51145 | 13 | 2 | 12186 | 40 |
UNC5C,ANK2 |
8.157e-04 | -7.11 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 9 | 16828 | 48 |
RUNX1T1,ST18,PTPRG,NPAS3,RELN,RIMS1,CACNA2D1,MYT1L,ANK2 |
8.204e-04 | -7.11 | presynaptic active zone cytoplasmic component | cellular component | GO:0098831 | 17 | 2 | 19108 | 48 |
RIMS1,RIMS2 |
8.295e-04 | -7.09 | regulation of exocytosis | biological process | GO:0017157 | 171 | 4 | 18204 | 45 |
CADPS2,RIMS2,SYT1,RIMS1 |
8.365e-04 | -7.09 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | 393 | 6 | 16828 | 48 |
STXBP5L,RELN,LRRTM4,CADPS2,DTNA,GRIA4 |
8.365e-04 | -7.09 | essential_thrombocythaemia | COSMIC cancer mutations | essential_thrombocythaemia | 393 | 6 | 16828 | 48 |
DTNA,GRIA4,STXBP5L,RELN,LRRTM4,CADPS2 |
8.435e-04 | -7.08 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 2 | 10285 | 30 |
NRG3,NRG1 |
8.737e-04 | -7.04 | multicellular organismal process | biological process | GO:0032501 | 6177 | 26 | 18204 | 45 |
PCDH9,CDH18,UNC5C,GRIK2,ANK2,CACNA2D1,NRG3,NFIA,RIMS1,APOE,NRG1,CNTN5,SLC1A3,LSAMP,CNTNAP2,TLL1,RELN,DTNA,KCNJ3,GRID2,FSTL5,MYT1L,CNTN4,NRXN1,NRXN3,EPHA5 |
8.748e-04 | -7.04 | actin-mediated cell contraction | biological process | GO:0070252 | 76 | 3 | 18204 | 45 |
KCNJ3,CACNA2D1,ANK2 |
8.972e-04 | -7.02 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 9 | 16828 | 48 |
CACNA2D1,RIMS1,MYT1L,ANK2,RELN,NPAS3,RUNX1T1,ST18,PTPRG |
9.022e-04 | -7.01 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 2 | 18094 | 45 |
NRG3,NRG1 |
9.267e-04 | -6.98 | GRIK5 (glutamate ionotropic receptor kainate type subunit 5) | protein interactions | 2901 | 18 | 2 | 19454 | 49 |
GRID2,GRIK2 |
9.623e-04 | -6.95 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 2 | 10285 | 30 |
NRG3,NRG1 |
9.623e-04 | -6.95 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 2 | 10285 | 30 |
NRG1,NRG3 |
9.929e-04 | -6.91 | transporter complex | cellular component | GO:1990351 | 461 | 6 | 19108 | 48 |
GRID2,CNTNAP2,CACNA2D1,KCNJ3,GRIK2,GRIA4 |
9.948e-04 | -6.91 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 2 | 18204 | 45 |
GRID2,NRXN1 |
1.028e-03 | -6.88 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 2 | 19108 | 48 |
GRID2,KCNJ3 |
1.034e-03 | -6.87 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 2 | 19454 | 49 |
NRXN1,NRXN3 |
1.038e-03 | -6.87 | - | gene3d domains | 1.10.287.70 | 148 | 4 | 14470 | 44 |
GRIK2,GRIA4,GRID2,KCNJ3 |
1.048e-03 | -6.86 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 9 | 16828 | 48 |
RUNX1T1,NRXN3,ST18,SYT1,CNTNAP2,GRID2,CACNA2D1,ZNF385D,GRIK2 |
1.075e-03 | -6.84 | C2_domain_sf | interpro domains | IPR035892 | 171 | 4 | 18521 | 49 |
RIMS2,SYT1,RIMS1,CADPS2 |
1.080e-03 | -6.83 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 48 |
SLC35F3,RALYL,NRG1,RUNX1T1,ZNF385D,KCNJ3,LRRTM4,STXBP5L,NRG3,TRPM3,RIMS2,SYT1,CDH18,CADPS2,KIF21A,GRID2,RIMS1,ZNF385B,APOE,RELN,PCDH9,NFIA,ST18,SLC1A3,CHN2,NPAS3,NRXN1,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,GRIA4,TLL1,EBF1,FSTL5,MYT1L,UNC5C,LSAMP,NRXN3,DTNA,GPC6,CNTN4,GLCE,PTPRG,CACNA2D1,EPHA5 |
1.089e-03 | -6.82 | Acetylcholine Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-264642 | 17 | 2 | 10285 | 30 |
RIMS1,SYT1 |
1.091e-03 | -6.82 | regulation of neurotransmitter secretion | biological process | GO:0046928 | 82 | 3 | 18204 | 45 |
RIMS2,SYT1,RIMS1 |
1.102e-03 | -6.81 | cognition | biological process | GO:0050890 | 319 | 5 | 18204 | 45 |
CNTNAP2,NRXN1,APOE,NRXN3,RELN |
1.104e-03 | -6.81 | regulation of synapse maturation | biological process | GO:0090128 | 20 | 2 | 18204 | 45 |
RELN,NRXN1 |
1.114e-03 | -6.80 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 8 | 16828 | 48 |
STXBP5L,RIMS2,NRG3,GPC6,CDH18,ST18,CNTNAP2,SLC35F3 |
1.130e-03 | -6.79 | cardiac muscle contraction | biological process | GO:0060048 | 83 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
1.130e-03 | -6.79 | positive regulation of ion transmembrane transporter activity | biological process | GO:0032414 | 83 | 3 | 18204 | 45 |
ANK2,CACNA2D1,RELN |
1.139e-03 | -6.78 | regulation of signaling | biological process | GO:0023051 | 3534 | 18 | 18204 | 45 |
CHN2,NRXN1,RIMS2,RIMS1,EPHA5,GRID2,CNTN4,NRG3,FSTL5,SYT1,SLC1A3,RELN,GRIK2,GRIA4,NRG1,APOE,GPC6,GLCE |
1.147e-03 | -6.77 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 49 |
CST3,NRXN1 |
1.147e-03 | -6.77 | gated channel activity | molecular function | GO:0022836 | 320 | 5 | 18094 | 45 |
KCNJ3,CACNA2D1,GRIK2,GRIA4,GRID2 |
1.159e-03 | -6.76 | ligand-gated monoatomic ion channel activity | molecular function | GO:0015276 | 186 | 4 | 18094 | 45 |
GRIA4,GRID2,KCNJ3,GRIK2 |
1.166e-03 | -6.75 | C2 | prosite domains | PS50004 | 142 | 4 | 12186 | 40 |
SYT1,CADPS2,RIMS2,RIMS1 |
1.170e-03 | -6.75 | export from cell | biological process | GO:0140352 | 485 | 6 | 18204 | 45 |
STXBP5L,CADPS2,RIMS2,SYT1,RIMS1,NRXN1 |
1.182e-03 | -6.74 | ligand-gated channel activity | molecular function | GO:0022834 | 187 | 4 | 18094 | 45 |
GRID2,GRIA4,KCNJ3,GRIK2 |
1.198e-03 | -6.73 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 3 | 19454 | 49 |
NRXN1,RIMS1,SYT1 |
1.218e-03 | -6.71 | ventricular cardiac muscle cell action potential | biological process | GO:0086005 | 21 | 2 | 18204 | 45 |
ANK2,KCNJ3 |
1.222e-03 | -6.71 | Serotonin Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-181429 | 18 | 2 | 10285 | 30 |
RIMS1,SYT1 |
1.222e-03 | -6.71 | Norepinephrine Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-181430 | 18 | 2 | 10285 | 30 |
SYT1,RIMS1 |
1.224e-03 | -6.71 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 43 | 16828 | 48 |
ZNF385B,GPC6,RIMS1,CNTN4,RELN,NRXN3,DTNA,LSAMP,SYT1,GRID2,CDH18,CADPS2,KIF21A,CHN2,SLC1A3,CACNA2D1,NRXN1,EPHA5,NPAS3,NFIA,PTPRG,ST18,GLCE,PCDH9,ANK2,ZNF385D,STXBP5L,CST3,CNTN5,LRRTM4,RALYL,RUNX1T1,NRG1,SLC35F3,CNTNAP2,LINGO2,TRPM3,NRG3,MYT1L,RIMS2,GRIA4,TLL1,FSTL5 |
1.225e-03 | -6.70 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 48 |
RIMS2,TRPM3,NRG3,RALYL,RUNX1T1,NRG1,SLC35F3,STXBP5L,LRRTM4,KCNJ3,ZNF385D,NFIA,ST18,PCDH9,NRXN1,NPAS3,CHN2,SLC1A3,GRID2,CDH18,CADPS2,KIF21A,SYT1,RELN,ZNF385B,APOE,RIMS1,EBF1,FSTL5,GRIA4,TLL1,MYT1L,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2,PTPRG,GLCE,EPHA5,CACNA2D1,NRXN3,DTNA,UNC5C,LSAMP,CNTN4,GPC6 |
1.225e-03 | -6.70 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 48 |
TRPM3,NRG3,RIMS2,RALYL,RUNX1T1,NRG1,SLC35F3,KCNJ3,ZNF385D,STXBP5L,LRRTM4,ST18,NFIA,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,SYT1,GRID2,CADPS2,CDH18,KIF21A,ZNF385B,APOE,RIMS1,RELN,GRIA4,TLL1,FSTL5,EBF1,MYT1L,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,PTPRG,GLCE,CACNA2D1,EPHA5,NRXN3,DTNA,UNC5C,LSAMP,GPC6,CNTN4 |
1.238e-03 | -6.69 | cervix | COSMIC cancer mutations | cervix | 11793 | 43 | 16828 | 48 |
NFIA,PTPRG,ST18,PCDH9,GLCE,NRXN1,EPHA5,NPAS3,CHN2,CACNA2D1,SLC1A3,GRID2,CDH18,CADPS2,KIF21A,NRXN3,DTNA,LSAMP,SYT1,CNTN4,RELN,ZNF385B,RIMS1,GPC6,FSTL5,GRIA4,TLL1,RIMS2,TRPM3,MYT1L,NRG3,LINGO2,RALYL,NRG1,RUNX1T1,CNTNAP2,SLC35F3,STXBP5L,CST3,CNTN5,LRRTM4,ZNF385D,ANK2 |
1.240e-03 | -6.69 | RAB27A (RAB27A, member RAS oncogene family) | protein interactions | 5873 | 84 | 3 | 19454 | 49 |
SYT1,RIMS1,RIMS2 |
1.246e-03 | -6.69 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 28 | 16828 | 48 |
TRPM3,NRG3,RIMS2,GRIA4,FSTL5,EBF1,GRIK2,ANK2,STXBP5L,RUNX1T1,CNTNAP2,LINGO2,CACNA2D1,SLC1A3,NRXN1,EPHA5,NFIA,PCDH9,ZNF385B,GPC6,RIMS1,RELN,NRXN3,DTNA,SYT1,GRID2,CDH18,KIF21A |
1.254e-03 | -6.68 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 28 | 16828 | 48 |
ZNF385B,GPC6,RIMS1,RELN,NRXN3,DTNA,SYT1,GRID2,CDH18,KIF21A,CACNA2D1,SLC1A3,NRXN1,EPHA5,NFIA,PCDH9,ANK2,GRIK2,STXBP5L,RUNX1T1,CNTNAP2,LINGO2,TRPM3,NRG3,RIMS2,GRIA4,FSTL5,EBF1 |
1.274e-03 | -6.67 | PDZ domain binding | molecular function | GO:0030165 | 86 | 3 | 18094 | 45 |
GRIK2,DTNA,GRID2 |
1.338e-03 | -6.62 | membrane depolarization during action potential | biological process | GO:0086010 | 22 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
1.364e-03 | -6.60 | GABA synthesis, release, reuptake and degradation | REACTOME pathways | R-HSA-888590 | 19 | 2 | 10285 | 30 |
RIMS1,SYT1 |
1.406e-03 | -6.57 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 3 | 18094 | 45 |
GRIA4,CST3,APOE |
1.439e-03 | -6.54 | channel activity | molecular function | GO:0015267 | 502 | 6 | 18094 | 45 |
GRIA4,GRID2,CACNA2D1,GRIK2,TRPM3,KCNJ3 |
1.454e-03 | -6.53 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 6 | 18094 | 45 |
GRID2,GRIA4,KCNJ3,TRPM3,GRIK2,CACNA2D1 |
1.463e-03 | -6.53 | ionotropic glutamate receptor signaling pathway | biological process | GO:0035235 | 23 | 2 | 18204 | 45 |
GRIA4,GRIK2 |
1.520e-03 | -6.49 | positive regulation of transporter activity | biological process | GO:0032411 | 92 | 3 | 18204 | 45 |
RELN,CACNA2D1,ANK2 |
1.593e-03 | -6.44 | postsynaptic density organization | biological process | GO:0097106 | 24 | 2 | 18204 | 45 |
NRXN1,RELN |
1.598e-03 | -6.44 | regulation of transport | biological process | GO:0051049 | 1621 | 11 | 18204 | 45 |
RIMS1,EPHA5,RIMS2,SYT1,ANK2,CACNA2D1,KCNJ3,CADPS2,RELN,APOE,NRG1 |
1.612e-03 | -6.43 | low-density lipoprotein particle receptor binding | molecular function | GO:0050750 | 24 | 2 | 18094 | 45 |
APOE,SYT1 |
1.632e-03 | -6.42 | nervous system process | biological process | GO:0050877 | 1376 | 10 | 18204 | 45 |
NRXN3,GRIK2,RIMS1,RELN,CNTNAP2,NRXN1,SLC1A3,CNTN5,GRID2,APOE |
1.714e-03 | -6.37 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 10 | 18204 | 45 |
RIMS1,LINGO2,RIMS2,RELN,UNC5C,NRXN1,SYT1,GRID2,NRG1,APOE |
1.729e-03 | -6.36 | regulation of ventricular cardiac muscle cell membrane repolarization | biological process | GO:0060307 | 25 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
1.731e-03 | -6.36 | cation channel complex | cellular component | GO:0034703 | 205 | 4 | 19108 | 48 |
GRIK2,KCNJ3,CACNA2D1,CNTNAP2 |
1.765e-03 | -6.34 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 45 |
UNC5C,CNTNAP2,NRXN1,EPHA5,NRXN3,RELN,APOE,CNTN5,CNTN4 |
1.800e-03 | -6.32 | neurotransmitter receptor activity | molecular function | GO:0030594 | 97 | 3 | 18094 | 45 |
GRIA4,GRID2,GRIK2 |
1.817e-03 | -6.31 | developmental process | biological process | GO:0032502 | 5716 | 24 | 18204 | 45 |
CNTN4,MYT1L,FSTL5,SYT1,GRID2,EPHA5,NRXN3,RIMS2,NRXN1,CNTN5,NRG1,APOE,RELN,TLL1,CNTNAP2,LSAMP,SLC1A3,NRG3,ANK2,RIMS1,NFIA,PCDH9,UNC5C,CDH18 |
1.832e-03 | -6.30 | SHC1 events in ERBB2 signaling | REACTOME pathways | R-HSA-1250196 | 22 | 2 | 10285 | 30 |
NRG1,NRG3 |
1.863e-03 | -6.29 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 48 |
LINGO2,CDH18,EBF1,UNC5C,TLL1,NFIA,PTPRG,RELN,RIMS1,MYT1L,ANK2 |
1.863e-03 | -6.29 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 48 |
MYT1L,EBF1,TLL1,NFIA,PTPRG,RELN,RIMS1,ANK2,LINGO2,CDH18,UNC5C |
1.875e-03 | -6.28 | human chr2q31.2-q31.3 | chromosome location | human chr2q31.2-q31.3 | 1 | 1 | 26134 | 49 |
ZNF385B |
1.875e-03 | -6.28 | human chr9p21.2-p21.1 | chromosome location | human chr9p21.2-p21.1 | 1 | 1 | 26134 | 49 |
LINGO2 |
1.875e-03 | -6.28 | human chr13q31.3-q32.1 | chromosome location | human chr13q31.3-q32.1 | 1 | 1 | 26134 | 49 |
GPC6 |
1.875e-03 | -6.28 | human chr4q25-q26 | chromosome location | human chr4q25-q26 | 1 | 1 | 26134 | 49 |
ANK2 |
1.875e-03 | -6.28 | human chr9q21.12-q21.13 | chromosome location | human chr9q21.12-q21.13 | 1 | 1 | 26134 | 49 |
TRPM3 |
1.875e-03 | -6.28 | human chr7q35-q36.1 | chromosome location | human chr7q35-q36.1 | 1 | 1 | 26134 | 49 |
CNTNAP2 |
1.875e-03 | -6.28 | human chr4q13.1-q13.2 | chromosome location | human chr4q13.1-q13.2 | 1 | 1 | 26134 | 49 |
EPHA5 |
1.875e-03 | -6.28 | human chr4q22.1-q22.2 | chromosome location | human chr4q22.1-q22.2 | 1 | 1 | 26134 | 49 |
GRID2 |
1.875e-03 | -6.28 | human chr3p26.3-p26.2 | chromosome location | human chr3p26.3-p26.2 | 1 | 1 | 26134 | 49 |
CNTN4 |
1.875e-03 | -6.28 | human chr14q24.3-q31.1 | chromosome location | human chr14q24.3-q31.1 | 1 | 1 | 26134 | 49 |
NRXN3 |
1.876e-03 | -6.28 | heart contraction | biological process | GO:0060047 | 99 | 3 | 18204 | 45 |
KCNJ3,CACNA2D1,ANK2 |
1.876e-03 | -6.28 | regulation of neurotransmitter transport | biological process | GO:0051588 | 99 | 3 | 18204 | 45 |
RIMS1,SYT1,RIMS2 |
1.909e-03 | -6.26 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | 14773 | 48 | 16828 | 48 |
PCDH9,ST18,NFIA,NPAS3,NRXN1,SLC1A3,CHN2,CADPS2,CDH18,KIF21A,GRID2,SYT1,RELN,RIMS1,ZNF385B,APOE,RIMS2,NRG3,TRPM3,SLC35F3,RALYL,RUNX1T1,NRG1,CST3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,GLCE,PTPRG,EPHA5,CACNA2D1,UNC5C,LSAMP,NRXN3,DTNA,CNTN4,GPC6,EBF1,FSTL5,GRIA4,TLL1,MYT1L,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2 |
1.909e-03 | -6.26 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | 14773 | 48 | 16828 | 48 |
MYT1L,TLL1,GRIA4,FSTL5,EBF1,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,PTPRG,GLCE,GPC6,CNTN4,DTNA,NRXN3,LSAMP,UNC5C,TRPM3,NRG3,RIMS2,KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,RUNX1T1,NRG1,RALYL,SLC35F3,CHN2,SLC1A3,NRXN1,NPAS3,NFIA,ST18,PCDH9,APOE,ZNF385B,RIMS1,RELN,SYT1,GRID2,KIF21A,CADPS2,CDH18 |
1.909e-03 | -6.26 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | 14773 | 48 | 16828 | 48 |
ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,MYT1L,GRIA4,TLL1,EBF1,FSTL5,GPC6,CNTN4,UNC5C,LSAMP,NRXN3,DTNA,CACNA2D1,EPHA5,GLCE,PTPRG,ZNF385D,KCNJ3,CST3,LRRTM4,STXBP5L,SLC35F3,RALYL,RUNX1T1,NRG1,NRG3,TRPM3,RIMS2,RIMS1,ZNF385B,APOE,RELN,SYT1,CADPS2,CDH18,KIF21A,GRID2,SLC1A3,CHN2,NPAS3,NRXN1,PCDH9,ST18,NFIA |
1.909e-03 | -6.26 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 14773 | 48 | 16828 | 48 |
EPHA5,CACNA2D1,GLCE,PTPRG,CNTN4,GPC6,UNC5C,LSAMP,NRXN3,DTNA,MYT1L,FSTL5,EBF1,GRIA4,TLL1,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,NFIA,ST18,RELN,RIMS1,ZNF385B,APOE,CADPS2,CDH18,KIF21A,GRID2,SYT1,RIMS2,NRG3,TRPM3,LRRTM4,CST3,STXBP5L,ZNF385D,KCNJ3,SLC35F3,RALYL,RUNX1T1,NRG1 |
1.916e-03 | -6.26 | classic | COSMIC cancer mutations | classic | 14774 | 48 | 16828 | 48 |
CNTN4,GPC6,NRXN3,DTNA,UNC5C,LSAMP,EPHA5,CACNA2D1,PTPRG,GLCE,CNTN5,ANK2,GRIK2,LINGO2,CNTNAP2,MYT1L,EBF1,FSTL5,GRIA4,TLL1,RELN,ZNF385B,APOE,RIMS1,GRID2,CADPS2,CDH18,KIF21A,SYT1,NRXN1,NPAS3,CHN2,SLC1A3,NFIA,ST18,PCDH9,STXBP5L,CST3,LRRTM4,KCNJ3,ZNF385D,RALYL,NRG1,RUNX1T1,SLC35F3,RIMS2,TRPM3,NRG3 |
1.930e-03 | -6.25 | side of membrane | cellular component | GO:0098552 | 715 | 7 | 19108 | 48 |
EPHA5,CNTN4,GPC6,CNTN5,LSAMP,KCNJ3,DTNA |
1.941e-03 | -6.24 | medulla | COSMIC cancer mutations | medulla | 14778 | 48 | 16828 | 48 |
SLC35F3,RUNX1T1,NRG1,RALYL,CST3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,RIMS2,NRG3,TRPM3,KIF21A,CADPS2,CDH18,GRID2,SYT1,RELN,RIMS1,APOE,ZNF385B,PCDH9,NFIA,ST18,NPAS3,NRXN1,SLC1A3,CHN2,LINGO2,CNTNAP2,CNTN5,GRIK2,ANK2,EBF1,FSTL5,TLL1,GRIA4,MYT1L,LSAMP,UNC5C,DTNA,NRXN3,CNTN4,GPC6,GLCE,PTPRG,EPHA5,CACNA2D1 |
1.946e-03 | -6.24 | secretion | biological process | GO:0046903 | 536 | 6 | 18204 | 45 |
RIMS1,CADPS2,RIMS2,NRXN1,SYT1,STXBP5L |
1.947e-03 | -6.24 | desmoplastic | COSMIC cancer mutations | desmoplastic | 14779 | 48 | 16828 | 48 |
KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,RALYL,NRG1,RUNX1T1,SLC35F3,TRPM3,NRG3,RIMS2,ZNF385B,APOE,RIMS1,RELN,SYT1,GRID2,CDH18,CADPS2,KIF21A,CHN2,SLC1A3,NRXN1,NPAS3,ST18,NFIA,PCDH9,ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,MYT1L,GRIA4,TLL1,EBF1,FSTL5,GPC6,CNTN4,NRXN3,DTNA,UNC5C,LSAMP,CACNA2D1,EPHA5,PTPRG,GLCE |
1.951e-03 | -6.24 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 3 | 12186 | 40 |
EPHA5,APOE,CNTNAP2 |
1.964e-03 | -6.23 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 3 | 18094 | 45 |
GRIK2,SLC1A3,GRIA4 |
1.986e-03 | -6.22 | actin filament-based movement | biological process | GO:0030048 | 101 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
1.996e-03 | -6.22 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 4 | 18204 | 45 |
LINGO2,GRID2,CNTNAP2,NRXN1 |
2.003e-03 | -6.21 | Dopamine Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-212676 | 23 | 2 | 10285 | 30 |
SYT1,RIMS1 |
2.016e-03 | -6.21 | postsynaptic specialization organization | biological process | GO:0099084 | 27 | 2 | 18204 | 45 |
NRXN1,RELN |
2.019e-03 | -6.21 | FN3_dom | interpro domains | IPR003961 | 203 | 4 | 18521 | 49 |
CNTN4,PTPRG,CNTN5,EPHA5 |
2.019e-03 | -6.21 | FN3_sf | interpro domains | IPR036116 | 203 | 4 | 18521 | 49 |
EPHA5,CNTN5,PTPRG,CNTN4 |
2.030e-03 | -6.20 | EGF-type_Asp/Asn_hydroxyl_site | interpro domains | IPR000152 | 95 | 3 | 18521 | 49 |
TLL1,NRXN3,NRXN1 |
2.085e-03 | -6.17 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 48 |
TRPM3,NRG3,RIMS2,KCNJ3,ZNF385D,STXBP5L,LRRTM4,CST3,RUNX1T1,NRG1,RALYL,SLC35F3,CHN2,SLC1A3,NRXN1,NPAS3,NFIA,ST18,PCDH9,APOE,ZNF385B,RIMS1,RELN,SYT1,GRID2,KIF21A,CDH18,CADPS2,MYT1L,TLL1,GRIA4,EBF1,FSTL5,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,PTPRG,GLCE,GPC6,CNTN4,DTNA,NRXN3,LSAMP,UNC5C |
2.085e-03 | -6.17 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 48 |
CNTN5,ANK2,GRIK2,LINGO2,CNTNAP2,MYT1L,FSTL5,EBF1,TLL1,GRIA4,CNTN4,GPC6,LSAMP,UNC5C,DTNA,NRXN3,EPHA5,CACNA2D1,GLCE,PTPRG,LRRTM4,CST3,STXBP5L,ZNF385D,KCNJ3,SLC35F3,NRG1,RUNX1T1,RALYL,RIMS2,NRG3,TRPM3,RELN,RIMS1,APOE,ZNF385B,KIF21A,CADPS2,CDH18,GRID2,SYT1,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,ST18,NFIA |
2.086e-03 | -6.17 | postsynaptic density membrane | cellular component | GO:0098839 | 101 | 3 | 19108 | 48 |
GRID2,GRIK2,GRIA4 |
2.086e-03 | -6.17 | potassium channel complex | cellular component | GO:0034705 | 101 | 3 | 19108 | 48 |
KCNJ3,GRIK2,CNTNAP2 |
2.101e-03 | -6.17 | regulation of heart rate | biological process | GO:0002027 | 103 | 3 | 18204 | 45 |
KCNJ3,ANK2,CACNA2D1 |
2.168e-03 | -6.13 | startle response | biological process | GO:0001964 | 28 | 2 | 18204 | 45 |
CNTNAP2,GRID2 |
2.181e-03 | -6.13 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 15 | 16828 | 48 |
STXBP5L,RELN,APOE,GRIK2,GRID2,CNTNAP2,NPAS3,TRPM3,SLC1A3,MYT1L,EBF1,TLL1,ST18,NFIA,PTPRG |
2.181e-03 | -6.13 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 15 | 16828 | 48 |
CNTNAP2,GRID2,GRIK2,APOE,RELN,STXBP5L,ST18,PTPRG,NFIA,TLL1,EBF1,MYT1L,SLC1A3,TRPM3,NPAS3 |
2.194e-03 | -6.12 | chemorepellent activity | molecular function | GO:0045499 | 28 | 2 | 18094 | 45 |
NRG1,NRG3 |
2.195e-03 | -6.12 | localization within membrane | biological process | GO:0051668 | 549 | 6 | 18204 | 45 |
STXBP5L,ANK2,APOE,RELN,GRIK2,NRXN1 |
2.219e-03 | -6.11 | regulation of postsynapse organization | biological process | GO:0099175 | 105 | 3 | 18204 | 45 |
RELN,GRID2,APOE |
2.232e-03 | -6.10 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 38 | 16828 | 48 |
NRG1,RUNX1T1,RALYL,CNTNAP2,SLC35F3,LINGO2,KCNJ3,ZNF385D,ANK2,GRIK2,STXBP5L,CST3,CNTN5,LRRTM4,GRIA4,EBF1,TRPM3,NRG3,MYT1L,RIMS2,DTNA,NRXN3,SYT1,LSAMP,UNC5C,GRID2,KIF21A,RIMS1,GPC6,CNTN4,RELN,PTPRG,ST18,NFIA,PCDH9,GLCE,CACNA2D1,NRXN1 |
2.236e-03 | -6.10 | regulation of secretion by cell | biological process | GO:1903530 | 551 | 6 | 18204 | 45 |
SYT1,APOE,RIMS2,CADPS2,EPHA5,RIMS1 |
2.253e-03 | -6.10 | GRIK2 (glutamate ionotropic receptor kainate type subunit 2) | protein interactions | 2898 | 28 | 2 | 19454 | 49 |
GRIK2,GRID2 |
2.253e-03 | -6.10 | breast-carcinoma-ductal_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductal_carcinoma | 14824 | 48 | 16828 | 48 |
ZNF385B,APOE,RIMS1,RELN,SYT1,GRID2,CADPS2,CDH18,KIF21A,CHN2,SLC1A3,NRXN1,NPAS3,ST18,NFIA,PCDH9,KCNJ3,ZNF385D,STXBP5L,LRRTM4,CST3,RALYL,RUNX1T1,NRG1,SLC35F3,TRPM3,NRG3,RIMS2,GPC6,CNTN4,NRXN3,DTNA,UNC5C,LSAMP,CACNA2D1,EPHA5,PTPRG,GLCE,ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,MYT1L,GRIA4,TLL1,EBF1,FSTL5 |
2.255e-03 | -6.09 | monoatomic ion transport | biological process | GO:0006811 | 964 | 8 | 18204 | 45 |
CACNA2D1,ANK2,GRID2,GRIA4,KCNJ3,TRPM3,GRIK2,SLC1A3 |
2.275e-03 | -6.09 | cell development | biological process | GO:0048468 | 2236 | 13 | 18204 | 45 |
SLC1A3,NRXN1,UNC5C,CNTNAP2,RELN,NRXN3,EPHA5,NRG1,APOE,ANK2,CNTN4,CNTN5,MYT1L |
2.280e-03 | -6.08 | regulation of postsynaptic membrane potential | biological process | GO:0060078 | 106 | 3 | 18204 | 45 |
GRIA4,GRIK2,GRID2 |
2.336e-03 | -6.06 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 45 |
APOE,CNTN4,CNTN5,NRXN1,UNC5C,CNTNAP2,RELN,NRXN3,EPHA5 |
2.361e-03 | -6.05 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 3 | 10285 | 30 |
CNTN5,LSAMP,CNTN4 |
2.367e-03 | -6.05 | Nuclear signaling by ERBB4 | REACTOME pathways | R-HSA-1251985 | 25 | 2 | 10285 | 30 |
NRG3,NRG1 |
2.382e-03 | -6.04 | SNARE binding | molecular function | GO:0000149 | 107 | 3 | 18094 | 45 |
STXBP5L,GRIK2,SYT1 |
2.382e-03 | -6.04 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 7 | 18094 | 45 |
GRIA4,KCNJ3,GRID2,SLC1A3,CACNA2D1,GRIK2,TRPM3 |
2.412e-03 | -6.03 | large_cell | COSMIC cancer mutations | large_cell | 14845 | 48 | 16828 | 48 |
RIMS2,NRG3,TRPM3,CST3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,SLC35F3,RALYL,NRG1,RUNX1T1,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,ST18,NFIA,RELN,RIMS1,ZNF385B,APOE,CDH18,CADPS2,KIF21A,GRID2,SYT1,MYT1L,FSTL5,EBF1,GRIA4,TLL1,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,EPHA5,CACNA2D1,GLCE,PTPRG,CNTN4,GPC6,UNC5C,LSAMP,NRXN3,DTNA |
2.414e-03 | -6.03 | skin-ankle-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-ankle-malignant_melanoma-acral_lentiginous | 330 | 5 | 16828 | 48 |
NRG3,CNTNAP2,SLC35F3,RIMS2,STXBP5L |
2.468e-03 | -6.00 | postsynapse organization | biological process | GO:0099173 | 109 | 3 | 18204 | 45 |
NRXN1,APOE,RELN |
2.472e-03 | -6.00 | fast, calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:0098746 | 1 | 1 | 18204 | 45 |
SYT1 |
2.472e-03 | -6.00 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | positive regulation of lateral motor column neuron migration | biological process | GO:1902078 | 1 | 1 | 18204 | 45 |
RELN |
2.472e-03 | -6.00 | synchronous neurotransmitter secretion | biological process | GO:0071911 | 1 | 1 | 18204 | 45 |
SYT1 |
2.472e-03 | -6.00 | regulation of motor neuron migration | biological process | GO:1905483 | 1 | 1 | 18204 | 45 |
RELN |
2.472e-03 | -6.00 | detection of cold stimulus involved in thermoception | biological process | GO:0120169 | 1 | 1 | 18204 | 45 |
GRIK2 |
2.472e-03 | -6.00 | sensory perception of cold stimulus | biological process | GO:0062035 | 1 | 1 | 18204 | 45 |
GRIK2 |
2.472e-03 | -6.00 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 45 |
CST3 |
2.472e-03 | -6.00 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 45 |
NRG3 |
2.472e-03 | -6.00 | positive regulation of motor neuron migration | biological process | GO:1905485 | 1 | 1 | 18204 | 45 |
RELN |
2.472e-03 | -6.00 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 45 |
CST3 |
2.472e-03 | -6.00 | regulation of lateral motor column neuron migration | biological process | GO:1902076 | 1 | 1 | 18204 | 45 |
RELN |
2.472e-03 | -6.00 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 45 |
APOE |
2.472e-03 | -6.00 | positive regulation of calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:1903235 | 1 | 1 | 18204 | 45 |
SYT1 |
2.472e-03 | -6.00 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 45 |
NRG3 |
2.487e-03 | -6.00 | netrin receptor activity involved in chemorepulsion | molecular function | GO:0005043 | 1 | 1 | 18094 | 45 |
UNC5C |
2.487e-03 | -6.00 | voltage-gated calcium channel activity involved in bundle of His cell action potential | molecular function | GO:0086057 | 1 | 1 | 18094 | 45 |
CACNA2D1 |
2.487e-03 | -6.00 | heparosan-N-sulfate-glucuronate 5-epimerase activity | molecular function | GO:0047464 | 1 | 1 | 18094 | 45 |
GLCE |
2.487e-03 | -6.00 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 45 |
APOE |
2.487e-03 | -6.00 | regulation of cardiac muscle cell membrane repolarization | biological process | GO:0099623 | 30 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
2.499e-03 | -5.99 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 6 | 18094 | 45 |
CNTN4,NRXN1,CDH18,NRXN3,NRG1,CNTN5 |
2.512e-03 | -5.99 | mossy fiber rosette | cellular component | GO:0097471 | 1 | 1 | 19108 | 48 |
GRIK2 |
2.512e-03 | -5.99 | reelin complex | cellular component | GO:0110157 | 1 | 1 | 19108 | 48 |
RELN |
2.519e-03 | -5.98 | Ganab (glucosidase II alpha subunit) | protein interactions | 293721 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atp1a2 (ATPase Na+/K+ transporting subunit alpha 2) | protein interactions | 24212 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sphkap (SPHK1 interactor, AKAP domain containing) | protein interactions | 316561 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Stxbp5l (syntaxin binding protein 5L) | protein interactions | 288080 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Lmnb2 (lamin B2) | protein interactions | 299625 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Kpna2l1 (karyopherin subunit alpha 2 like 1) | protein interactions | 100359600 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ranbp2 (RAN binding protein 2) | protein interactions | 294429 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Kifc2 (kinesin family member C2) | protein interactions | 300053 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Eif3b (eukaryotic translation initiation factor 3, subunit B) | protein interactions | 288516 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sec11a (SEC11 homolog A, signal peptidase complex subunit) | protein interactions | 65166 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC286987 (hemiferrin, transferrin-like protein) | protein interactions | 286987 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Fstl4 (follistatin-like 4) | protein interactions | 303130 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Vwa5b2 (von Willebrand factor A domain containing 5B2) | protein interactions | 303812 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Srsf4 (serine and arginine rich splicing factor 4) | protein interactions | 362612 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dnaaf3 (dynein, axonemal, assembly factor 3) | protein interactions | 100359753 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Nnt (nicotinamide nucleotide transhydrogenase) | protein interactions | 310378 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Trip11 (thyroid hormone receptor interactor 11) | protein interactions | 314393 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hdgfl3 (HDGF like 3) | protein interactions | 252941 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rps26-ps11 (ribosomal protein S26, pseudogene 11) | protein interactions | 100360508 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hmga1 (high mobility group AT-hook 1) | protein interactions | 117062 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Phb2 (prohibitin 2) | protein interactions | 114766 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Snrnp27 (small nuclear ribonucleoprotein U4/U6.U5 subunit 27) | protein interactions | 362392 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Kiaa0232 (KIAA0232 homolog) | protein interactions | 680039 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Stoml2 (stomatin like 2) | protein interactions | 298203 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Usp15 (ubiquitin specific peptidase 15) | protein interactions | 171329 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Taf15 (TATA-box binding protein associated factor 15) | protein interactions | 287571 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dynll1 (dynein light chain LC8-type 1) | protein interactions | 58945 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Glg1 (golgi glycoprotein 1) | protein interactions | 29476 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rnf13 (ring finger protein 13) | protein interactions | 681578 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hspa4 (heat shock protein family A (Hsp70) member 4) | protein interactions | 266759 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pgam1 (phosphoglycerate mutase 1) | protein interactions | 24642 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ins2 (insulin 2) | protein interactions | 24506 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hnrnph3 (heterogeneous nuclear ribonucleoprotein H3) | protein interactions | 361838 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ttc22 (tetratricopeptide repeat domain 22) | protein interactions | 298300 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hm13 (histocompatibility minor 13) | protein interactions | 311545 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cep135 (centrosomal protein 135) | protein interactions | 305288 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rab5c (RAB5C, member RAS oncogene family) | protein interactions | 287709 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ptmal5 (prothymosin alpha like 5) | protein interactions | 100359583 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Lrp8 (low density lipoprotein receptor-related protein 8, apolipoprotein e receptor) | protein interactions | 16975 | 1 | 1 | 19454 | 49 |
RELN |
2.519e-03 | -5.98 | Mroh6 (maestro heat-like repeat family member 6) | protein interactions | 100359562 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC102554637 (anionic trypsin-2-like) | protein interactions | 102554637 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pgk2 (phosphoglycerate kinase 2) | protein interactions | 316265 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Gps1 (G protein pathway suppressor 1) | protein interactions | 117039 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ndufb8 (NADH:ubiquinone oxidoreductase subunit B8) | protein interactions | 293991 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Kif5b (kinesin family member 5B) | protein interactions | 117550 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tceal3 (transcription elongation factor A like 3) | protein interactions | 501628 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cplx2 (complexin 2) | protein interactions | 116657 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Amz2 (archaelysin family metallopeptidase 2) | protein interactions | 360650 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cyp2c55 (cytochrome P450, family 2, subfamily c, polypeptide 55) | protein interactions | 100361492 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cct3 (chaperonin containing TCP1 subunit 3) | protein interactions | 295230 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Fam114a2 (family with sequence similarity 114, member A2) | protein interactions | 303155 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Itln1 (intelectin 1) | protein interactions | 498284 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Bst2 (bone marrow stromal cell antigen 2) | protein interactions | 378947 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Gaa (alpha glucosidase) | protein interactions | 367562 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rps12l1 (ribosomal protein S12 like 1) | protein interactions | 100360573 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atp6v0d1 (ATPase H+ transporting V0 subunit D1) | protein interactions | 291969 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Abca4 (ATP binding cassette subfamily A member 4) | protein interactions | 310836 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ptma (prothymosin alpha) | protein interactions | 29222 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Syvn1 (synoviolin 1) | protein interactions | 361712 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pcsk1n (proprotein convertase subtilisin/kexin type 1 inhibitor) | protein interactions | 246333 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Gorasp2 (golgi reassembly stacking protein 2) | protein interactions | 113961 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sel1l2 (SEL1L2 adaptor subunit of SYVN1 ubiquitin ligase) | protein interactions | 311470 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ranbp1 (RAN binding protein 1) | protein interactions | 360739 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atxn2 (ataxin 2) | protein interactions | 288663 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sod1 (superoxide dismutase 1) | protein interactions | 24786 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Vgf (VGF nerve growth factor inducible) | protein interactions | 29461 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Psma3l (proteasome subunit alpha type 3-like) | protein interactions | 408248 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sh3glb1 (SH3 domain -containing GRB2-like endophilin B1) | protein interactions | 292156 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Gpd2 (glycerol-3-phosphate dehydrogenase 2) | protein interactions | 25062 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tgoln2 (trans-golgi network protein 2) | protein interactions | 192152 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ndufs1 (NADH:ubiquinone oxidoreductase core subunit S1) | protein interactions | 301458 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sec16a (SEC16 homolog A, endoplasmic reticulum export factor) | protein interactions | 100360302 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Os9 (OS9, endoplasmic reticulum lectin) | protein interactions | 362891 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Mlec (malectin) | protein interactions | 304543 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Srprb (SRP receptor subunit beta) | protein interactions | 300965 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cep192 (centrosomal protein 192) | protein interactions | 307347 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ciao2b (cytosolic iron-sulfur assembly component 2B) | protein interactions | 680987 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Copb2 (COPI coat complex subunit beta 2) | protein interactions | 60384 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Erbb4 (erb-b2 receptor tyrosine kinase 4) | protein interactions | 13869 | 1 | 1 | 19454 | 49 |
NRG1 |
2.519e-03 | -5.98 | Cul3 (cullin 3) | protein interactions | 301555 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cox5b (cytochrome c oxidase subunit 5B) | protein interactions | 94194 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tardbp (TAR DNA binding protein) | protein interactions | 298648 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Actg2 (actin gamma 2, smooth muscle) | protein interactions | 25365 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Krt8 (keratin 8) | protein interactions | 25626 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Nomo1 (Nodal modulator 1) | protein interactions | 361578 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hmgn3 (high mobility group nucleosomal binding domain 3) | protein interactions | 113990 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tmem263 (transmembrane protein 263) | protein interactions | 362857 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ermp1 (endoplasmic reticulum metallopeptidase 1) | protein interactions | 373544 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Purb (purine rich element binding protein B) | protein interactions | 498407 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sncb (synuclein, beta) | protein interactions | 113893 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Scgn (secretagogin, EF-hand calcium binding protein) | protein interactions | 306942 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Scg5 (secretogranin V) | protein interactions | 25719 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tnpo1 (transportin 1) | protein interactions | 309126 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cdc37 (cell division cycle 37, HSP90 cochaperone) | protein interactions | 114562 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ccar2 (cell cycle and apoptosis regulator 2) | protein interactions | 306007 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Stip1 (stress-induced phosphoprotein 1) | protein interactions | 192277 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | U2af2 (U2 small nuclear RNA auxiliary factor 2) | protein interactions | 308335 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hnrnpr (heterogeneous nuclear ribonucleoprotein R) | protein interactions | 319110 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | C1qbp (complement C1q binding protein) | protein interactions | 29681 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Trim28 (tripartite motif-containing 28) | protein interactions | 116698 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rpl31-ps10 (ribosomal protein L31, pseudogene 10) | protein interactions | 502887 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Phb1l1 (prohibitin 1 like 1) | protein interactions | 302688 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hba-a2 (hemoglobin alpha, adult chain 2) | protein interactions | 360504 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Chmp4b (charged multivesicular body protein 4B) | protein interactions | 100359642 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Spcs2 (signal peptidase complex subunit 2) | protein interactions | 293142 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tmed2 (transmembrane p24 trafficking protein 2) | protein interactions | 65165 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dnajb11 (DnaJ heat shock protein family (Hsp40) member B11) | protein interactions | 360734 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rpl17-ps1 (ribosomal protein L17, pseudogene 1) | protein interactions | 499485 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dynll2 (dynein light chain LC8-type 2) | protein interactions | 140734 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Psap (prosaposin) | protein interactions | 25524 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cope (COPI coat complex subunit epsilon) | protein interactions | 290659 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Akap7 (A-kinase anchoring protein 7) | protein interactions | 361458 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tuba1c (tubulin, alpha 1C) | protein interactions | 300218 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pdhb (pyruvate dehydrogenase E1 subunit beta) | protein interactions | 289950 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ndufv3-ps1 (NADH:ubiquinone oxidoreductase subunit V3, pseudogene 1) | protein interactions | 685005 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Anxa5 (annexin A5) | protein interactions | 25673 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Arsb (arylsulfatase B) | protein interactions | 25227 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dync1i2 (dynein cytoplasmic 1 intermediate chain 2) | protein interactions | 116659 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ppard (peroxisome proliferator-activated receptor delta) | protein interactions | 25682 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC100365839 (40S ribosomal protein S3a-like) | protein interactions | 100365839 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Jpt1 (Jupiter microtubule associated homolog 1) | protein interactions | 287828 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hnrnpul2 (heterogeneous nuclear ribonucleoprotein U-like 2) | protein interactions | 309197 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cse1l (chromosome segregation 1 like) | protein interactions | 362273 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Snrpa (small nuclear ribonucleoprotein polypeptide A) | protein interactions | 292729 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tpd52l2 (TPD52 like 2) | protein interactions | 296480 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Dnah17 (dynein, axonemal, heavy chain 17) | protein interactions | 287845 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Babam1 (BRISC and BRCA1 A complex member 1) | protein interactions | 290631 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ptms (parathymosin) | protein interactions | 83801 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Krt83 (keratin 83) | protein interactions | 407759 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atp6v0a1 (ATPase H+ transporting V0 subunit a1) | protein interactions | 29757 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pgam5 (PGAM family member 5, mitochondrial serine/threonine protein phosphatase) | protein interactions | 288731 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC297756 (ribosomal protein S8-like) | protein interactions | 297756 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Fam114a1 (family with sequence similarity 114, member A1) | protein interactions | 498366 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Zc3h13 (zinc finger CCCH type containing 13) | protein interactions | 305955 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pdia6 (protein disulfide isomerase family A, member 6) | protein interactions | 286906 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Rps27-ps8 (ribosomal protein S27, pseudogene 8) | protein interactions | 100359517 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atp5f1d (ATP synthase F1 subunit delta) | protein interactions | 245965 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Zmpste24 (zinc metallopeptidase STE24) | protein interactions | 313564 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tor1aip2 (torsin 1A interacting protein 2) | protein interactions | 304881 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Mcm3 (minichromosome maintenance complex component 3) | protein interactions | 316273 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Copg1 (COPI coat complex subunit gamma 1) | protein interactions | 297428 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Camk2b (calcium/calmodulin-dependent protein kinase II beta) | protein interactions | 24245 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cnbp (CCHC-type zinc finger, nucleic acid binding protein) | protein interactions | 64530 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hmgn5b (high mobility group nucleosome binding domain 5B) | protein interactions | 120097335 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cd81 (Cd81 molecule) | protein interactions | 25621 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Atp5mc2 (ATP synthase membrane subunit c locus 2) | protein interactions | 171082 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Hmgn2 (high mobility group nucleosomal binding domain 2) | protein interactions | 114637 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Pgrmc1 (progesterone receptor membrane component 1) | protein interactions | 291948 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Qpct (glutaminyl-peptide cyclotransferase) | protein interactions | 313837 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Scfd1 (sec1 family domain containing 1) | protein interactions | 54350 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tuba4a (tubulin, alpha 4A) | protein interactions | 316531 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Grpel1 (GrpE-like 1, mitochondrial) | protein interactions | 79563 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC100360522 (ribosomal protein P1-like) | protein interactions | 100360522 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Cep162 (centrosomal protein 162) | protein interactions | 300880 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Myef2 (myelin expression factor 2) | protein interactions | 679712 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | LOC100361008 (Cytochrome c oxidase subunit 5A, mitochondrial-like) | protein interactions | 100361008 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Tmem109 (transmembrane protein 109) | protein interactions | 361732 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Marcksl1 (MARCKS-like 1) | protein interactions | 81520 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Timm44 (translocase of inner mitochondrial membrane 44) | protein interactions | 29635 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Nudc (nuclear distribution C, dynein complex regulator) | protein interactions | 29648 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Slc7a5 (solute carrier family 7 member 5) | protein interactions | 50719 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Gcn1 (GCN1 activator of EIF2AK4) | protein interactions | 690632 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sel1l (SEL1L adaptor subunit of SYVN1 ubiquitin ligase) | protein interactions | 314352 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Copa (COPI coat complex subunit alpha) | protein interactions | 304978 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Copb1 (COPI coat complex subunit beta 1) | protein interactions | 114023 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Nolc1 (nucleolar and coiled-body phosphoprotein 1) | protein interactions | 64896 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Ina (internexin neuronal intermediate filament protein, alpha) | protein interactions | 24503 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Iapp (islet amyloid polypeptide) | protein interactions | 24476 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Acad10 (acyl-CoA dehydrogenase family, member 10) | protein interactions | 304500 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Vil1 (villin 1) | protein interactions | 316521 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 49 |
NRXN1 |
2.519e-03 | -5.98 | Gfpt1 (glutamine fructose-6-phosphate transaminase 1) | protein interactions | 297417 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Nbas (NBAS subunit of NRZ tethering complex) | protein interactions | 690073 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Npm1-ps9 (nucleophosmin 1, pseudogene 9) | protein interactions | 300303 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.519e-03 | -5.98 | Actr1a (actin related protein 1A) | protein interactions | 294010 | 1 | 1 | 19454 | 49 |
STXBP5L |
2.536e-03 | -5.98 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 14 | 16828 | 48 |
EPHA5,EBF1,FSTL5,NFIA,PTPRG,RELN,STXBP5L,GRIK2,ANK2,KIF21A,SYT1,RUNX1T1,DTNA,NRXN3 |
2.564e-03 | -5.97 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 17 | 16828 | 48 |
NRG1,RUNX1T1,NRXN3,SLC35F3,CNTNAP2,LINGO2,KIF21A,GRIK2,ZNF385D,STXBP5L,RELN,EBF1,TRPM3,CHN2,NRG3,NPAS3,EPHA5 |
2.564e-03 | -5.97 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 17 | 16828 | 48 |
EBF1,NRG3,TRPM3,CHN2,NPAS3,EPHA5,CNTNAP2,SLC35F3,NRG1,RUNX1T1,NRXN3,LINGO2,KIF21A,GRIK2,ZNF385D,RELN,STXBP5L |
2.614e-03 | -5.95 | FN3 | smart domains | SM00060 | 149 | 4 | 9717 | 38 |
EPHA5,CNTN4,CNTN5,PTPRG |
2.641e-03 | -5.94 | Reelin_subrepeat-B | pfam domains | PF21471 | 1 | 1 | 17795 | 47 |
RELN |
2.641e-03 | -5.94 | Glce_b_sandwich | pfam domains | PF21174 | 1 | 1 | 17795 | 47 |
GLCE |
2.641e-03 | -5.94 | C5-epim_C | pfam domains | PF06662 | 1 | 1 | 17795 | 47 |
GLCE |
2.646e-03 | -5.93 | Reelin_subrepeat-B | interpro domains | IPR049419 | 1 | 1 | 18521 | 49 |
RELN |
2.646e-03 | -5.93 | Reelin | interpro domains | IPR034968 | 1 | 1 | 18521 | 49 |
RELN |
2.646e-03 | -5.93 | C5-epimerase | interpro domains | IPR039721 | 1 | 1 | 18521 | 49 |
GLCE |
2.646e-03 | -5.93 | CNTN4_Ig6 | interpro domains | IPR033007 | 1 | 1 | 18521 | 49 |
CNTN4 |
2.646e-03 | -5.93 | C5-epim_C | interpro domains | IPR010598 | 1 | 1 | 18521 | 49 |
GLCE |
2.646e-03 | -5.93 | NRG1 | interpro domains | IPR018250 | 1 | 1 | 18521 | 49 |
NRG1 |
2.646e-03 | -5.93 | CBFA2T1 | interpro domains | IPR013290 | 1 | 1 | 18521 | 49 |
RUNX1T1 |
2.646e-03 | -5.93 | K_chnl_inward-rec_Kir3 | interpro domains | IPR003274 | 1 | 1 | 18521 | 49 |
KCNJ3 |
2.646e-03 | -5.93 | EphA5_rcpt_lig-bd | interpro domains | IPR034277 | 1 | 1 | 18521 | 49 |
EPHA5 |
2.646e-03 | -5.93 | Death_UNC5C | interpro domains | IPR042154 | 1 | 1 | 18521 | 49 |
UNC5C |
2.655e-03 | -5.93 | positive regulation of calcium ion transmembrane transporter activity | biological process | GO:1901021 | 31 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
2.660e-03 | -5.93 | Matrin/U1-like-C_Znf_C2H2 | interpro domains | IPR003604 | 29 | 2 | 18521 | 49 |
ZNF385B,ZNF385D |
2.734e-03 | -5.90 | heart process | biological process | GO:0003015 | 113 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
2.734e-03 | -5.90 | regulation of regulated secretory pathway | biological process | GO:1903305 | 113 | 3 | 18204 | 45 |
SYT1,RIMS1,RIMS2 |
2.740e-03 | -5.90 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 3 | 16828 | 48 |
FSTL5,LSAMP,NRXN3 |
2.788e-03 | -5.88 | muscle contraction | biological process | GO:0006936 | 238 | 4 | 18204 | 45 |
KCNJ3,DTNA,CACNA2D1,ANK2 |
2.827e-03 | -5.87 | ligand-gated ion channel signaling pathway | biological process | GO:1990806 | 32 | 2 | 18204 | 45 |
GRIK2,GRIA4 |
2.827e-03 | -5.87 | positive regulation of nervous system process | biological process | GO:0031646 | 32 | 2 | 18204 | 45 |
RIMS2,RIMS1 |
2.861e-03 | -5.86 | protein tyrosine kinase activator activity | molecular function | GO:0030296 | 32 | 2 | 18094 | 45 |
NRG1,NRG3 |
2.872e-03 | -5.85 | acinar_carcinoma | COSMIC cancer mutations | acinar_carcinoma | 1978 | 13 | 16828 | 48 |
NRXN3,RUNX1T1,SLC35F3,CNTNAP2,LINGO2,KIF21A,ANK2,GPC6,PTPRG,ST18,TRPM3,MYT1L,EPHA5 |
2.872e-03 | -5.85 | pancreas-carcinoma-acinar_carcinoma | COSMIC cancer mutations | pancreas-carcinoma-acinar_carcinoma | 1978 | 13 | 16828 | 48 |
MYT1L,TRPM3,EPHA5,ST18,PTPRG,ANK2,GPC6,CNTNAP2,SLC35F3,NRXN3,RUNX1T1,KIF21A,LINGO2 |
2.937e-03 | -5.83 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 49 |
PCDH9,NRXN1 |
2.986e-03 | -5.81 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 27 | 16828 | 48 |
TLL1,GRIA4,FSTL5,TRPM3,NRG3,MYT1L,RUNX1T1,NRG1,LINGO2,GRIK2,ANK2,CST3,CNTN5,PTPRG,ST18,GLCE,SLC1A3,NPAS3,EPHA5,DTNA,NRXN3,UNC5C,GRID2,KIF21A,CDH18,RIMS1,RELN |
2.996e-03 | -5.81 | regulation of cell growth | biological process | GO:0001558 | 401 | 5 | 18204 | 45 |
APOE,NRG3,RIMS1,SYT1,RIMS2 |
3.016e-03 | -5.80 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 3 | 18204 | 45 |
NRXN1,GRID2,LINGO2 |
3.017e-03 | -5.80 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 6 | 16828 | 48 |
RELN,NPAS3,ANK2,KCNJ3,FSTL5,CNTNAP2 |
3.024e-03 | -5.80 | Death | pfam domains | PF00531 | 31 | 2 | 17795 | 47 |
UNC5C,ANK2 |
3.032e-03 | -5.80 | regulation of localization | biological process | GO:0032879 | 2028 | 12 | 18204 | 45 |
CADPS2,RELN,RIMS2,EPHA5,RIMS1,APOE,NRG1,KCNJ3,GPC6,ANK2,CACNA2D1,SYT1 |
3.106e-03 | -5.77 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 45 | 16828 | 48 |
NRXN1,NPAS3,CHN2,SLC1A3,ST18,PCDH9,RELN,ZNF385B,RIMS1,GRID2,CADPS2,CDH18,KIF21A,SYT1,RIMS2,TRPM3,NRG3,STXBP5L,LRRTM4,CST3,KCNJ3,ZNF385D,RALYL,NRG1,RUNX1T1,SLC35F3,EPHA5,CACNA2D1,PTPRG,GLCE,CNTN4,GPC6,NRXN3,UNC5C,LSAMP,MYT1L,EBF1,FSTL5,GRIA4,TLL1,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2 |
3.140e-03 | -5.76 | regulation of cell morphogenesis | biological process | GO:0022604 | 246 | 4 | 18204 | 45 |
SYT1,RIMS1,RIMS2,RELN |
3.169e-03 | -5.75 | Galactose-binding domain-like | gene3d domains | 2.60.120.260 | 97 | 3 | 14470 | 44 |
RELN,CNTNAP2,EPHA5 |
3.210e-03 | -5.74 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 6 | 18094 | 45 |
GRIK2,TRPM3,CACNA2D1,SLC1A3,KCNJ3,GRIA4 |
3.227e-03 | -5.74 | forebrain development | biological process | GO:0030900 | 408 | 5 | 18204 | 45 |
NRG3,EPHA5,RELN,CNTNAP2,PCDH9 |
3.260e-03 | -5.73 | meninges | COSMIC cancer mutations | meninges | 514 | 6 | 16828 | 48 |
RELN,RIMS2,RIMS1,KCNJ3,SLC35F3,NFIA |
3.260e-03 | -5.73 | meningioma | COSMIC cancer mutations | meningioma | 514 | 6 | 16828 | 48 |
SLC35F3,NFIA,RIMS2,RELN,RIMS1,KCNJ3 |
3.330e-03 | -5.70 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 3 | 16828 | 48 |
FSTL5,NRG3,NRG1 |
3.346e-03 | -5.70 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 7 | 18204 | 45 |
GRIK2,SLC1A3,GRID2,CACNA2D1,GRIA4,TRPM3,KCNJ3 |
3.376e-03 | -5.69 | neuron fate specification | biological process | GO:0048665 | 35 | 2 | 18204 | 45 |
MYT1L,NFIA |
3.401e-03 | -5.68 | Downregulation of ERBB2 signaling | REACTOME pathways | R-HSA-8863795 | 30 | 2 | 10285 | 30 |
NRG1,NRG3 |
3.430e-03 | -5.68 | ZDHHC15 (zinc finger DHHC-type palmitoyltransferase 15) | protein interactions | 158866 | 120 | 3 | 19454 | 49 |
STXBP5L,RIMS2,NRXN1 |
3.452e-03 | -5.67 | Retrograde endocannabinoid signaling | KEGG pathways | hsa04723 | 101 | 3 | 7161 | 22 |
GRIA4,KCNJ3,RIMS1 |
3.452e-03 | -5.67 | Retrograde endocannabinoid signaling | KEGG pathways | ko04723 | 101 | 3 | 7161 | 22 |
RIMS1,KCNJ3,GRIA4 |
3.457e-03 | -5.67 | regulation of biological quality | biological process | GO:0065008 | 2936 | 15 | 18204 | 45 |
GPC6,GRIA4,APOE,GRIK2,RELN,CNTN4,CACNA2D1,GRID2,ANK2,KCNJ3,EPHA5,RIMS1,LINGO2,RIMS2,NRXN1 |
3.487e-03 | -5.66 | cell cortex region | cellular component | GO:0099738 | 35 | 2 | 19108 | 48 |
RIMS2,RIMS1 |
3.504e-03 | -5.65 | FN3 | prosite domains | PS50853 | 192 | 4 | 12186 | 40 |
CNTN4,CNTN5,EPHA5,PTPRG |
3.568e-03 | -5.64 | positive regulation of synaptic transmission, glutamatergic | biological process | GO:0051968 | 36 | 2 | 18204 | 45 |
RELN,NRXN1 |
3.629e-03 | -5.62 | HS-GAG biosynthesis | REACTOME pathways | R-HSA-2022928 | 31 | 2 | 10285 | 30 |
GLCE,GPC6 |
3.635e-03 | -5.62 | KIR31CHANNEL | prints domains | PR01327 | 1 | 1 | 5227 | 19 |
KCNJ3 |
3.635e-03 | -5.62 | NEUREGULIN | prints domains | PR01089 | 1 | 1 | 5227 | 19 |
NRG1 |
3.635e-03 | -5.62 | MTG8PROTEIN | prints domains | PR01876 | 1 | 1 | 5227 | 19 |
RUNX1T1 |
3.644e-03 | -5.61 | Znf_FYVE-rel | interpro domains | IPR017455 | 34 | 2 | 18521 | 49 |
RIMS2,RIMS1 |
3.644e-03 | -5.61 | Death_domain | interpro domains | IPR000488 | 34 | 2 | 18521 | 49 |
ANK2,UNC5C |
3.714e-03 | -5.60 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 48 |
GRIK2,ZNF385D,CACNA2D1,CNTNAP2,SYT1,ST18,NRXN3,RUNX1T1,GRID2 |
3.717e-03 | -5.59 | limbic system development | biological process | GO:0021761 | 126 | 3 | 18204 | 45 |
RELN,EPHA5,CNTNAP2 |
3.732e-03 | -5.59 | membrane protein complex | cellular component | GO:0098796 | 1261 | 9 | 19108 | 48 |
CNTNAP2,SLC1A3,CACNA2D1,STXBP5L,GRIA4,GRID2,GRIK2,KCNJ3,CDH18 |
3.814e-03 | -5.57 | postsynaptic specialization membrane | cellular component | GO:0099634 | 125 | 3 | 19108 | 48 |
GRIA4,GRIK2,GRID2 |
3.843e-03 | -5.56 | zf-met | pfam domains | PF12874 | 35 | 2 | 17795 | 47 |
ZNF385D,ZNF385B |
3.879e-03 | -5.55 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 4 | 18204 | 45 |
PCDH9,CDH18,CNTN4,GRID2 |
3.913e-03 | -5.54 | GPR183 (G protein-coupled receptor 183) | protein interactions | 1880 | 37 | 2 | 19454 | 49 |
NRXN3,GPC6 |
4.101e-03 | -5.50 | dense core granule | cellular component | GO:0031045 | 38 | 2 | 19108 | 48 |
SYT1,CACNA2D1 |
4.162e-03 | -5.48 | ion binding | molecular function | GO:0043167 | 6007 | 24 | 18094 | 45 |
KIF21A,RIMS2,APOE,FSTL5,DTNA,PCDH9,CACNA2D1,NRXN1,EPHA5,RUNX1T1,GLCE,MYT1L,SYT1,TLL1,NRXN3,CADPS2,ST18,SLC1A3,ZNF385B,ZNF385D,RELN,CHN2,EBF1,RIMS1 |
4.178e-03 | -5.48 | long-term memory | biological process | GO:0007616 | 39 | 2 | 18204 | 45 |
APOE,RELN |
4.187e-03 | -5.48 | C2 | pfam domains | PF00168 | 123 | 3 | 17795 | 47 |
RIMS1,SYT1,RIMS2 |
4.251e-03 | -5.46 | ASX_HYDROXYL | prosite domains | PS00010 | 100 | 3 | 12186 | 40 |
NRXN3,TLL1,NRXN1 |
4.339e-03 | -5.44 | E (envelope protein) | protein interactions | 14254599 | 39 | 2 | 19454 | 49 |
RIMS1,RIMS2 |
4.391e-03 | -5.43 | positive regulation of dendritic spine development | biological process | GO:0060999 | 40 | 2 | 18204 | 45 |
RELN,APOE |
4.391e-03 | -5.43 | regulation of membrane repolarization | biological process | GO:0060306 | 40 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
4.650e-03 | -5.37 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 5 | 18094 | 45 |
CACNA2D1,TRPM3,GRIK2,SLC1A3,KCNJ3 |
4.728e-03 | -5.35 | telencephalon development | biological process | GO:0021537 | 276 | 4 | 18204 | 45 |
CNTNAP2,RELN,NRG3,EPHA5 |
4.915e-03 | -5.32 | DEATH | smart domains | SM00005 | 27 | 2 | 9717 | 38 |
ANK2,UNC5C |
4.938e-03 | -5.31 | protein localization to M-band | biological process | GO:0036309 | 2 | 1 | 18204 | 45 |
ANK2 |
4.938e-03 | -5.31 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 45 |
CST3 |
4.938e-03 | -5.31 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 45 |
CST3 |
4.938e-03 | -5.31 | superior temporal gyrus development | biological process | GO:0071109 | 2 | 1 | 18204 | 45 |
CNTNAP2 |
4.938e-03 | -5.31 | protein localization to T-tubule | biological process | GO:0036371 | 2 | 1 | 18204 | 45 |
ANK2 |
4.938e-03 | -5.31 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 45 |
APOE |
4.955e-03 | -5.31 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 48 |
DTNA,CNTN5,RELN |
4.968e-03 | -5.30 | extracellularly glutamate-gated ion channel activity | molecular function | GO:0005234 | 2 | 1 | 18094 | 45 |
GRIK2 |
4.968e-03 | -5.30 | syntaxin-3 binding | molecular function | GO:0030348 | 2 | 1 | 18094 | 45 |
SYT1 |
5.018e-03 | -5.29 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 48 |
APOE |
5.018e-03 | -5.29 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 48 |
APOE |
5.018e-03 | -5.29 | GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) | protein interactions | 2891 | 42 | 2 | 19454 | 49 |
GRIK2,GRID2 |
5.018e-03 | -5.29 | FGF1 (fibroblast growth factor 1) | protein interactions | 2246 | 42 | 2 | 19454 | 49 |
SYT1,GPC6 |
5.031e-03 | -5.29 | Plec (plectin) | protein interactions | 64204 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Lrrfip2 (LRR binding FLII interacting protein 2) | protein interactions | 301035 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Tpm4 (tropomyosin 4) | protein interactions | 24852 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 65028 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Gnb1 (G protein subunit beta 1) | protein interactions | 24400 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Mfap1a (microfibrillar-associated protein 1A) | protein interactions | 499878 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Eif4b (eukaryotic translation initiation factor 4B) | protein interactions | 300253 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Ndufv3 (NADH:ubiquinone oxidoreductase subunit V3) | protein interactions | 64539 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Sec31a (SEC31 homolog A, COPII coat complex component) | protein interactions | 93646 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Mycbp (Myc binding protein) | protein interactions | 100361133 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Cox4i1 (cytochrome c oxidase subunit 4i1) | protein interactions | 29445 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Sytl4 (synaptotagmin-like 4) | protein interactions | 140594 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Chchd3 (coiled-coil-helix-coiled-coil-helix domain containing 3) | protein interactions | 296966 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Thy1 (Thy-1 cell surface antigen) | protein interactions | 24832 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Eef1b2 (eukaryotic translation elongation factor 1 beta 2) | protein interactions | 363241 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Ckap4 (cytoskeleton-associated protein 4) | protein interactions | 362859 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Lmo7 (LIM domain 7) | protein interactions | 361084 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Rab3a (RAB3A, member RAS oncogene family) | protein interactions | 25531 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Nucb1 (nucleobindin 1) | protein interactions | 84595 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Myo18a (myosin XVIIIa) | protein interactions | 360570 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Tnpo2 (transportin 2) | protein interactions | 304670 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Ncl (nucleolin) | protein interactions | 25135 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Ndufv2 (NADH:ubiquinone oxidoreductase core subunit V2) | protein interactions | 81728 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Gsn (gelsolin) | protein interactions | 296654 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Hadha (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) | protein interactions | 170670 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Myl12b (myosin light chain 12B) | protein interactions | 50685 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Tcp1 (t-complex 1) | protein interactions | 24818 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Atp5pd (ATP synthase peripheral stalk subunit d) | protein interactions | 641434 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Dnaja2 (DnaJ heat shock protein family (Hsp40) member A2) | protein interactions | 84026 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Dbn1 (drebrin 1) | protein interactions | 81653 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Psmd3 (proteasome 26S subunit, non-ATPase 3) | protein interactions | 287670 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Psma3 (proteasome 20S subunit alpha 3) | protein interactions | 29670 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Rplp1 (ribosomal protein lateral stalk subunit P1) | protein interactions | 140661 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Atp5pf (ATP synthase peripheral stalk subunit F6) | protein interactions | 94271 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Ubap2l (ubiquitin associated protein 2-like) | protein interactions | 361984 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Tmod3 (tropomodulin 3) | protein interactions | 300838 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Rab5b (RAB5B, member RAS oncogene family) | protein interactions | 288779 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Rpsa (ribosomal protein SA) | protein interactions | 29236 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Prdx2 (peroxiredoxin 2) | protein interactions | 29338 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Tufm (Tu translation elongation factor, mitochondrial) | protein interactions | 293481 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.031e-03 | -5.29 | Rcn1 (reticulocalbin 1) | protein interactions | 362182 | 2 | 1 | 19454 | 49 |
STXBP5L |
5.225e-03 | -5.25 | hippocampal mossy fiber to CA3 synapse | cellular component | GO:0098686 | 43 | 2 | 19108 | 48 |
GRIK2,SYT1 |
5.276e-03 | -5.24 | Lgl_C | pfam domains | PF08596 | 2 | 1 | 17795 | 47 |
STXBP5L |
5.276e-03 | -5.24 | Neuregulin | pfam domains | PF02158 | 2 | 1 | 17795 | 47 |
NRG1 |
5.284e-03 | -5.24 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 49 |
PTPRG |
5.284e-03 | -5.24 | Neuregulin_C | interpro domains | IPR002154 | 2 | 1 | 18521 | 49 |
NRG1 |
5.284e-03 | -5.24 | Solute_c_fam_35_mem_F3/F4 | interpro domains | IPR026505 | 2 | 1 | 18521 | 49 |
SLC35F3 |
5.284e-03 | -5.24 | Chimaerin_SH2 | interpro domains | IPR035840 | 2 | 1 | 18521 | 49 |
CHN2 |
5.284e-03 | -5.24 | CAPS | interpro domains | IPR033227 | 2 | 1 | 18521 | 49 |
CADPS2 |
5.284e-03 | -5.24 | RhoGAP_chimaerin | interpro domains | IPR037860 | 2 | 1 | 18521 | 49 |
CHN2 |
5.284e-03 | -5.24 | CHN1/CHN2 | interpro domains | IPR017356 | 2 | 1 | 18521 | 49 |
CHN2 |
5.284e-03 | -5.24 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 49 |
DTNA |
5.284e-03 | -5.24 | Lgl_C_dom | interpro domains | IPR013905 | 2 | 1 | 18521 | 49 |
STXBP5L |
5.284e-03 | -5.24 | CCSER | interpro domains | IPR029627 | 2 | 1 | 18521 | 49 |
CCSER1 |
5.362e-03 | -5.23 | ankle | COSMIC cancer mutations | ankle | 398 | 5 | 16828 | 48 |
STXBP5L,RIMS2,NRG3,SLC35F3,CNTNAP2 |
5.402e-03 | -5.22 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 11 | 16828 | 48 |
LINGO2,CDH18,GRID2,FSTL5,EBF1,SYT1,NRG1,NRXN3,NPAS3,RELN,TRPM3 |
5.459e-03 | -5.21 | protein localization to membrane | biological process | GO:0072657 | 462 | 5 | 18204 | 45 |
GRIK2,ANK2,RELN,APOE,NRXN1 |
5.515e-03 | -5.20 | ZF_FYVE | prosite domains | PS50178 | 34 | 2 | 12186 | 40 |
RIMS2,RIMS1 |
5.597e-03 | -5.19 | GPM6A (glycoprotein M6A) | protein interactions | 2823 | 143 | 3 | 19454 | 49 |
ANK2,CACNA2D1,SYT1 |
5.606e-03 | -5.18 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 45 |
NRXN1,CNTNAP2,NRXN3 |
5.657e-03 | -5.17 | ZnF_U1 | smart domains | SM00451 | 29 | 2 | 9717 | 38 |
ZNF385D,ZNF385B |
5.664e-03 | -5.17 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 39 | 16828 | 48 |
PTPRG,ST18,PCDH9,NRXN1,EPHA5,NPAS3,CHN2,CACNA2D1,SLC1A3,GRID2,CADPS2,KIF21A,NRXN3,DTNA,UNC5C,SYT1,LSAMP,RELN,ZNF385B,GPC6,RIMS1,FSTL5,EBF1,GRIA4,TLL1,RIMS2,TRPM3,NRG3,MYT1L,LINGO2,RALYL,NRG1,SLC35F3,CNTNAP2,STXBP5L,KCNJ3,ZNF385D,GRIK2,ANK2 |
5.694e-03 | -5.17 | positive regulation of cellular component organization | biological process | GO:0051130 | 1122 | 8 | 18204 | 45 |
LINGO2,RELN,CNTNAP2,NRXN1,SYT1,GRID2,APOE,NRG1 |
5.704e-03 | -5.17 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 43 | 16828 | 48 |
NFIA,ST18,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,SYT1,GRID2,CADPS2,CDH18,KIF21A,ZNF385B,RIMS1,RELN,TRPM3,NRG3,RALYL,NRG1,RUNX1T1,SLC35F3,KCNJ3,ZNF385D,STXBP5L,LRRTM4,PTPRG,GLCE,CACNA2D1,EPHA5,NRXN3,UNC5C,LSAMP,GPC6,GRIA4,TLL1,FSTL5,EBF1,MYT1L,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5 |
5.771e-03 | -5.15 | neuron recognition | biological process | GO:0008038 | 46 | 2 | 18204 | 45 |
CNTN4,CNTNAP2 |
5.826e-03 | -5.15 | Activation of Na-permeable Kainate Receptors | REACTOME pathways | R-HSA-451307 | 2 | 1 | 10285 | 30 |
GRIK2 |
5.885e-03 | -5.14 | - | gene3d domains | 2.60.120.200 | 121 | 3 | 14470 | 44 |
NRXN1,CNTNAP2,NRXN3 |
5.946e-03 | -5.12 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 48 |
TLL1,KCNJ3,CACNA2D1,ANK2,GRID2 |
6.018e-03 | -5.11 | regulation of long-term synaptic potentiation | biological process | GO:1900271 | 47 | 2 | 18204 | 45 |
RELN,APOE |
6.044e-03 | -5.11 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 45 |
LINGO2,RELN,GRID2,NRXN1 |
6.107e-03 | -5.10 | pseudomyxoma_peritonei | COSMIC cancer mutations | pseudomyxoma_peritonei | 585 | 6 | 16828 | 48 |
LINGO2,NRG1,PTPRG,RIMS1,CNTNAP2,ANK2 |
6.107e-03 | -5.10 | peritoneum-appendix-other-pseudomyxoma_peritonei | COSMIC cancer mutations | peritoneum-appendix-other-pseudomyxoma_peritonei | 585 | 6 | 16828 | 48 |
ANK2,RIMS1,CNTNAP2,PTPRG,NRG1,LINGO2 |
6.116e-03 | -5.10 | muscle system process | biological process | GO:0003012 | 297 | 4 | 18204 | 45 |
CACNA2D1,ANK2,DTNA,KCNJ3 |
6.157e-03 | -5.09 | appendix | COSMIC cancer mutations | appendix | 586 | 6 | 16828 | 48 |
ANK2,RIMS1,LINGO2,PTPRG,NRG1,CNTNAP2 |
6.207e-03 | -5.08 | peritoneum | COSMIC cancer mutations | peritoneum | 587 | 6 | 16828 | 48 |
LINGO2,RIMS1,CNTNAP2,ANK2,NRG1,PTPRG |
6.250e-03 | -5.08 | SLC34A2 (solute carrier family 34 member 2) | protein interactions | 10568 | 47 | 2 | 19454 | 49 |
CACNA2D1,LINGO2 |
6.277e-03 | -5.07 | ErbB Signaling Pathway | WikiPathways | WP673 | 54 | 2 | 5310 | 12 |
NRG1,NRG3 |
6.277e-03 | -5.07 | Apoptosis-related network due to altered Notch3 in ovarian cancer | WikiPathways | WP2864 | 54 | 2 | 5310 | 12 |
APOE,NRG1 |
6.412e-03 | -5.05 | stomach-carcinoma-adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-adenocarcinoma | 15150 | 48 | 16828 | 48 |
GPC6,CNTN4,UNC5C,LSAMP,NRXN3,DTNA,CACNA2D1,EPHA5,GLCE,PTPRG,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2,MYT1L,GRIA4,TLL1,EBF1,FSTL5,RIMS1,ZNF385B,APOE,RELN,SYT1,CADPS2,CDH18,KIF21A,GRID2,SLC1A3,CHN2,NPAS3,NRXN1,PCDH9,ST18,NFIA,ZNF385D,KCNJ3,CST3,LRRTM4,STXBP5L,SLC35F3,RALYL,RUNX1T1,NRG1,NRG3,TRPM3,RIMS2 |
6.497e-03 | -5.04 | small molecule binding | molecular function | GO:0036094 | 6197 | 24 | 18094 | 45 |
NRXN1,CACNA2D1,EPHA5,RUNX1T1,KIF21A,RIMS2,FSTL5,APOE,DTNA,PCDH9,SLC1A3,ZNF385D,ZNF385B,RELN,CHN2,RIMS1,EBF1,GLCE,MYT1L,SYT1,ST18,CADPS2,NRXN3,TLL1 |
6.527e-03 | -5.03 | positive regulation of cation channel activity | biological process | GO:2001259 | 49 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
6.550e-03 | -5.03 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 44 |
CACNA2D1,NPAS3 |
6.568e-03 | -5.03 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 6 | 16828 | 48 |
STXBP5L,GRIK2,MYT1L,ST18,PTPRG,NRG1 |
6.573e-03 | -5.02 | import into cell | biological process | GO:0098657 | 687 | 6 | 18204 | 45 |
APOE,SLC1A3,KCNJ3,ANK2,CACNA2D1,SYT1 |
6.579e-03 | -5.02 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 10 | 16828 | 48 |
EBF1,CNTNAP2,TLL1,ST18,RELN,RIMS2,NRXN1,MYT1L,GPC6,ANK2 |
6.579e-03 | -5.02 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 10 | 16828 | 48 |
ST18,TLL1,CNTNAP2,EBF1,ANK2,GPC6,MYT1L,NRXN1,RIMS2,RELN |
6.579e-03 | -5.02 | calcium ion binding | molecular function | GO:0005509 | 683 | 6 | 18094 | 45 |
GLCE,NRXN1,FSTL5,SYT1,PCDH9,TLL1 |
6.613e-03 | -5.02 | positive regulation of monoatomic ion transmembrane transport | biological process | GO:0034767 | 155 | 3 | 18204 | 45 |
ANK2,CACNA2D1,RELN |
6.640e-03 | -5.01 | bone-femur-chondrosarcoma | COSMIC cancer mutations | bone-femur-chondrosarcoma | 419 | 5 | 16828 | 48 |
UNC5C,ST18,ZNF385B,STXBP5L,CNTN4 |
6.678e-03 | -5.01 | central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_II | COSMIC cancer mutations | central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_II | 43 | 2 | 16828 | 48 |
DTNA,RELN |
6.687e-03 | -5.01 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 48 |
GPC6,SLC1A3,EPHA5,UNC5C,CNTNAP2,KCNJ3,NRXN1 |
6.794e-03 | -4.99 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | 265 | 4 | 16828 | 48 |
EBF1,RELN,NRXN3,UNC5C |
6.835e-03 | -4.99 | protein localization | biological process | GO:0008104 | 1954 | 11 | 18204 | 45 |
RIMS2,RIMS1,NRXN1,ANK2,GRID2,STXBP5L,RELN,CADPS2,GRIK2,CNTNAP2,APOE |
6.896e-03 | -4.98 | Signaling by ERBB4 | REACTOME pathways | R-HSA-1236394 | 43 | 2 | 10285 | 30 |
NRG3,NRG1 |
6.929e-03 | -4.97 | regulation of developmental process | biological process | GO:0050793 | 2540 | 13 | 18204 | 45 |
RELN,UNC5C,APOE,NRG1,RIMS2,LINGO2,RIMS1,NRXN1,CST3,GRID2,SYT1,CNTN4,RUNX1T1 |
6.987e-03 | -4.96 | skin-neck-malignant_melanoma | COSMIC cancer mutations | skin-neck-malignant_melanoma | 1223 | 9 | 16828 | 48 |
GRID2,CDH18,CNTNAP2,RELN,RIMS2,TRPM3,ZNF385B,GPC6,ZNF385D |
7.046e-03 | -4.96 | cellular macromolecule localization | biological process | GO:0070727 | 1962 | 11 | 18204 | 45 |
NRXN1,CNTNAP2,RIMS2,RELN,CADPS2,GRIK2,RIMS1,APOE,GRID2,ANK2,STXBP5L |
7.054e-03 | -4.95 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 45 |
NRXN1,SLC1A3 |
7.157e-03 | -4.94 | angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | angioimmunoblastic_T_cell_lymphoma | 269 | 4 | 16828 | 48 |
NRXN3,UNC5C,EBF1,RELN |
7.211e-03 | -4.93 | Retinoid metabolism and transport | REACTOME pathways | R-HSA-975634 | 44 | 2 | 10285 | 30 |
APOE,GPC6 |
7.284e-03 | -4.92 | neck | COSMIC cancer mutations | neck | 1231 | 9 | 16828 | 48 |
RELN,RIMS2,GPC6,ZNF385D,TRPM3,ZNF385B,CDH18,GRID2,CNTNAP2 |
7.341e-03 | -4.91 | positive regulation of cell growth | biological process | GO:0030307 | 161 | 3 | 18204 | 45 |
SYT1,RIMS1,RIMS2 |
7.398e-03 | -4.91 | positive regulation of synaptic vesicle exocytosis | biological process | GO:2000302 | 3 | 1 | 18204 | 45 |
SYT1 |
7.398e-03 | -4.91 | regulation of SA node cell action potential | biological process | GO:0098907 | 3 | 1 | 18204 | 45 |
ANK2 |
7.398e-03 | -4.91 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 45 |
NRXN1 |
7.398e-03 | -4.91 | calcium ion transmembrane transport via high voltage-gated calcium channel | biological process | GO:0061577 | 3 | 1 | 18204 | 45 |
CACNA2D1 |
7.398e-03 | -4.91 | lateral motor column neuron migration | biological process | GO:0097477 | 3 | 1 | 18204 | 45 |
RELN |
7.398e-03 | -4.91 | membrane depolarization during bundle of His cell action potential | biological process | GO:0086048 | 3 | 1 | 18204 | 45 |
CACNA2D1 |
7.398e-03 | -4.91 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 45 |
APOE |
7.398e-03 | -4.91 | regulation of synaptic activity | biological process | GO:0060025 | 3 | 1 | 18204 | 45 |
RELN |
7.398e-03 | -4.91 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 45 |
APOE |
7.398e-03 | -4.91 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 45 |
NRG3 |
7.411e-03 | -4.90 | cell-cell adhesion mediator activity | molecular function | GO:0098632 | 52 | 2 | 18094 | 45 |
CNTN5,CNTN4 |
7.421e-03 | -4.90 | regulation of developmental growth | biological process | GO:0048638 | 314 | 4 | 18204 | 45 |
RIMS2,RIMS1,SYT1,APOE |
7.479e-03 | -4.90 | human chr5p14.3 | chromosome location | human chr5p14.3 | 4 | 1 | 26134 | 49 |
CDH18 |
7.518e-03 | -4.89 | clathrin-sculpted acetylcholine transport vesicle membrane | cellular component | GO:0060201 | 3 | 1 | 19108 | 48 |
SYT1 |
7.518e-03 | -4.89 | clathrin-sculpted acetylcholine transport vesicle | cellular component | GO:0060200 | 3 | 1 | 19108 | 48 |
SYT1 |
7.538e-03 | -4.89 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 49 |
NRXN1 |
7.538e-03 | -4.89 | Rps26 (ribosomal protein S26) | protein interactions | 27139 | 3 | 1 | 19454 | 49 |
STXBP5L |
7.538e-03 | -4.89 | Tpm1 (tropomyosin 1) | protein interactions | 24851 | 3 | 1 | 19454 | 49 |
STXBP5L |
7.538e-03 | -4.89 | NAB2 (mRNA-binding protein NAB2) | protein interactions | 852755 | 3 | 1 | 19454 | 49 |
RALYL |
7.538e-03 | -4.89 | PRDM12 (PR/SET domain 12) | protein interactions | 59335 | 3 | 1 | 19454 | 49 |
RUNX1T1 |
7.538e-03 | -4.89 | SHF (Src homology 2 domain containing F) | protein interactions | 90525 | 3 | 1 | 19454 | 49 |
CHN2 |
7.538e-03 | -4.89 | Vcp (valosin-containing protein) | protein interactions | 116643 | 3 | 1 | 19454 | 49 |
STXBP5L |
7.556e-03 | -4.89 | anatomical structure development | biological process | GO:0048856 | 5207 | 21 | 18204 | 45 |
SLC1A3,LSAMP,CDH18,TLL1,UNC5C,CNTNAP2,RELN,NRG1,APOE,PCDH9,CNTN5,NRXN1,NFIA,EPHA5,NRXN3,ANK2,GRID2,CNTN4,NRG3,FSTL5,MYT1L |
7.677e-03 | -4.87 | HADHA (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) | protein interactions | 3030 | 491 | 5 | 19454 | 49 |
APOE,NRXN3,EPHA5,GPC6,KIF21A |
7.851e-03 | -4.85 | homophilic cell adhesion via plasma membrane adhesion molecules | biological process | GO:0007156 | 165 | 3 | 18204 | 45 |
CNTN4,PCDH9,CDH18 |
7.851e-03 | -4.85 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 45 |
CACNA2D1,SLC1A3,KCNJ3 |
7.884e-03 | -4.84 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 11 | 18204 | 45 |
GRIK2,RELN,UNC5C,PTPRG,ST18,NRG1,GRIA4,EPHA5,NFIA,NRG3,GRID2 |
7.903e-03 | -4.84 | NHR2 | pfam domains | PF08788 | 3 | 1 | 17795 | 47 |
RUNX1T1 |
7.903e-03 | -4.84 | UPA_2 | pfam domains | PF17809 | 3 | 1 | 17795 | 47 |
ANK2 |
7.916e-03 | -4.84 | NHR2 | interpro domains | IPR014896 | 3 | 1 | 18521 | 49 |
RUNX1T1 |
7.916e-03 | -4.84 | Ankyrin_UPA | interpro domains | IPR040745 | 3 | 1 | 18521 | 49 |
ANK2 |
7.916e-03 | -4.84 | Reeler_dom | interpro domains | IPR002861 | 3 | 1 | 18521 | 49 |
RELN |
7.916e-03 | -4.84 | BMP_1/tolloid-like | interpro domains | IPR015446 | 3 | 1 | 18521 | 49 |
TLL1 |
7.916e-03 | -4.84 | Reeler_sf | interpro domains | IPR042307 | 3 | 1 | 18521 | 49 |
RELN |
7.916e-03 | -4.84 | ZnMP_TLD/BMP1 | interpro domains | IPR034036 | 3 | 1 | 18521 | 49 |
TLL1 |
7.916e-03 | -4.84 | CBFA2T1/2/3 | interpro domains | IPR013289 | 3 | 1 | 18521 | 49 |
RUNX1T1 |
8.085e-03 | -4.82 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 45 |
SLC1A3,APOE,KCNJ3,CACNA2D1,ANK2 |
8.116e-03 | -4.81 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 6 | 18094 | 45 |
CACNA2D1,GRIK2,TRPM3,SLC1A3,KCNJ3,GRIA4 |
8.165e-03 | -4.81 | membrane depolarization | biological process | GO:0051899 | 55 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
8.181e-03 | -4.81 | PLTP (phospholipid transfer protein) | protein interactions | 5360 | 54 | 2 | 19454 | 49 |
APOE,GPC6 |
8.248e-03 | -4.80 | positive regulation of developmental growth | biological process | GO:0048639 | 168 | 3 | 18204 | 45 |
RIMS1,SYT1,RIMS2 |
8.288e-03 | -4.79 | ear | COSMIC cancer mutations | ear | 624 | 6 | 16828 | 48 |
FSTL5,RELN,NPAS3,KCNJ3,CNTNAP2,ANK2 |
8.476e-03 | -4.77 | large_intestine-colon-adenoma | COSMIC cancer mutations | large_intestine-colon-adenoma | 627 | 6 | 16828 | 48 |
CNTN5,CACNA2D1,CNTNAP2,GRIK2,RUNX1T1,ZNF385B |
8.550e-03 | -4.76 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 5 | 18204 | 45 |
CNTNAP2,NRXN1,NRG1,LINGO2,GRID2 |
8.594e-03 | -4.76 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | REACTOME pathways | R-HSA-112314 | 146 | 3 | 10285 | 30 |
KCNJ3,GRIA4,GRIK2 |
8.618e-03 | -4.75 | regulation of vesicle-mediated transport | biological process | GO:0060627 | 516 | 5 | 18204 | 45 |
APOE,CADPS2,RIMS2,SYT1,RIMS1 |
8.630e-03 | -4.75 | thalamus | COSMIC cancer mutations | thalamus | 284 | 4 | 16828 | 48 |
RELN,EBF1,DTNA,GRIA4 |
8.726e-03 | -4.74 | Toxicity of botulinum toxin type G (BoNT/G) | REACTOME pathways | R-HSA-5250989 | 3 | 1 | 10285 | 30 |
SYT1 |
8.726e-03 | -4.74 | Toxicity of botulinum toxin type B (BoNT/B) | REACTOME pathways | R-HSA-5250958 | 3 | 1 | 10285 | 30 |
SYT1 |
8.776e-03 | -4.74 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 2 | 19454 | 49 |
NRXN3,APOE |
9.046e-03 | -4.71 | regulation of neuronal synaptic plasticity | biological process | GO:0048168 | 58 | 2 | 18204 | 45 |
GRIK2,APOE |
9.085e-03 | -4.70 | monoatomic cation channel activity | molecular function | GO:0005261 | 331 | 4 | 18094 | 45 |
CACNA2D1,GRIK2,TRPM3,KCNJ3 |
9.093e-03 | -4.70 | Cell adhesion molecules (CAMs) | KEGG pathways | ko04514 | 143 | 3 | 7161 | 22 |
NRXN3,NRXN1,CNTNAP2 |
9.093e-03 | -4.70 | Cell adhesion molecules (CAMs) | KEGG pathways | hsa04514 | 143 | 3 | 7161 | 22 |
NRXN1,NRXN3,CNTNAP2 |
9.095e-03 | -4.70 | - | gene3d domains | 2.60.40.2660 | 3 | 1 | 14470 | 44 |
ANK2 |
9.095e-03 | -4.70 | Reeler domain | gene3d domains | 2.60.40.4060 | 3 | 1 | 14470 | 44 |
RELN |
9.172e-03 | -4.69 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 7 | 19454 | 49 |
ANK2,SYT1,RIMS1,KIF21A,LSAMP,SLC1A3,APOE |
9.225e-03 | -4.69 | transporter activity | molecular function | GO:0005215 | 1211 | 8 | 18094 | 45 |
GRIA4,KCNJ3,APOE,GRID2,SLC1A3,CACNA2D1,GRIK2,TRPM3 |
9.293e-03 | -4.68 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_II | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_II | 51 | 2 | 16828 | 48 |
CNTN5,RELN |
9.315e-03 | -4.68 | nodular | COSMIC cancer mutations | nodular | 1515 | 10 | 16828 | 48 |
GRIK2,RELN,NPAS3,CNTN4,TLL1,ST18,KIF21A,CDH18,GRID2,EBF1 |
9.340e-03 | -4.67 | human chr6q16.3 | chromosome location | human chr6q16.3 | 5 | 1 | 26134 | 49 |
GRIK2 |
9.349e-03 | -4.67 | protein localization to synapse | biological process | GO:0035418 | 59 | 2 | 18204 | 45 |
RELN,NRXN1 |
9.349e-03 | -4.67 | regulation of dendritic spine development | biological process | GO:0060998 | 59 | 2 | 18204 | 45 |
RELN,APOE |
9.364e-03 | -4.67 | signaling receptor activity | molecular function | GO:0038023 | 1474 | 9 | 18094 | 45 |
NRXN1,GRIK2,GPC6,EPHA5,GRID2,UNC5C,PTPRG,GRIA4,NRXN3 |
9.364e-03 | -4.67 | molecular transducer activity | molecular function | GO:0060089 | 1474 | 9 | 18094 | 45 |
UNC5C,PTPRG,GRIA4,NRXN3,GRIK2,NRXN1,GPC6,GRID2,EPHA5 |
9.390e-03 | -4.67 | SNAP25 (synaptosome associated protein 25) | protein interactions | 6616 | 58 | 2 | 19454 | 49 |
SYT1,RIMS1 |
9.391e-03 | -4.67 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 48 |
GLCE,PTPRG,CACNA2D1,EPHA5,UNC5C,LSAMP,NRXN3,DTNA,GPC6,CNTN4,GRIA4,TLL1,EBF1,FSTL5,MYT1L,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,PCDH9,NFIA,ST18,SLC1A3,CHN2,NPAS3,NRXN1,SYT1,CDH18,CADPS2,KIF21A,GRID2,RIMS1,ZNF385B,RELN,NRG3,TRPM3,RIMS2,SLC35F3,RALYL,RUNX1T1,NRG1,ZNF385D,KCNJ3,LRRTM4,STXBP5L |
9.597e-03 | -4.65 | Signaling by ERBB2 | REACTOME pathways | R-HSA-1227986 | 51 | 2 | 10285 | 30 |
NRG1,NRG3 |
9.656e-03 | -4.64 | regulation of action potential | biological process | GO:0098900 | 60 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
9.656e-03 | -4.64 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 45 |
CNTNAP2,GRIK2 |
9.769e-03 | -4.63 | syntaxin binding | molecular function | GO:0019905 | 60 | 2 | 18094 | 45 |
STXBP5L,SYT1 |
9.813e-03 | -4.62 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 7 | 16828 | 48 |
SYT1,SLC35F3,CNTNAP2,NRG1,TLL1,NRXN3,EPHA5 |
9.813e-03 | -4.62 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 7 | 16828 | 48 |
EPHA5,NRXN3,NRG1,TLL1,SLC35F3,CNTNAP2,SYT1 |
9.816e-03 | -4.62 | REELIN | prosite domains | PS51019 | 3 | 1 | 12186 | 40 |
RELN |
9.834e-03 | -4.62 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 9 | 16828 | 48 |
KIF21A,EBF1,GRID2,ST18,TLL1,RELN,NPAS3,CNTN4,GRIK2 |
9.852e-03 | -4.62 | positive regulation of synaptic vesicle fusion to presynaptic active zone membrane | biological process | GO:0031632 | 4 | 1 | 18204 | 45 |
SYT1 |
9.852e-03 | -4.62 | positive regulation of AMPA receptor activity | biological process | GO:2000969 | 4 | 1 | 18204 | 45 |
RELN |
9.852e-03 | -4.62 | regulation of calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:1903233 | 4 | 1 | 18204 | 45 |
SYT1 |
9.852e-03 | -4.62 | spinal cord motor neuron migration | biological process | GO:0097476 | 4 | 1 | 18204 | 45 |
RELN |
9.852e-03 | -4.62 | positive regulation of high voltage-gated calcium channel activity | biological process | GO:1901843 | 4 | 1 | 18204 | 45 |
CACNA2D1 |
9.852e-03 | -4.62 | regulation of atrial cardiac muscle cell action potential | biological process | GO:0098910 | 4 | 1 | 18204 | 45 |
ANK2 |
9.852e-03 | -4.62 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 45 |
APOE |
9.852e-03 | -4.62 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 45 |
APOE |
9.852e-03 | -4.62 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 45 |
APOE |
9.852e-03 | -4.62 | response to methylmercury | biological process | GO:0051597 | 4 | 1 | 18204 | 45 |
ANK2 |
9.852e-03 | -4.62 | calcium-dependent activation of synaptic vesicle fusion | biological process | GO:0099502 | 4 | 1 | 18204 | 45 |
SYT1 |
9.852e-03 | -4.62 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 45 |
CST3 |
9.852e-03 | -4.62 | protein localization to juxtaparanode region of axon | biological process | GO:0071205 | 4 | 1 | 18204 | 45 |
CNTNAP2 |
9.852e-03 | -4.62 | clustering of voltage-gated potassium channels | biological process | GO:0045163 | 4 | 1 | 18204 | 45 |
CNTNAP2 |
9.852e-03 | -4.62 | positive regulation of synaptic vesicle membrane organization | biological process | GO:1901634 | 4 | 1 | 18204 | 45 |
SYT1 |
9.912e-03 | -4.61 | calcium ion sensor activity | molecular function | GO:0061891 | 4 | 1 | 18094 | 45 |
SYT1 |
9.912e-03 | -4.61 | AMPA glutamate receptor activity | molecular function | GO:0004971 | 4 | 1 | 18094 | 45 |
GRIA4 |
9.912e-03 | -4.61 | voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization | molecular function | GO:0086089 | 4 | 1 | 18094 | 45 |
KCNJ3 |
9.912e-03 | -4.61 | G-protein activated inward rectifier potassium channel activity | molecular function | GO:0015467 | 4 | 1 | 18094 | 45 |
KCNJ3 |
9.963e-03 | -4.61 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 156 | 3 | 16828 | 48 |
GRIK2,NRXN3,EBF1 |
1.001e-02 | -4.60 | clathrin-sculpted glutamate transport vesicle membrane | cellular component | GO:0060203 | 4 | 1 | 19108 | 48 |
SYT1 |
1.001e-02 | -4.60 | clathrin-sculpted glutamate transport vesicle | cellular component | GO:0060199 | 4 | 1 | 19108 | 48 |
SYT1 |
1.001e-02 | -4.60 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 48 |
APOE |
1.004e-02 | -4.60 | Ywhaq (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta) | protein interactions | 25577 | 4 | 1 | 19454 | 49 |
STXBP5L |
1.004e-02 | -4.60 | CALY (calcyon neuron specific vesicular protein) | protein interactions | 50632 | 4 | 1 | 19454 | 49 |
NRG1 |
1.004e-02 | -4.60 | Psmc5 (proteasome 26S subunit, ATPase 5) | protein interactions | 81827 | 4 | 1 | 19454 | 49 |
STXBP5L |
1.004e-02 | -4.60 | Baz2b (bromodomain adjacent to zinc finger domain, 2B) | protein interactions | 407823 | 4 | 1 | 19454 | 49 |
CACNA2D1 |
1.004e-02 | -4.60 | Clta (clathrin, light chain A) | protein interactions | 83800 | 4 | 1 | 19454 | 49 |
STXBP5L |
1.004e-02 | -4.60 | Map1b (microtubule-associated protein 1B) | protein interactions | 29456 | 4 | 1 | 19454 | 49 |
STXBP5L |
1.010e-02 | -4.60 | negative regulation of cell projection organization | biological process | GO:0031345 | 181 | 3 | 18204 | 45 |
APOE,PTPRG,GLCE |
1.020e-02 | -4.59 | transport | biological process | GO:0006810 | 3615 | 16 | 18204 | 45 |
NRXN1,RIMS1,RIMS2,KCNJ3,SYT1,GRID2,STXBP5L,ANK2,CACNA2D1,SLC35F3,SLC1A3,GRIK2,CADPS2,TRPM3,APOE,GRIA4 |
1.028e-02 | -4.58 | telencephalon cell migration | biological process | GO:0022029 | 62 | 2 | 18204 | 45 |
RELN,NRG3 |
1.034e-02 | -4.57 | Metabolism of fat-soluble vitamins | REACTOME pathways | R-HSA-6806667 | 53 | 2 | 10285 | 30 |
APOE,GPC6 |
1.035e-02 | -4.57 | OBSCN (obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF) | protein interactions | 84033 | 61 | 2 | 19454 | 49 |
ANK2,SLC1A3 |
1.045e-02 | -4.56 | regulation of monoatomic ion transmembrane transport | biological process | GO:0034765 | 347 | 4 | 18204 | 45 |
KCNJ3,RELN,CACNA2D1,ANK2 |
1.052e-02 | -4.55 | COE1_HLH | pfam domains | PF16423 | 4 | 1 | 17795 | 47 |
EBF1 |
1.052e-02 | -4.55 | COE1_DBD | pfam domains | PF16422 | 4 | 1 | 17795 | 47 |
EBF1 |
1.052e-02 | -4.55 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 47 |
APOE |
1.052e-02 | -4.55 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 47 |
NFIA |
1.052e-02 | -4.55 | VGCC_alpha2 | pfam domains | PF08473 | 4 | 1 | 17795 | 47 |
CACNA2D1 |
1.052e-02 | -4.55 | LLGL | pfam domains | PF08366 | 4 | 1 | 17795 | 47 |
STXBP5L |
1.052e-02 | -4.55 | VWA_N | pfam domains | PF08399 | 4 | 1 | 17795 | 47 |
CACNA2D1 |
1.052e-02 | -4.55 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 47 |
NFIA |
1.052e-02 | -4.55 | TRPM_tetra | pfam domains | PF16519 | 4 | 1 | 17795 | 47 |
TRPM3 |
1.054e-02 | -4.55 | Lethal2_giant | interpro domains | IPR000664 | 4 | 1 | 18521 | 49 |
STXBP5L |
1.054e-02 | -4.55 | TRPM_tetra | interpro domains | IPR032415 | 4 | 1 | 18521 | 49 |
TRPM3 |
1.054e-02 | -4.55 | LLGL2 | interpro domains | IPR013577 | 4 | 1 | 18521 | 49 |
STXBP5L |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | VDCC_a2/dsu | interpro domains | IPR013680 | 4 | 1 | 18521 | 49 |
CACNA2D1 |
1.054e-02 | -4.55 | Transcription_factor_COE | interpro domains | IPR003523 | 4 | 1 | 18521 | 49 |
EBF1 |
1.054e-02 | -4.55 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 49 |
APOE |
1.054e-02 | -4.55 | VWA_N | interpro domains | IPR013608 | 4 | 1 | 18521 | 49 |
CACNA2D1 |
1.054e-02 | -4.55 | COE_DBD_sf | interpro domains | IPR038173 | 4 | 1 | 18521 | 49 |
EBF1 |
1.054e-02 | -4.55 | TRPM_tetra_sf | interpro domains | IPR037162 | 4 | 1 | 18521 | 49 |
TRPM3 |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | COE_HLH | interpro domains | IPR032201 | 4 | 1 | 18521 | 49 |
EBF1 |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | COE_DBD | interpro domains | IPR032200 | 4 | 1 | 18521 | 49 |
EBF1 |
1.054e-02 | -4.55 | Transcription_factor_COE_CS | interpro domains | IPR018350 | 4 | 1 | 18521 | 49 |
EBF1 |
1.054e-02 | -4.55 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | COE_IPT | interpro domains | IPR038006 | 4 | 1 | 18521 | 49 |
EBF1 |
1.062e-02 | -4.55 | membrane organization | biological process | GO:0061024 | 761 | 6 | 18204 | 45 |
CNTNAP2,NRXN1,APOE,RIMS1,RELN,ANK2 |
1.071e-02 | -4.54 | Heparan sulfate/heparin (HS-GAG) metabolism | REACTOME pathways | R-HSA-1638091 | 54 | 2 | 10285 | 30 |
GPC6,GLCE |
1.074e-02 | -4.53 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 10 | 18204 | 45 |
SLC1A3,NRXN1,RIMS1,GRIK2,RIMS2,RELN,NRG1,APOE,GLCE,SYT1 |
1.075e-02 | -4.53 | Ephrin A reverse signaling | Pathway Interaction DB | ephrinarevpathway | 3 | 1 | 2226 | 8 |
EPHA5 |
1.082e-02 | -4.53 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 10 | 18204 | 45 |
SYT1,GLCE,APOE,NRG1,RIMS1,GRIK2,RIMS2,RELN,SLC1A3,NRXN1 |
1.084e-02 | -4.52 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 47 | 16828 | 48 |
MYT1L,TLL1,GRIA4,FSTL5,EBF1,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,PTPRG,GLCE,GPC6,CNTN4,DTNA,NRXN3,LSAMP,UNC5C,TRPM3,NRG3,RIMS2,KCNJ3,ZNF385D,STXBP5L,LRRTM4,RUNX1T1,NRG1,RALYL,SLC35F3,CHN2,SLC1A3,NRXN1,NPAS3,ST18,NFIA,PCDH9,APOE,ZNF385B,RIMS1,RELN,SYT1,GRID2,KIF21A,CADPS2,CDH18 |
1.087e-02 | -4.52 | ETOFAMILY | prints domains | PR01875 | 3 | 1 | 5227 | 19 |
RUNX1T1 |
1.101e-02 | -4.51 | NLGN2 (neuroligin 2) | protein interactions | 57555 | 63 | 2 | 19454 | 49 |
NRXN3,NRXN1 |
1.105e-02 | -4.51 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 45 |
GRIA4,GRIK2,SLC1A3 |
1.106e-02 | -4.50 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 48 |
MYT1L,FSTL5,EBF1,TLL1,GRIA4,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,EPHA5,CACNA2D1,GLCE,PTPRG,CNTN4,GPC6,LSAMP,UNC5C,DTNA,NRXN3,RIMS2,NRG3,TRPM3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,SLC35F3,NRG1,RUNX1T1,RALYL,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,NFIA,ST18,RELN,RIMS1,ZNF385B,KIF21A,CDH18,CADPS2,GRID2,SYT1 |
1.106e-02 | -4.50 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 48 |
NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,ST18,NFIA,RELN,RIMS1,ZNF385B,CADPS2,CDH18,KIF21A,GRID2,SYT1,RIMS2,NRG3,TRPM3,LRRTM4,STXBP5L,ZNF385D,KCNJ3,SLC35F3,RALYL,RUNX1T1,NRG1,EPHA5,CACNA2D1,GLCE,PTPRG,CNTN4,GPC6,UNC5C,LSAMP,NRXN3,DTNA,MYT1L,EBF1,FSTL5,GRIA4,TLL1,CNTN5,ANK2,GRIK2,LINGO2,CNTNAP2 |
1.120e-02 | -4.49 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 49 |
NPAS3 |
1.121e-02 | -4.49 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 45 |
GRIK2,SLC1A3,GRIA4 |
1.126e-02 | -4.49 | forebrain cell migration | biological process | GO:0021885 | 65 | 2 | 18204 | 45 |
NRG3,RELN |
1.151e-02 | -4.46 | pallium development | biological process | GO:0021543 | 190 | 3 | 18204 | 45 |
CNTNAP2,RELN,EPHA5 |
1.156e-02 | -4.46 | liver-carcinoma | COSMIC cancer mutations | liver-carcinoma | 15337 | 48 | 16828 | 48 |
ST18,NFIA,PCDH9,NRXN1,NPAS3,CHN2,SLC1A3,GRID2,CDH18,CADPS2,KIF21A,SYT1,RELN,ZNF385B,APOE,RIMS1,RIMS2,TRPM3,NRG3,RALYL,RUNX1T1,NRG1,SLC35F3,STXBP5L,CST3,LRRTM4,KCNJ3,ZNF385D,PTPRG,GLCE,EPHA5,CACNA2D1,NRXN3,DTNA,UNC5C,LSAMP,CNTN4,GPC6,EBF1,FSTL5,GRIA4,TLL1,MYT1L,LINGO2,CNTNAP2,CNTN5,ANK2,GRIK2 |
1.159e-02 | -4.46 | ERBB signaling pathway | biological process | GO:0038127 | 66 | 2 | 18204 | 45 |
NRG3,NRG1 |
1.162e-02 | -4.46 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 1 | 10285 | 30 |
SLC1A3 |
1.162e-02 | -4.46 | Activation of AMPA receptors | REACTOME pathways | R-HSA-399710 | 4 | 1 | 10285 | 30 |
GRIA4 |
1.162e-02 | -4.46 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 1 | 10285 | 30 |
SLC1A3 |
1.178e-02 | -4.44 | C2 domain | gene3d domains | 2.60.40.150 | 156 | 3 | 14470 | 44 |
RIMS1,RIMS2,SYT1 |
1.183e-02 | -4.44 | C2 | smart domains | SM00239 | 122 | 3 | 9717 | 38 |
SYT1,RIMS1,RIMS2 |
1.193e-02 | -4.43 | excitatory postsynaptic potential | biological process | GO:0060079 | 67 | 2 | 18204 | 45 |
GRIK2,GRID2 |
1.205e-02 | -4.42 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 48 | 16828 | 48 |
RUNX1T1,NRG1,RALYL,SLC35F3,KCNJ3,ZNF385D,STXBP5L,LRRTM4,CST3,TRPM3,NRG3,RIMS2,SYT1,GRID2,KIF21A,CDH18,CADPS2,APOE,ZNF385B,RIMS1,RELN,ST18,NFIA,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,TLL1,GRIA4,EBF1,FSTL5,MYT1L,DTNA,NRXN3,LSAMP,UNC5C,GPC6,CNTN4,PTPRG,GLCE,CACNA2D1,EPHA5 |
1.207e-02 | -4.42 | cell adhesion mediator activity | molecular function | GO:0098631 | 67 | 2 | 18094 | 45 |
CNTN5,CNTN4 |
1.211e-02 | -4.41 | - | gene3d domains | 6.10.250.230 | 4 | 1 | 14470 | 44 |
RUNX1T1 |
1.211e-02 | -4.41 | Transcription factor COE1, DNA-binding domain | gene3d domains | 2.60.40.3180 | 4 | 1 | 14470 | 44 |
EBF1 |
1.211e-02 | -4.41 | TRPM, tetramerisation domain | gene3d domains | 1.20.5.1010 | 4 | 1 | 14470 | 44 |
TRPM3 |
1.211e-02 | -4.41 | - | gene3d domains | 1.10.287.4280 | 4 | 1 | 14470 | 44 |
EBF1 |
1.223e-02 | -4.40 | plasma membrane signaling receptor complex | cellular component | GO:0098802 | 191 | 3 | 19108 | 48 |
GRIK2,GRIA4,GRID2 |
1.230e-02 | -4.40 | regulation of homophilic cell adhesion | biological process | GO:1903385 | 5 | 1 | 18204 | 45 |
PTPRG |
1.230e-02 | -4.40 | bundle of His cell action potential | biological process | GO:0086043 | 5 | 1 | 18204 | 45 |
CACNA2D1 |
1.230e-02 | -4.40 | atrial cardiac muscle cell membrane repolarization | biological process | GO:0099624 | 5 | 1 | 18204 | 45 |
KCNJ3 |
1.230e-02 | -4.40 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 1 | 18204 | 45 |
SLC1A3 |
1.230e-02 | -4.40 | membrane depolarization during SA node cell action potential | biological process | GO:0086046 | 5 | 1 | 18204 | 45 |
ANK2 |
1.230e-02 | -4.40 | detection of temperature stimulus involved in thermoception | biological process | GO:0050960 | 5 | 1 | 18204 | 45 |
GRIK2 |
1.230e-02 | -4.40 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 45 |
NRXN1 |
1.230e-02 | -4.40 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 45 |
APOE |
1.230e-02 | -4.40 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 45 |
APOE |
1.230e-02 | -4.40 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 1 | 18204 | 45 |
APOE |
1.230e-02 | -4.40 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 45 |
APOE |
1.230e-02 | -4.40 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 45 |
APOE |
1.230e-02 | -4.40 | ERBB2-ERBB4 signaling pathway | biological process | GO:0038135 | 5 | 1 | 18204 | 45 |
NRG1 |
1.230e-02 | -4.40 | bundle of His cell to Purkinje myocyte signaling | biological process | GO:0086028 | 5 | 1 | 18204 | 45 |
CACNA2D1 |
1.230e-02 | -4.40 | membrane repolarization during atrial cardiac muscle cell action potential | biological process | GO:0098914 | 5 | 1 | 18204 | 45 |
KCNJ3 |
1.230e-02 | -4.40 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 1 | 18204 | 45 |
SLC1A3 |
1.237e-02 | -4.39 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 1 | 18094 | 45 |
SLC1A3 |
1.237e-02 | -4.39 | ErbB-3 class receptor binding | molecular function | GO:0043125 | 5 | 1 | 18094 | 45 |
NRG1 |
1.237e-02 | -4.39 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 1 | 18094 | 45 |
SLC1A3 |
1.237e-02 | -4.39 | netrin receptor activity | molecular function | GO:0005042 | 5 | 1 | 18094 | 45 |
UNC5C |
1.237e-02 | -4.39 | metal ion sensor activity | molecular function | GO:0140784 | 5 | 1 | 18094 | 45 |
SYT1 |
1.237e-02 | -4.39 | kainate selective glutamate receptor activity | molecular function | GO:0015277 | 5 | 1 | 18094 | 45 |
GRIK2 |
1.237e-02 | -4.39 | voltage-gated calcium channel activity involved in cardiac muscle cell action potential | molecular function | GO:0086007 | 5 | 1 | 18094 | 45 |
CACNA2D1 |
1.250e-02 | -4.38 | kainate selective glutamate receptor complex | cellular component | GO:0032983 | 5 | 1 | 19108 | 48 |
GRIK2 |
1.250e-02 | -4.38 | clathrin-sculpted monoamine transport vesicle | cellular component | GO:0070081 | 5 | 1 | 19108 | 48 |
SYT1 |
1.250e-02 | -4.38 | clathrin-sculpted monoamine transport vesicle membrane | cellular component | GO:0070083 | 5 | 1 | 19108 | 48 |
SYT1 |
1.253e-02 | -4.38 | DLX4 (distal-less homeobox 4) | protein interactions | 1748 | 5 | 1 | 19454 | 49 |
GPC6 |
1.253e-02 | -4.38 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 49 |
NRXN1 |
1.253e-02 | -4.38 | TRPM6 (transient receptor potential cation channel subfamily M member 6) | protein interactions | 140803 | 5 | 1 | 19454 | 49 |
TRPM3 |
1.253e-02 | -4.38 | Calu (calumenin) | protein interactions | 12321 | 5 | 1 | 19454 | 49 |
CACNA2D1 |
1.253e-02 | -4.38 | Ncam1 (neural cell adhesion molecule 1) | protein interactions | 24586 | 5 | 1 | 19454 | 49 |
STXBP5L |
1.305e-02 | -4.34 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 49 |
PCDH9 |
1.307e-02 | -4.34 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 40 |
NFIA |
1.307e-02 | -4.34 | COE | prosite domains | PS01345 | 4 | 1 | 12186 | 40 |
EBF1 |
1.307e-02 | -4.34 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 40 |
NFIA |
1.312e-02 | -4.33 | scaffold protein binding | molecular function | GO:0097110 | 70 | 2 | 18094 | 45 |
GRIK2,GRID2 |
1.314e-02 | -4.33 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 47 |
PCDH9 |
1.314e-02 | -4.33 | EGF_Tenascin | pfam domains | PF18720 | 5 | 1 | 17795 | 47 |
RELN |
1.314e-02 | -4.33 | TAFH | pfam domains | PF07531 | 5 | 1 | 17795 | 47 |
RUNX1T1 |
1.314e-02 | -4.33 | UPA | pfam domains | PF17217 | 5 | 1 | 17795 | 47 |
UNC5C |
1.315e-02 | -4.33 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 47 |
NRXN1,NRG1 |
1.316e-02 | -4.33 | TAFH_NHR1 | interpro domains | IPR003894 | 5 | 1 | 18521 | 49 |
RUNX1T1 |
1.316e-02 | -4.33 | Sialidase_sf | interpro domains | IPR036278 | 5 | 1 | 18521 | 49 |
RELN |
1.316e-02 | -4.33 | UPA | interpro domains | IPR033772 | 5 | 1 | 18521 | 49 |
UNC5C |
1.316e-02 | -4.33 | EGF_Tenascin | interpro domains | IPR041161 | 5 | 1 | 18521 | 49 |
RELN |
1.316e-02 | -4.33 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 49 |
PCDH9 |
1.316e-02 | -4.33 | UNC5 | interpro domains | IPR037936 | 5 | 1 | 18521 | 49 |
UNC5C |
1.316e-02 | -4.33 | TAFH/NHR1_dom_sf | interpro domains | IPR037249 | 5 | 1 | 18521 | 49 |
RUNX1T1 |
1.316e-02 | -4.33 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 4 | 19108 | 48 |
SYT1,GRIK2,GRIA4,GRID2 |
1.336e-02 | -4.32 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 48 |
CACNA2D1,TLL1,KCNJ3,GRID2 |
1.346e-02 | -4.31 | GPC4 (glypican 4) | protein interactions | 2239 | 70 | 2 | 19454 | 49 |
LRRTM4,GPC6 |
1.357e-02 | -4.30 | intracellular calcium ion homeostasis | biological process | GO:0006874 | 202 | 3 | 18204 | 45 |
GRIK2,ANK2,APOE |
1.359e-02 | -4.30 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 48 |
LRRTM4,STXBP5L,ZNF385D,KCNJ3,SLC35F3,NRG1,RUNX1T1,RALYL,RIMS2,NRG3,TRPM3,RELN,RIMS1,ZNF385B,KIF21A,CADPS2,CDH18,GRID2,SYT1,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,ST18,NFIA,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,MYT1L,EBF1,FSTL5,TLL1,GRIA4,CNTN4,GPC6,LSAMP,UNC5C,DTNA,NRXN3,EPHA5,CACNA2D1,GLCE,PTPRG |
1.393e-02 | -4.27 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 19 | 16828 | 48 |
PCDH9,TLL1,ST18,PTPRG,FSTL5,NRG3,RIMS2,CNTNAP2,NRG1,NRXN3,KIF21A,CDH18,GPC6,ZNF385D,ANK2,GRIK2,RELN,STXBP5L,CNTN4 |
1.405e-02 | -4.27 | neuron fate commitment | biological process | GO:0048663 | 73 | 2 | 18204 | 45 |
MYT1L,NFIA |
1.405e-02 | -4.27 | chemical synaptic transmission, postsynaptic | biological process | GO:0099565 | 73 | 2 | 18204 | 45 |
GRID2,GRIK2 |
1.420e-02 | -4.25 | RAB3A (RAB3A, member RAS oncogene family) | protein interactions | 5864 | 72 | 2 | 19454 | 49 |
RIMS1,RIMS2 |
1.439e-02 | -4.24 | endocytic vesicle membrane | cellular component | GO:0030666 | 203 | 3 | 19108 | 48 |
GRIA4,APOE,SYT1 |
1.446e-02 | -4.24 | LETHAL2GIANT | prints domains | PR00962 | 4 | 1 | 5227 | 19 |
STXBP5L |
1.450e-02 | -4.23 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 48 |
GRID2,CACNA2D1,TLL1,KCNJ3 |
1.450e-02 | -4.23 | Reelin signalling pathway | REACTOME pathways | R-HSA-8866376 | 5 | 1 | 10285 | 30 |
RELN |
1.450e-02 | -4.23 | GRB7 events in ERBB2 signaling | REACTOME pathways | R-HSA-1306955 | 5 | 1 | 10285 | 30 |
NRG1 |
1.458e-02 | -4.23 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 47 | 16828 | 48 |
RALYL,NRG1,RUNX1T1,SLC35F3,KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,TRPM3,NRG3,RIMS2,SYT1,GRID2,CADPS2,CDH18,KIF21A,ZNF385B,APOE,RIMS1,RELN,NFIA,ST18,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,GRIA4,TLL1,EBF1,FSTL5,MYT1L,NRXN3,UNC5C,LSAMP,GPC6,CNTN4,PTPRG,GLCE,CACNA2D1,EPHA5 |
1.458e-02 | -4.23 | ovary | COSMIC cancer mutations | ovary | 14770 | 47 | 16828 | 48 |
RIMS2,TRPM3,NRG3,STXBP5L,LRRTM4,CST3,KCNJ3,ZNF385D,NRG1,RUNX1T1,RALYL,SLC35F3,NRXN1,NPAS3,CHN2,SLC1A3,ST18,PCDH9,RELN,APOE,ZNF385B,RIMS1,GRID2,KIF21A,CADPS2,CDH18,SYT1,MYT1L,FSTL5,EBF1,TLL1,GRIA4,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,EPHA5,CACNA2D1,PTPRG,GLCE,CNTN4,GPC6,DTNA,NRXN3,LSAMP,UNC5C |
1.467e-02 | -4.22 | regulation of heart contraction | biological process | GO:0008016 | 208 | 3 | 18204 | 45 |
CACNA2D1,ANK2,KCNJ3 |
1.474e-02 | -4.22 | chemorepulsion of axon | biological process | GO:0061643 | 6 | 1 | 18204 | 45 |
UNC5C |
1.474e-02 | -4.22 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 45 |
APOE |
1.474e-02 | -4.22 | activation of transmembrane receptor protein tyrosine kinase activity | biological process | GO:0007171 | 6 | 1 | 18204 | 45 |
NRG1 |
1.474e-02 | -4.22 | T-tubule organization | biological process | GO:0033292 | 6 | 1 | 18204 | 45 |
ANK2 |
1.474e-02 | -4.22 | D-amino acid transport | biological process | GO:0042940 | 6 | 1 | 18204 | 45 |
SLC1A3 |
1.474e-02 | -4.22 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 45 |
SLC1A3 |
1.474e-02 | -4.22 | endocardial cell differentiation | biological process | GO:0060956 | 6 | 1 | 18204 | 45 |
NRG1 |
1.474e-02 | -4.22 | acrosomal vesicle exocytosis | biological process | GO:0060478 | 6 | 1 | 18204 | 45 |
RIMS1 |
1.474e-02 | -4.22 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 45 |
APOE |
1.474e-02 | -4.22 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 1 | 18204 | 45 |
SLC1A3 |
1.474e-02 | -4.22 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 45 |
NRG3 |
1.474e-02 | -4.22 | positive regulation of dopamine secretion | biological process | GO:0033603 | 6 | 1 | 18204 | 45 |
SYT1 |
1.474e-02 | -4.22 | paranodal junction assembly | biological process | GO:0030913 | 6 | 1 | 18204 | 45 |
ANK2 |
1.474e-02 | -4.22 | cerebral cortex tangential migration | biological process | GO:0021800 | 6 | 1 | 18204 | 45 |
RELN |
1.474e-02 | -4.22 | cardiac endothelial cell differentiation | biological process | GO:0003348 | 6 | 1 | 18204 | 45 |
NRG1 |
1.474e-02 | -4.22 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 45 |
CST3 |
1.479e-02 | -4.21 | regulation of behavior | biological process | GO:0050795 | 75 | 2 | 18204 | 45 |
APOE,RELN |
1.479e-02 | -4.21 | regulation of calcium ion transmembrane transporter activity | biological process | GO:1901019 | 75 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
1.483e-02 | -4.21 | ankyrin repeat binding | molecular function | GO:0071532 | 6 | 1 | 18094 | 45 |
KIF21A |
1.483e-02 | -4.21 | GPI-linked ephrin receptor activity | molecular function | GO:0005004 | 6 | 1 | 18094 | 45 |
EPHA5 |
1.483e-02 | -4.21 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 45 |
APOE |
1.488e-02 | -4.21 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 48 |
PCDH9,ANK2 |
1.490e-02 | -4.21 | human chr4q32.2 | chromosome location | human chr4q32.2 | 8 | 1 | 26134 | 49 |
FSTL5 |
1.498e-02 | -4.20 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 48 |
APOE |
1.502e-02 | -4.20 | GRID2IP (Grid2 interacting protein) | protein interactions | 392862 | 6 | 1 | 19454 | 49 |
GRID2 |
1.502e-02 | -4.20 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 49 |
NRXN1 |
1.502e-02 | -4.20 | Tubb4b (tubulin, beta 4B class IVb) | protein interactions | 296554 | 6 | 1 | 19454 | 49 |
STXBP5L |
1.502e-02 | -4.20 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 49 |
DTNA |
1.502e-02 | -4.20 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 49 |
APOE |
1.502e-02 | -4.20 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 49 |
APOE |
1.502e-02 | -4.20 | CNTN4 (contactin 4) | protein interactions | 152330 | 6 | 1 | 19454 | 49 |
CNTN4 |
1.502e-02 | -4.20 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 49 |
DTNA |
1.511e-02 | -4.19 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 44 |
APOE |
1.511e-02 | -4.19 | TAFH/NHR1 domain | gene3d domains | 1.20.120.1110 | 5 | 1 | 14470 | 44 |
RUNX1T1 |
1.516e-02 | -4.19 | positive regulation of exocytosis | biological process | GO:0045921 | 76 | 2 | 18204 | 45 |
CADPS2,SYT1 |
1.526e-02 | -4.18 | clathrin-coated endocytic vesicle membrane | cellular component | GO:0030669 | 75 | 2 | 19108 | 48 |
APOE,SYT1 |
1.527e-02 | -4.18 | Constitutive Signaling by Aberrant PI3K in Cancer | REACTOME pathways | R-HSA-2219530 | 65 | 2 | 10285 | 30 |
NRG1,NRG3 |
1.528e-02 | -4.18 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 47 | 16828 | 48 |
RALYL,NRG1,RUNX1T1,SLC35F3,STXBP5L,CST3,KCNJ3,ZNF385D,RIMS2,TRPM3,NRG3,GRID2,CADPS2,CDH18,KIF21A,SYT1,RELN,ZNF385B,APOE,RIMS1,NFIA,ST18,PCDH9,NRXN1,NPAS3,CHN2,SLC1A3,LINGO2,CNTNAP2,CNTN5,ANK2,GRIK2,FSTL5,EBF1,GRIA4,TLL1,MYT1L,NRXN3,DTNA,UNC5C,LSAMP,CNTN4,GPC6,PTPRG,GLCE,EPHA5,CACNA2D1 |
1.543e-02 | -4.17 | positive regulation of monoatomic ion transport | biological process | GO:0043270 | 212 | 3 | 18204 | 45 |
ANK2,CACNA2D1,RELN |
1.571e-02 | -4.15 | Synaptic vesicle cycle | KEGG pathways | hsa04721 | 63 | 2 | 7161 | 22 |
SYT1,RIMS1 |
1.571e-02 | -4.15 | Synaptic vesicle cycle | KEGG pathways | ko04721 | 63 | 2 | 7161 | 22 |
RIMS1,SYT1 |
1.575e-02 | -4.15 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 47 |
GPC6 |
1.575e-02 | -4.15 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 47 |
DTNA |
1.575e-02 | -4.15 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 47 |
DTNA |
1.575e-02 | -4.15 | Astacin | pfam domains | PF01400 | 6 | 1 | 17795 | 47 |
TLL1 |
1.577e-02 | -4.15 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 49 |
DTNA |
1.577e-02 | -4.15 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 49 |
DTNA |
1.577e-02 | -4.15 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 49 |
GPC6 |
1.577e-02 | -4.15 | hnRNP_C | interpro domains | IPR017347 | 6 | 1 | 18521 | 49 |
RALYL |
1.577e-02 | -4.15 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 49 |
GPC6 |
1.577e-02 | -4.15 | Peptidase_M12A | interpro domains | IPR001506 | 6 | 1 | 18521 | 49 |
TLL1 |
1.582e-02 | -4.15 | regulation of monoatomic ion transmembrane transporter activity | biological process | GO:0032412 | 214 | 3 | 18204 | 45 |
RELN,CACNA2D1,ANK2 |
1.582e-02 | -4.15 | positive regulation of transmembrane transport | biological process | GO:0034764 | 214 | 3 | 18204 | 45 |
CACNA2D1,RELN,ANK2 |
1.595e-02 | -4.14 | localization | biological process | GO:0051179 | 4474 | 18 | 18204 | 45 |
KCNJ3,CACNA2D1,ANK2,GRID2,STXBP5L,SYT1,NRXN1,RIMS2,RIMS1,GRIA4,APOE,TRPM3,SLC35F3,SLC1A3,CNTNAP2,RELN,CADPS2,GRIK2 |
1.604e-02 | -4.13 | enzyme activator activity | molecular function | GO:0008047 | 599 | 5 | 18094 | 45 |
APOE,NRG3,STXBP5L,NRG1,CHN2 |
1.608e-02 | -4.13 | regulation of growth | biological process | GO:0040008 | 603 | 5 | 18204 | 45 |
SYT1,RIMS1,NRG3,RIMS2,APOE |
1.613e-02 | -4.13 | FCHO2 (FCH and mu domain containing endocytic adaptor 2) | protein interactions | 115548 | 77 | 2 | 19454 | 49 |
EPHA5,PTPRG |
1.617e-02 | -4.12 | Signaling by PTK6 | REACTOME pathways | R-HSA-8848021 | 67 | 2 | 10285 | 30 |
NRG3,NRG1 |
1.631e-02 | -4.12 | TAFH | prosite domains | PS51119 | 5 | 1 | 12186 | 40 |
RUNX1T1 |
1.641e-02 | -4.11 | Galactose-bd-like_sf | interpro domains | IPR008979 | 74 | 2 | 18521 | 49 |
CNTNAP2,EPHA5 |
1.652e-02 | -4.10 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 49 |
APOE,RELN |
1.673e-02 | -4.09 | zinc ion binding | molecular function | GO:0008270 | 836 | 6 | 18094 | 45 |
TLL1,ST18,ZNF385B,ZNF385D,MYT1L,DTNA |
1.675e-02 | -4.09 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 49 |
UNC5C |
1.684e-02 | -4.08 | presynaptic active zone | cellular component | GO:0048786 | 79 | 2 | 19108 | 48 |
RIMS2,RIMS1 |
1.700e-02 | -4.07 | positive regulation of transport | biological process | GO:0051050 | 844 | 6 | 18204 | 45 |
CACNA2D1,RELN,ANK2,CADPS2,SYT1,APOE |
1.702e-02 | -4.07 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 45 |
SLC1A3,NRXN1,CNTNAP2 |
1.715e-02 | -4.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 29 | 16828 | 48 |
NRG3,MYT1L,TRPM3,TLL1,GRIA4,FSTL5,ANK2,GRIK2,CST3,CNTN5,NRG1,RUNX1T1,LINGO2,SLC1A3,CACNA2D1,NPAS3,EPHA5,NRXN1,GLCE,ST18,PTPRG,RIMS1,RELN,UNC5C,DTNA,NRXN3,KIF21A,CDH18,GRID2 |
1.718e-02 | -4.06 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 45 |
APOE |
1.718e-02 | -4.06 | dense core granule exocytosis | biological process | GO:1990504 | 7 | 1 | 18204 | 45 |
CADPS2 |
1.718e-02 | -4.06 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 45 |
APOE |
1.718e-02 | -4.06 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | biological process | GO:2001269 | 7 | 1 | 18204 | 45 |
ST18 |
1.718e-02 | -4.06 | positive regulation of voltage-gated calcium channel activity | biological process | GO:1901387 | 7 | 1 | 18204 | 45 |
CACNA2D1 |
1.718e-02 | -4.06 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 45 |
NRG3 |
1.718e-02 | -4.06 | cerebellar granular layer formation | biological process | GO:0021684 | 7 | 1 | 18204 | 45 |
GRID2 |
1.718e-02 | -4.06 | dorsal root ganglion development | biological process | GO:1990791 | 7 | 1 | 18204 | 45 |
UNC5C |
1.718e-02 | -4.06 | SA node cell to atrial cardiac muscle cell signaling | biological process | GO:0086018 | 7 | 1 | 18204 | 45 |
ANK2 |
1.718e-02 | -4.06 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 45 |
APOE |
1.718e-02 | -4.06 | positive regulation of long-term synaptic depression | biological process | GO:1900454 | 7 | 1 | 18204 | 45 |
GRID2 |
1.718e-02 | -4.06 | positive regulation of gap junction assembly | biological process | GO:1903598 | 7 | 1 | 18204 | 45 |
CNTNAP2 |
1.718e-02 | -4.06 | anterior/posterior axon guidance | biological process | GO:0033564 | 7 | 1 | 18204 | 45 |
UNC5C |
1.718e-02 | -4.06 | SA node cell action potential | biological process | GO:0086015 | 7 | 1 | 18204 | 45 |
ANK2 |
1.718e-02 | -4.06 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 45 |
NFIA |
1.718e-02 | -4.06 | cerebellar granule cell differentiation | biological process | GO:0021707 | 7 | 1 | 18204 | 45 |
GRID2 |
1.733e-02 | -4.06 | STX2 (syntaxin 2) | protein interactions | 2054 | 80 | 2 | 19454 | 49 |
STXBP5L,SYT1 |
1.743e-02 | -4.05 | regulation of transmembrane transporter activity | biological process | GO:0022898 | 222 | 3 | 18204 | 45 |
ANK2,RELN,CACNA2D1 |
1.750e-02 | -4.05 | SV2B (synaptic vesicle glycoprotein 2B) | protein interactions | 9899 | 7 | 1 | 19454 | 49 |
SYT1 |
1.750e-02 | -4.05 | CHL1 (cell adhesion molecule L1 like) | protein interactions | 10752 | 7 | 1 | 19454 | 49 |
ANK2 |
1.750e-02 | -4.05 | CDH18 (cadherin 18) | protein interactions | 1016 | 7 | 1 | 19454 | 49 |
CDH18 |
1.750e-02 | -4.05 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 49 |
NPAS3 |
1.752e-02 | -4.04 | central_nervous_system-brain-glioma | COSMIC cancer mutations | central_nervous_system-brain-glioma | 15470 | 48 | 16828 | 48 |
TLL1,GRIA4,EBF1,FSTL5,MYT1L,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,GLCE,PTPRG,CACNA2D1,EPHA5,LSAMP,UNC5C,DTNA,NRXN3,GPC6,CNTN4,NRG3,TRPM3,RIMS2,SLC35F3,RUNX1T1,NRG1,RALYL,ZNF385D,KCNJ3,LRRTM4,CST3,STXBP5L,PCDH9,NFIA,ST18,SLC1A3,CHN2,NPAS3,NRXN1,SYT1,KIF21A,CDH18,CADPS2,GRID2,RIMS1,APOE,ZNF385B,RELN |
1.771e-02 | -4.03 | receptor tyrosine kinase binding | molecular function | GO:0030971 | 82 | 2 | 18094 | 45 |
NRG1,NRG3 |
1.774e-02 | -4.03 | GRIP1 (glutamate receptor interacting protein 1) | protein interactions | 23426 | 81 | 2 | 19454 | 49 |
GRIK2,GRIA4 |
1.783e-02 | -4.03 | other | COSMIC cancer mutations | other | 14843 | 47 | 16828 | 48 |
MYT1L,GRIA4,TLL1,FSTL5,EBF1,ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,GLCE,PTPRG,GPC6,CNTN4,UNC5C,LSAMP,NRXN3,DTNA,NRG3,TRPM3,RIMS2,ZNF385D,KCNJ3,CST3,STXBP5L,SLC35F3,RALYL,NRG1,RUNX1T1,SLC1A3,CHN2,NPAS3,NRXN1,PCDH9,NFIA,ST18,RIMS1,ZNF385B,APOE,RELN,SYT1,CDH18,CADPS2,KIF21A,GRID2 |
1.791e-02 | -4.02 | positive regulation of calcium ion transmembrane transport | biological process | GO:1904427 | 83 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
1.835e-02 | -4.00 | EamA | pfam domains | PF00892 | 7 | 1 | 17795 | 47 |
SLC35F3 |
1.835e-02 | -4.00 | SDF | pfam domains | PF00375 | 7 | 1 | 17795 | 47 |
SLC1A3 |
1.835e-02 | -4.00 | MUN | pfam domains | PF06292 | 7 | 1 | 17795 | 47 |
CADPS2 |
1.838e-02 | -4.00 | EamA_dom | interpro domains | IPR000620 | 7 | 1 | 18521 | 49 |
SLC35F3 |
1.838e-02 | -4.00 | Munc13_1 | interpro domains | IPR014770 | 7 | 1 | 18521 | 49 |
CADPS2 |
1.838e-02 | -4.00 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 1 | 18521 | 49 |
SLC1A3 |
1.838e-02 | -4.00 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 1 | 18521 | 49 |
SLC1A3 |
1.838e-02 | -4.00 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 1 | 18521 | 49 |
SLC1A3 |
1.838e-02 | -4.00 | MUN_dom | interpro domains | IPR010439 | 7 | 1 | 18521 | 49 |
CADPS2 |
1.847e-02 | -3.99 | FBXO2 (F-box protein 2) | protein interactions | 26232 | 403 | 4 | 19454 | 49 |
EPHA5,CACNA2D1,PTPRG,PCDH9 |
1.851e-02 | -3.99 | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | 9263 | 34 | 16828 | 48 |
SLC35F3,CNTNAP2,RALYL,RUNX1T1,CNTN5,LRRTM4,STXBP5L,ANK2,KCNJ3,FSTL5,EBF1,GRIA4,TLL1,RIMS2,TRPM3,CADPS2,CDH18,KIF21A,GRID2,UNC5C,SYT1,LSAMP,NRXN3,RELN,CNTN4,GPC6,APOE,PCDH9,ST18,PTPRG,NFIA,EPHA5,CACNA2D1,CHN2 |
1.858e-02 | -3.99 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 49 |
GLCE,NFIA |
1.860e-02 | -3.98 | human chr8q21.2 | chromosome location | human chr8q21.2 | 10 | 1 | 26134 | 49 |
RALYL |
1.860e-02 | -3.98 | human chr11q22.1 | chromosome location | human chr11q22.1 | 10 | 1 | 26134 | 49 |
CNTN5 |
1.861e-02 | -3.98 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 45 |
NRG1,PTPRG,NFIA,NRG3,EPHA5 |
1.885e-02 | -3.97 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 7 | 18094 | 45 |
GRID2,GRIK2,TRPM3,CACNA2D1,SLC1A3,GRIA4,KCNJ3 |
1.885e-02 | -3.97 | heparan sulfate biosynthesis (late stages) | BIOCYC pathways | META_PWY-6558 | 17 | 1 | 902 | 1 |
GLCE |
1.900e-02 | -3.96 | TMEM185A (transmembrane protein 185A) | protein interactions | 84548 | 84 | 2 | 19454 | 49 |
PTPRG,CACNA2D1 |
1.907e-02 | -3.96 | metal ion transport | biological process | GO:0030001 | 630 | 5 | 18204 | 45 |
TRPM3,KCNJ3,SLC1A3,ANK2,CACNA2D1 |
1.915e-02 | -3.96 | protein localization to cell junction | biological process | GO:1902414 | 86 | 2 | 18204 | 45 |
NRXN1,RELN |
1.920e-02 | -3.95 | EGF_1 | prosite domains | PS00022 | 174 | 3 | 12186 | 40 |
NRG3,RELN,NRG1 |
1.926e-02 | -3.95 | BCL6 (BCL6 transcription repressor) | protein interactions | 604 | 226 | 3 | 19454 | 49 |
EBF1,RUNX1T1,PCDH9 |
1.935e-02 | -3.95 | calcium ion homeostasis | biological process | GO:0055074 | 231 | 3 | 18204 | 45 |
GRIK2,ANK2,APOE |
1.940e-02 | -3.94 | TAFH | smart domains | SM00549 | 5 | 1 | 9717 | 38 |
RUNX1T1 |
1.940e-02 | -3.94 | DUF1041 | smart domains | SM01145 | 5 | 1 | 9717 | 38 |
CADPS2 |
1.946e-02 | -3.94 | blood circulation | biological process | GO:0008015 | 418 | 4 | 18204 | 45 |
APOE,KCNJ3,CACNA2D1,ANK2 |
1.951e-02 | -3.94 | Lipoprotein metabolism | REACTOME pathways | R-HSA-174824 | 74 | 2 | 10285 | 30 |
APOE,RELN |
1.952e-02 | -3.94 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 5 | 18094 | 45 |
KCNJ3,SLC1A3,CACNA2D1,TRPM3,GRIK2 |
1.954e-02 | -3.94 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 40 |
GPC6 |
1.954e-02 | -3.94 | ASTACIN | prosite domains | PS51864 | 6 | 1 | 12186 | 40 |
TLL1 |
1.961e-02 | -3.93 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 45 |
APOE |
1.961e-02 | -3.93 | positive regulation of vesicle fusion | biological process | GO:0031340 | 8 | 1 | 18204 | 45 |
SYT1 |
1.961e-02 | -3.93 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 45 |
APOE |
1.961e-02 | -3.93 | thermoception | biological process | GO:0050955 | 8 | 1 | 18204 | 45 |
GRIK2 |
1.961e-02 | -3.93 | reelin-mediated signaling pathway | biological process | GO:0038026 | 8 | 1 | 18204 | 45 |
RELN |
1.961e-02 | -3.93 | thiamine transport | biological process | GO:0015888 | 8 | 1 | 18204 | 45 |
SLC35F3 |
1.961e-02 | -3.93 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 45 |
APOE |
1.961e-02 | -3.93 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 45 |
SLC1A3 |
1.961e-02 | -3.93 | negative regulation of synaptic transmission, glutamatergic | biological process | GO:0051967 | 8 | 1 | 18204 | 45 |
GRIK2 |
1.961e-02 | -3.93 | protein import | biological process | GO:0017038 | 8 | 1 | 18204 | 45 |
APOE |
1.961e-02 | -3.93 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 45 |
APOE |
1.973e-02 | -3.93 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 45 |
SLC1A3 |
1.973e-02 | -3.93 | phosphorylation-dependent protein binding | molecular function | GO:0140031 | 8 | 1 | 18094 | 45 |
ANK2 |
1.992e-02 | -3.92 | clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane | cellular component | GO:0061202 | 8 | 1 | 19108 | 48 |
SYT1 |
1.992e-02 | -3.92 | clathrin-sculpted gamma-aminobutyric acid transport vesicle | cellular component | GO:0061200 | 8 | 1 | 19108 | 48 |
SYT1 |
1.992e-02 | -3.92 | paranodal junction | cellular component | GO:0033010 | 8 | 1 | 19108 | 48 |
CNTNAP2 |
1.998e-02 | -3.91 | PCDHA6 (protocadherin alpha 6) | protein interactions | 56142 | 8 | 1 | 19454 | 49 |
RELN |
1.998e-02 | -3.91 | PRSS33 (serine protease 33) | protein interactions | 260429 | 8 | 1 | 19454 | 49 |
CACNA2D1 |
1.998e-02 | -3.91 | DEFB104A (defensin beta 104A) | protein interactions | 140596 | 8 | 1 | 19454 | 49 |
PTPRG |
1.998e-02 | -3.91 | CDH6 (cadherin 6) | protein interactions | 1004 | 8 | 1 | 19454 | 49 |
CDH18 |
1.998e-02 | -3.91 | GRIK4 (glutamate ionotropic receptor kainate type subunit 4) | protein interactions | 2900 | 8 | 1 | 19454 | 49 |
GRIK2 |
1.998e-02 | -3.91 | PKD1L1-AS1 (PKD1L1 antisense RNA 1) | protein interactions | 80099 | 8 | 1 | 19454 | 49 |
CACNA2D1 |
1.998e-02 | -3.91 | KCNJ9 (potassium inwardly rectifying channel subfamily J member 9) | protein interactions | 3765 | 8 | 1 | 19454 | 49 |
KCNJ3 |
1.998e-02 | -3.91 | TAFA1 (TAFA chemokine like family member 1) | protein interactions | 407738 | 8 | 1 | 19454 | 49 |
NRXN3 |
2.002e-02 | -3.91 | Axon guidance | REACTOME pathways | R-HSA-422475 | 549 | 5 | 10285 | 30 |
NRG3,UNC5C,NRG1,ANK2,EPHA5 |
2.007e-02 | -3.91 | establishment of localization | biological process | GO:0051234 | 3887 | 16 | 18204 | 45 |
NRXN1,RIMS2,RIMS1,KCNJ3,CACNA2D1,ANK2,STXBP5L,GRID2,SYT1,SLC35F3,SLC1A3,CADPS2,GRIK2,GRIA4,APOE,TRPM3 |
2.015e-02 | -3.90 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 48 |
GRIA4,CDH18,KIF21A,FSTL5,STXBP5L |
2.016e-02 | -3.90 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 49 |
NRXN1,CNTNAP2,NRXN3 |
2.042e-02 | -3.89 | cell fate specification | biological process | GO:0001708 | 89 | 2 | 18204 | 45 |
MYT1L,NFIA |
2.042e-02 | -3.89 | multicellular organismal response to stress | biological process | GO:0033555 | 89 | 2 | 18204 | 45 |
GRIK2,RELN |
2.058e-02 | -3.88 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 5 | 16828 | 48 |
CNTNAP2,CACNA2D1,EPHA5,CNTN5,FSTL5 |
2.068e-02 | -3.88 | pelvis | COSMIC cancer mutations | pelvis | 984 | 7 | 16828 | 48 |
CHN2,RIMS1,ANK2,CNTN5,PTPRG,LSAMP,GRID2 |
2.073e-02 | -3.88 | CCNL2 (cyclin L2) | protein interactions | 81669 | 88 | 2 | 19454 | 49 |
LRRTM4,PTPRG |
2.073e-02 | -3.88 | NLGN3 (neuroligin 3) | protein interactions | 54413 | 88 | 2 | 19454 | 49 |
NRXN1,NRXN3 |
2.073e-02 | -3.88 | BTN2A2 (butyrophilin subfamily 2 member A2) | protein interactions | 10385 | 88 | 2 | 19454 | 49 |
SLC1A3,SYT1 |
2.087e-02 | -3.87 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 5 | 16828 | 48 |
CACNA2D1,CNTNAP2,EPHA5,CNTN5,FSTL5 |
2.094e-02 | -3.87 | LSDAT_euk | pfam domains | PF18139 | 8 | 1 | 17795 | 47 |
TRPM3 |
2.097e-02 | -3.86 | TRPM_SLOG | interpro domains | IPR041491 | 8 | 1 | 18521 | 49 |
TRPM3 |
2.102e-02 | -3.86 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 4 | 18204 | 45 |
NRG3,EPHA5,PTPRG,NRG1 |
2.102e-02 | -3.86 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 4 | 18204 | 45 |
APOE,SLC1A3,GRIK2,ANK2 |
2.106e-02 | -3.86 | heparan sulfate biosynthesis (late stages) | BIOCYC pathways | HUMAN_PWY-6558 | 19 | 1 | 902 | 1 |
GLCE |
2.110e-02 | -3.86 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 1 | 14470 | 44 |
SLC1A3 |
2.112e-02 | -3.86 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 7 | 19454 | 49 |
SYT1,ANK2,SLC1A3,LSAMP,NRG1,APOE,TRPM3 |
2.133e-02 | -3.85 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 46 | 16828 | 48 |
RELN,RIMS1,ZNF385B,KIF21A,CDH18,CADPS2,GRID2,SYT1,NPAS3,NRXN1,SLC1A3,CHN2,PCDH9,NFIA,ST18,LRRTM4,STXBP5L,ZNF385D,KCNJ3,SLC35F3,NRG1,RUNX1T1,RALYL,RIMS2,NRG3,TRPM3,CNTN4,GPC6,LSAMP,UNC5C,DTNA,NRXN3,EPHA5,CACNA2D1,GLCE,PTPRG,CNTN5,GRIK2,ANK2,LINGO2,CNTNAP2,MYT1L,FSTL5,EBF1,TLL1,GRIA4 |
2.135e-02 | -3.85 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | 79 | 2 | 16828 | 48 |
NRG1,LINGO2 |
2.151e-02 | -3.84 | voltage-gated potassium channel complex | cellular component | GO:0008076 | 90 | 2 | 19108 | 48 |
KCNJ3,CNTNAP2 |
2.162e-02 | -3.83 | PLXNA3 (plexin A3) | protein interactions | 55558 | 90 | 2 | 19454 | 49 |
KIF21A,NRG1 |
2.162e-02 | -3.83 | ASTACIN | prints domains | PR00480 | 6 | 1 | 5227 | 19 |
TLL1 |
2.183e-02 | -3.82 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 45 |
GRIK2,ANK2,SLC1A3,APOE |
2.203e-02 | -3.82 | SA node cell to atrial cardiac muscle cell communication | biological process | GO:0086070 | 9 | 1 | 18204 | 45 |
ANK2 |
2.203e-02 | -3.82 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 45 |
APOE |
2.203e-02 | -3.82 | ERBB2-ERBB3 signaling pathway | biological process | GO:0038133 | 9 | 1 | 18204 | 45 |
NRG1 |
2.203e-02 | -3.82 | protein localization to axon | biological process | GO:0099612 | 9 | 1 | 18204 | 45 |
CNTNAP2 |
2.203e-02 | -3.82 | ERBB3 signaling pathway | biological process | GO:0038129 | 9 | 1 | 18204 | 45 |
NRG1 |
2.203e-02 | -3.82 | netrin-activated signaling pathway | biological process | GO:0038007 | 9 | 1 | 18204 | 45 |
UNC5C |
2.203e-02 | -3.82 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 45 |
APOE |
2.203e-02 | -3.82 | cerebellar granular layer morphogenesis | biological process | GO:0021683 | 9 | 1 | 18204 | 45 |
GRID2 |
2.207e-02 | -3.81 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 49 |
SYT1,ANK2 |
2.224e-02 | -3.81 | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 377 | 4 | 16828 | 48 |
EPHA5,NRXN1,RIMS1,TRPM3 |
2.224e-02 | -3.81 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 10 | 19454 | 49 |
TLL1,DTNA,NFIA,PTPRG,NRG3,KCNJ3,ZNF385B,GRIK2,RIMS1,STXBP5L |
2.227e-02 | -3.80 | human chr8q11.23 | chromosome location | human chr8q11.23 | 12 | 1 | 26134 | 49 |
ST18 |
2.237e-02 | -3.80 | T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | T_cell_large_granular_lymphocytic_leukaemia | 81 | 2 | 16828 | 48 |
NRG1,LINGO2 |
2.239e-02 | -3.80 | chromaffin granule membrane | cellular component | GO:0042584 | 9 | 1 | 19108 | 48 |
SYT1 |
2.239e-02 | -3.80 | Composition of Lipid Particles | WikiPathways | WP3601 | 10 | 1 | 5310 | 12 |
APOE |
2.244e-02 | -3.80 | stomach | COSMIC cancer mutations | stomach | 15550 | 48 | 16828 | 48 |
RELN,ZNF385B,APOE,RIMS1,GRID2,CDH18,CADPS2,KIF21A,SYT1,NRXN1,NPAS3,CHN2,SLC1A3,ST18,NFIA,PCDH9,STXBP5L,LRRTM4,CST3,KCNJ3,ZNF385D,RALYL,RUNX1T1,NRG1,SLC35F3,RIMS2,TRPM3,NRG3,CNTN4,GPC6,NRXN3,DTNA,UNC5C,LSAMP,EPHA5,CACNA2D1,PTPRG,GLCE,CNTN5,ANK2,GRIK2,LINGO2,CNTNAP2,MYT1L,FSTL5,EBF1,GRIA4,TLL1 |
2.245e-02 | -3.80 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 49 |
APOE |
2.245e-02 | -3.80 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 1 | 19454 | 49 |
LSAMP |
2.245e-02 | -3.80 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 1 | 19454 | 49 |
LSAMP |
2.245e-02 | -3.80 | Plk2 (polo like kinase 2) | protein interactions | 20620 | 9 | 1 | 19454 | 49 |
CACNA2D1 |
2.245e-02 | -3.80 | Ubc (ubiquitin C) | protein interactions | 50522 | 9 | 1 | 19454 | 49 |
STXBP5L |
2.245e-02 | -3.80 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 49 |
APOE |
2.249e-02 | -3.79 | large_intestine-rectum | COSMIC cancer mutations | large_intestine-rectum | 569 | 5 | 16828 | 48 |
ZNF385D,GPC6,NRXN3,PTPRG,RUNX1T1 |
2.249e-02 | -3.79 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 4 | 18204 | 45 |
GRIK2,ANK2,SLC1A3,APOE |
2.249e-02 | -3.79 | postsynapse | cellular component | GO:0098794 | 646 | 5 | 19108 | 48 |
GRID2,ANK2,GRIK2,LRRTM4,GRIA4 |
2.276e-02 | -3.78 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 1 | 12186 | 40 |
SLC1A3 |
2.276e-02 | -3.78 | MHD1 | prosite domains | PS51258 | 7 | 1 | 12186 | 40 |
CADPS2 |
2.276e-02 | -3.78 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 1 | 12186 | 40 |
SLC1A3 |
2.286e-02 | -3.78 | clathrin-coated endocytic vesicle | cellular component | GO:0045334 | 93 | 2 | 19108 | 48 |
APOE,SYT1 |
2.307e-02 | -3.77 | hippocampus development | biological process | GO:0021766 | 95 | 2 | 18204 | 45 |
RELN,EPHA5 |
2.345e-02 | -3.75 | LMAN2L (lectin, mannose binding 2 like) | protein interactions | 81562 | 94 | 2 | 19454 | 49 |
CACNA2D1,LINGO2 |
2.351e-02 | -3.75 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 4 | 18204 | 45 |
APOE,PTPRG,GRID2,RELN |
2.357e-02 | -3.75 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 49 |
CST3 |
2.402e-02 | -3.73 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 45 |
ANK2,CACNA2D1,TRPM3 |
2.420e-02 | -3.72 | fibula | COSMIC cancer mutations | fibula | 387 | 4 | 16828 | 48 |
EPHA5,NRXN1,RIMS1,TRPM3 |
2.445e-02 | -3.71 | cellular response to cocaine | biological process | GO:0071314 | 10 | 1 | 18204 | 45 |
SLC1A3 |
2.445e-02 | -3.71 | regulation of gap junction assembly | biological process | GO:1903596 | 10 | 1 | 18204 | 45 |
CNTNAP2 |
2.445e-02 | -3.71 | regulation of high voltage-gated calcium channel activity | biological process | GO:1901841 | 10 | 1 | 18204 | 45 |
CACNA2D1 |
2.445e-02 | -3.71 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 45 |
NRXN1 |
2.445e-02 | -3.71 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | inhibitory postsynaptic potential | biological process | GO:0060080 | 10 | 1 | 18204 | 45 |
GRIK2 |
2.445e-02 | -3.71 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 45 |
APOE |
2.445e-02 | -3.71 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 45 |
NRXN1 |
2.445e-02 | -3.71 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 45 |
NRG3 |
2.445e-02 | -3.71 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 45 |
NRG3 |
2.450e-02 | -3.71 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 5 | 16828 | 48 |
GRIA4,FSTL5,STXBP5L,CDH18,KIF21A |
2.452e-02 | -3.71 | regulation of transporter activity | biological process | GO:0032409 | 253 | 3 | 18204 | 45 |
ANK2,RELN,CACNA2D1 |
2.483e-02 | -3.70 | HER-positive_carcinoma | COSMIC cancer mutations | HER-positive_carcinoma | 2025 | 11 | 16828 | 48 |
KCNJ3,NRG3,CNTN4,RELN,RIMS2,EPHA5,NRG1,RUNX1T1,GLCE,UNC5C,EBF1 |
2.483e-02 | -3.70 | breast-carcinoma-HER-positive_carcinoma | COSMIC cancer mutations | breast-carcinoma-HER-positive_carcinoma | 2025 | 11 | 16828 | 48 |
NRG1,RUNX1T1,GLCE,UNC5C,EBF1,KCNJ3,NRG3,CNTN4,RELN,RIMS2,EPHA5 |
2.491e-02 | -3.69 | C6orf136 (chromosome 6 open reading frame 136) | protein interactions | 221545 | 10 | 1 | 19454 | 49 |
KIF21A |
2.491e-02 | -3.69 | ALKAL2 (ALK and LTK ligand 2) | protein interactions | 285016 | 10 | 1 | 19454 | 49 |
CACNA2D1 |
2.491e-02 | -3.69 | RAB37 (RAB37, member RAS oncogene family) | protein interactions | 326624 | 10 | 1 | 19454 | 49 |
RIMS1 |
2.495e-02 | -3.69 | cellular localization | biological process | GO:0051641 | 2660 | 12 | 18204 | 45 |
APOE,GRIK2,RELN,CADPS2,CNTNAP2,SYT1,STXBP5L,GRID2,ANK2,RIMS1,RIMS2,NRXN1 |
2.501e-02 | -3.69 | lung-carcinoma-mixed_small_cell_carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-mixed_small_cell_carcinoma-adenocarcinoma | 86 | 2 | 16828 | 48 |
NRXN3,ANK2 |
2.516e-02 | -3.68 | amide binding | molecular function | GO:0033218 | 254 | 3 | 18094 | 45 |
APOE,CST3,GRIA4 |
2.518e-02 | -3.68 | EDTRNSPORT | prints domains | PR00173 | 7 | 1 | 5227 | 19 |
SLC1A3 |
2.528e-02 | -3.68 | positive regulation of growth | biological process | GO:0045927 | 256 | 3 | 18204 | 45 |
SYT1,RIMS1,RIMS2 |
2.534e-02 | -3.68 | DMD (dystrophin) | protein interactions | 1756 | 98 | 2 | 19454 | 49 |
CADPS2,DTNA |
2.550e-02 | -3.67 | heparan sulfate biosynthesis | BIOCYC pathways | META_PWY-6564 | 23 | 1 | 902 | 1 |
GLCE |
2.555e-02 | -3.67 | regulation of cellular process | biological process | GO:0050794 | 11468 | 35 | 18204 | 45 |
CADPS2,GRIK2,PTPRG,UNC5C,EBF1,ST18,NPAS3,LINGO2,RIMS1,NFIA,ZNF385B,CHN2,CACNA2D1,ANK2,NRG3,RUNX1T1,RELN,SLC1A3,CNTNAP2,GLCE,NRG1,GRIA4,APOE,GPC6,RIMS2,EPHA5,NRXN1,GRID2,CST3,CNTN4,MYT1L,FSTL5,SYT1,DTNA,KCNJ3 |
2.555e-02 | -3.67 | mixed_small_cell_carcinoma-adenocarcinoma | COSMIC cancer mutations | mixed_small_cell_carcinoma-adenocarcinoma | 87 | 2 | 16828 | 48 |
NRXN3,ANK2 |
2.580e-02 | -3.66 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 45 |
RELN,GRID2,LINGO2,NRXN1 |
2.591e-02 | -3.65 | positive regulation of molecular function | biological process | GO:0044093 | 1192 | 7 | 18204 | 45 |
EPHA5,RELN,ST18,NRG1,APOE,CACNA2D1,ANK2 |
2.594e-02 | -3.65 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 49 |
NRXN1 |
2.594e-02 | -3.65 | human chr3p14.2 | chromosome location | human chr3p14.2 | 14 | 1 | 26134 | 49 |
PTPRG |
2.596e-02 | -3.65 | Anchoring fibril formation | REACTOME pathways | R-HSA-2214320 | 9 | 1 | 10285 | 30 |
TLL1 |
2.596e-02 | -3.65 | Crosslinking of collagen fibrils | REACTOME pathways | R-HSA-2243919 | 9 | 1 | 10285 | 30 |
TLL1 |
2.597e-02 | -3.65 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 45 |
GLCE,GRID2,RELN,APOE,PTPRG |
2.611e-02 | -3.65 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 47 |
NPAS3 |
2.611e-02 | -3.65 | FYVE_2 | pfam domains | PF02318 | 10 | 1 | 17795 | 47 |
RIMS2 |
2.615e-02 | -3.64 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 49 |
NPAS3 |
2.615e-02 | -3.64 | FYVE_2 | interpro domains | IPR041282 | 10 | 1 | 18521 | 49 |
RIMS2 |
2.616e-02 | -3.64 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 2 | 19108 | 48 |
CDH18,DTNA |
2.619e-02 | -3.64 | peptide binding | molecular function | GO:0042277 | 258 | 3 | 18094 | 45 |
GRIA4,APOE,CST3 |
2.639e-02 | -3.63 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | REACTOME pathways | R-HSA-6811558 | 87 | 2 | 10285 | 30 |
NRG3,NRG1 |
2.657e-02 | -3.63 | regulation of blood circulation | biological process | GO:1903522 | 261 | 3 | 18204 | 45 |
KCNJ3,ANK2,CACNA2D1 |
2.687e-02 | -3.62 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 1 | 18204 | 45 |
SLC1A3 |
2.687e-02 | -3.62 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 45 |
APOE |
2.687e-02 | -3.62 | regulation of membrane repolarization during action potential | biological process | GO:0098903 | 11 | 1 | 18204 | 45 |
CACNA2D1 |
2.687e-02 | -3.62 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 45 |
NRG3 |
2.687e-02 | -3.62 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 45 |
APOE |
2.687e-02 | -3.62 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 45 |
NRG3 |
2.687e-02 | -3.62 | regulation of neurotransmitter receptor localization to postsynaptic specialization membrane | biological process | GO:0098696 | 11 | 1 | 18204 | 45 |
GPC6 |
2.687e-02 | -3.62 | heparin biosynthetic process | biological process | GO:0030210 | 11 | 1 | 18204 | 45 |
GLCE |
2.687e-02 | -3.62 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 45 |
APOE |
2.687e-02 | -3.62 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 45 |
NRG3 |
2.687e-02 | -3.62 | cardiac muscle cell myoblast differentiation | biological process | GO:0060379 | 11 | 1 | 18204 | 45 |
NRG1 |
2.687e-02 | -3.62 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 1 | 18204 | 45 |
SLC1A3 |
2.703e-02 | -3.61 | racemase and epimerase activity, acting on carbohydrates and derivatives | molecular function | GO:0016857 | 11 | 1 | 18094 | 45 |
GLCE |
2.703e-02 | -3.61 | voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099508 | 11 | 1 | 18094 | 45 |
KCNJ3 |
2.703e-02 | -3.61 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 45 |
NRXN1 |
2.704e-02 | -3.61 | - | gene3d domains | 1.10.357.50 | 9 | 1 | 14470 | 44 |
CADPS2 |
2.711e-02 | -3.61 | macromolecule localization | biological process | GO:0033036 | 2376 | 11 | 18204 | 45 |
CADPS2,RIMS2,RELN,GRIK2,RIMS1,NRXN1,CNTNAP2,STXBP5L,ANK2,GRID2,APOE |
2.722e-02 | -3.60 | DEATH-like_dom_sf | interpro domains | IPR011029 | 97 | 2 | 18521 | 49 |
ANK2,UNC5C |
2.728e-02 | -3.60 | TMPRSS13 (transmembrane serine protease 13) | protein interactions | 84000 | 102 | 2 | 19454 | 49 |
GLCE,GPC6 |
2.729e-02 | -3.60 | inorganic cation import across plasma membrane | biological process | GO:0098659 | 104 | 2 | 18204 | 45 |
KCNJ3,CACNA2D1 |
2.729e-02 | -3.60 | inorganic ion import across plasma membrane | biological process | GO:0099587 | 104 | 2 | 18204 | 45 |
CACNA2D1,KCNJ3 |
2.737e-02 | -3.60 | DUS4L (dihydrouridine synthase 4 like) | protein interactions | 11062 | 11 | 1 | 19454 | 49 |
PTPRG |
2.737e-02 | -3.60 | C22orf42 (chromosome 22 open reading frame 42) | protein interactions | 150297 | 11 | 1 | 19454 | 49 |
EPHA5 |
2.737e-02 | -3.60 | PLA2G5 (phospholipase A2 group V) | protein interactions | 5322 | 11 | 1 | 19454 | 49 |
CACNA2D1 |
2.737e-02 | -3.60 | PIP5K1P1 (phosphatidylinositol-4-phosphate 5-kinase type 1 pseudogene 1) | protein interactions | 206426 | 11 | 1 | 19454 | 49 |
NRXN3 |
2.737e-02 | -3.60 | TAL2 (TAL bHLH transcription factor 2) | protein interactions | 6887 | 11 | 1 | 19454 | 49 |
RUNX1T1 |
2.737e-02 | -3.60 | Katna1 (katanin p60 (ATPase-containing) subunit A1) | protein interactions | 23924 | 11 | 1 | 19454 | 49 |
RIMS1 |
2.737e-02 | -3.60 | Kif21b (kinesin family member 21B) | protein interactions | 16565 | 11 | 1 | 19454 | 49 |
KIF21A |
2.737e-02 | -3.60 | SV2C (synaptic vesicle glycoprotein 2C) | protein interactions | 22987 | 11 | 1 | 19454 | 49 |
SYT1 |
2.737e-02 | -3.60 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 49 |
NRXN1 |
2.737e-02 | -3.60 | Caskin1 (CASK interacting protein 1) | protein interactions | 140722 | 11 | 1 | 19454 | 49 |
SYT1 |
2.746e-02 | -3.60 | large_intestine-caecum-adenoma | COSMIC cancer mutations | large_intestine-caecum-adenoma | 229 | 3 | 16828 | 48 |
RIMS2,UNC5C,MYT1L |
2.758e-02 | -3.59 | ErbB signaling pathway | KEGG pathways | hsa04012 | 85 | 2 | 7161 | 22 |
NRG1,NRG3 |
2.758e-02 | -3.59 | ErbB signaling pathway | KEGG pathways | ko04012 | 85 | 2 | 7161 | 22 |
NRG3,NRG1 |
2.765e-02 | -3.59 | regulation of monoatomic ion transport | biological process | GO:0043269 | 466 | 4 | 18204 | 45 |
KCNJ3,CACNA2D1,RELN,ANK2 |
2.772e-02 | -3.59 | heparan sulfate biosynthesis | BIOCYC pathways | HUMAN_PWY-6564 | 25 | 1 | 902 | 1 |
GLCE |
2.777e-02 | -3.58 | human chr12q21.2 | chromosome location | human chr12q21.2 | 15 | 1 | 26134 | 49 |
SYT1 |
2.800e-02 | -3.58 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 6 | 19454 | 49 |
DTNA,CDH18,APOE,EPHA5,ANK2,GRIK2 |
2.801e-02 | -3.58 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 48 |
EBF1,ANK2,RIMS1,ST18,NRXN3 |
2.811e-02 | -3.57 | PI3K/AKT Signaling in Cancer | REACTOME pathways | R-HSA-2219528 | 90 | 2 | 10285 | 30 |
NRG1,NRG3 |
2.828e-02 | -3.57 | RRP7A (ribosomal RNA processing 7 homolog A) | protein interactions | 27341 | 104 | 2 | 19454 | 49 |
SYT1,NFIA |
2.844e-02 | -3.56 | EphrinA-EPHA pathway | Pathway Interaction DB | ephrina_ephapathway | 8 | 1 | 2226 | 8 |
EPHA5 |
2.868e-02 | -3.55 | SBP_bac_3 | pfam domains | PF00497 | 11 | 1 | 17795 | 47 |
GRIA4 |
2.873e-02 | -3.55 | Solute-binding_3/MltF_N | interpro domains | IPR001638 | 11 | 1 | 18521 | 49 |
GRIA4 |
2.880e-02 | -3.55 | Neurotoxicity of clostridium toxins | REACTOME pathways | R-HSA-168799 | 10 | 1 | 10285 | 30 |
SYT1 |
2.880e-02 | -3.55 | Netrin mediated repulsion signals | REACTOME pathways | R-HSA-418886 | 10 | 1 | 10285 | 30 |
UNC5C |
2.887e-02 | -3.54 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 3 | 18094 | 45 |
SLC1A3,GRIK2,GRIA4 |
2.891e-02 | -3.54 | central_nervous_system-thalamus-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-thalamus-glioma-astrocytoma_Grade_IV | 93 | 2 | 16828 | 48 |
EBF1,GRIA4 |
2.917e-02 | -3.53 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 40 |
CST3 |
2.927e-02 | -3.53 | regulation of synaptic vesicle membrane organization | biological process | GO:1901632 | 12 | 1 | 18204 | 45 |
SYT1 |
2.927e-02 | -3.53 | positive regulation of catecholamine secretion | biological process | GO:0033605 | 12 | 1 | 18204 | 45 |
SYT1 |
2.927e-02 | -3.53 | ventricular cardiac muscle cell membrane repolarization | biological process | GO:0099625 | 12 | 1 | 18204 | 45 |
KCNJ3 |
2.927e-02 | -3.53 | regulation of synaptic vesicle fusion to presynaptic active zone membrane | biological process | GO:0031630 | 12 | 1 | 18204 | 45 |
SYT1 |
2.927e-02 | -3.53 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | biological process | GO:2001267 | 12 | 1 | 18204 | 45 |
ST18 |
2.927e-02 | -3.53 | neuronal ion channel clustering | biological process | GO:0045161 | 12 | 1 | 18204 | 45 |
CNTNAP2 |
2.927e-02 | -3.53 | membrane repolarization during ventricular cardiac muscle cell action potential | biological process | GO:0098915 | 12 | 1 | 18204 | 45 |
KCNJ3 |
2.927e-02 | -3.53 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 45 |
CST3 |
2.927e-02 | -3.53 | endocardium development | biological process | GO:0003157 | 12 | 1 | 18204 | 45 |
NRG1 |
2.927e-02 | -3.53 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 45 |
CST3 |
2.945e-02 | -3.53 | voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization | molecular function | GO:1902282 | 12 | 1 | 18094 | 45 |
KCNJ3 |
2.959e-02 | -3.52 | human chr2q24.1 | chromosome location | human chr2q24.1 | 16 | 1 | 26134 | 49 |
KCNJ3 |
2.963e-02 | -3.52 | enzyme binding | molecular function | GO:0019899 | 2086 | 10 | 18094 | 45 |
RIMS1,NRG3,NRG1,CNTNAP2,UNC5C,ANK2,CST3,APOE,GRIK2,RIMS2 |
2.971e-02 | -3.52 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 8 | 18204 | 45 |
APOE,ANK2,STXBP5L,SLC1A3,SLC35F3,RIMS2,CADPS2,RIMS1 |
2.972e-02 | -3.52 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 11 | 16828 | 48 |
ANK2,RELN,STXBP5L,SYT1,DTNA,RUNX1T1,KIF21A,EPHA5,NFIA,PTPRG,FSTL5 |
2.974e-02 | -3.52 | clathrin-sculpted vesicle | cellular component | GO:0060198 | 12 | 1 | 19108 | 48 |
SYT1 |
2.974e-02 | -3.52 | L-type voltage-gated calcium channel complex | cellular component | GO:1990454 | 12 | 1 | 19108 | 48 |
CACNA2D1 |
2.974e-02 | -3.52 | paranode region of axon | cellular component | GO:0033270 | 12 | 1 | 19108 | 48 |
CNTNAP2 |
2.974e-02 | -3.52 | juxtaparanode region of axon | cellular component | GO:0044224 | 12 | 1 | 19108 | 48 |
CNTNAP2 |
2.982e-02 | -3.51 | CACNA1S (calcium voltage-gated channel subunit alpha1 S) | protein interactions | 779 | 12 | 1 | 19454 | 49 |
RIMS2 |
2.982e-02 | -3.51 | ISG20 (interferon stimulated exonuclease gene 20) | protein interactions | 3669 | 12 | 1 | 19454 | 49 |
PTPRG |
2.982e-02 | -3.51 | CDH9 (cadherin 9) | protein interactions | 1007 | 12 | 1 | 19454 | 49 |
CDH18 |
2.982e-02 | -3.51 | TIGD3 (tigger transposable element derived 3) | protein interactions | 220359 | 12 | 1 | 19454 | 49 |
RALYL |
2.982e-02 | -3.51 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 1 | 19454 | 49 |
APOE |
3.007e-02 | -3.50 | haemangiopericytic | COSMIC cancer mutations | haemangiopericytic | 95 | 2 | 16828 | 48 |
KCNJ3,SLC35F3 |
3.007e-02 | -3.50 | meninges-meningioma-haemangiopericytic | COSMIC cancer mutations | meninges-meningioma-haemangiopericytic | 95 | 2 | 16828 | 48 |
SLC35F3,KCNJ3 |
3.031e-02 | -3.50 | DRD2 (dopamine receptor D2) | protein interactions | 1813 | 108 | 2 | 19454 | 49 |
CADPS2,KCNJ3 |
3.031e-02 | -3.50 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 49 |
GPC6,NRXN3 |
3.032e-02 | -3.50 | Glycosaminoglycan biosynthesis, heparan sulfate backbone | KEGG pathways | M00059 | 10 | 1 | 7161 | 22 |
GLCE |
3.032e-02 | -3.50 | Glycosaminoglycan biosynthesis, heparan sulfate backbone | KEGG pathways | hsa_M00059 | 10 | 1 | 7161 | 22 |
GLCE |
3.040e-02 | -3.49 | Ig_E-set | interpro domains | IPR014756 | 103 | 2 | 18521 | 49 |
EBF1,KCNJ3 |
3.046e-02 | -3.49 | Negative regulation of the PI3K/AKT network | REACTOME pathways | R-HSA-199418 | 94 | 2 | 10285 | 30 |
NRG3,NRG1 |
3.065e-02 | -3.49 | tibia | COSMIC cancer mutations | tibia | 836 | 6 | 16828 | 48 |
FSTL5,CNTN5,LRRTM4,TRPM3,NRXN3,LSAMP |
3.067e-02 | -3.48 | cortical cytoskeleton | cellular component | GO:0030863 | 109 | 2 | 19108 | 48 |
RIMS2,RIMS1 |
3.112e-02 | -3.47 | distal axon | cellular component | GO:0150034 | 273 | 3 | 19108 | 48 |
GRIK2,UNC5C,PCDH9 |
3.125e-02 | -3.47 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 47 |
NFIA |
3.130e-02 | -3.46 | V_SNARE_CC | interpro domains | IPR042855 | 12 | 1 | 18521 | 49 |
STXBP5L |
3.130e-02 | -3.46 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 49 |
NFIA |
3.139e-02 | -3.46 | regulation of transmembrane transport | biological process | GO:0034762 | 485 | 4 | 18204 | 45 |
CACNA2D1,RELN,ANK2,KCNJ3 |
3.167e-02 | -3.45 | thalamus development | biological process | GO:0021794 | 13 | 1 | 18204 | 45 |
CNTNAP2 |
3.167e-02 | -3.45 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 45 |
NRXN1 |
3.167e-02 | -3.45 | detection of calcium ion | biological process | GO:0005513 | 13 | 1 | 18204 | 45 |
SYT1 |
3.167e-02 | -3.45 | regulation of postsynaptic density assembly | biological process | GO:0099151 | 13 | 1 | 18204 | 45 |
GRID2 |
3.167e-02 | -3.45 | positive regulation of calcium ion-dependent exocytosis | biological process | GO:0045956 | 13 | 1 | 18204 | 45 |
SYT1 |
3.167e-02 | -3.45 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 45 |
NFIA |
3.167e-02 | -3.45 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 45 |
APOE |
3.167e-02 | -3.45 | cerebellar granular layer development | biological process | GO:0021681 | 13 | 1 | 18204 | 45 |
GRID2 |
3.167e-02 | -3.45 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 1 | 18204 | 45 |
APOE |
3.167e-02 | -3.45 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 45 |
NRG3 |
3.167e-02 | -3.45 | calcium ion transport into cytosol | biological process | GO:0060402 | 13 | 1 | 18204 | 45 |
CACNA2D1 |
3.167e-02 | -3.45 | motor neuron migration | biological process | GO:0097475 | 13 | 1 | 18204 | 45 |
RELN |
3.167e-02 | -3.45 | cardioblast differentiation | biological process | GO:0010002 | 13 | 1 | 18204 | 45 |
NRG1 |
3.167e-02 | -3.45 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 45 |
APOE |
3.172e-02 | -3.45 | extracellular region | cellular component | GO:0005576 | 4350 | 17 | 19108 | 48 |
NRG1,LINGO2,RIMS2,GRIA4,GPC6,NRG3,CNTN4,CST3,FSTL5,LRRTM4,CACNA2D1,PTPRG,TLL1,APOE,CNTN5,RELN,LSAMP |
3.186e-02 | -3.45 | myosin II binding | molecular function | GO:0045159 | 13 | 1 | 18094 | 45 |
STXBP5L |
3.218e-02 | -3.44 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 48 |
APOE |
3.226e-02 | -3.43 | ACBD7 (acyl-CoA binding domain containing 7) | protein interactions | 414149 | 13 | 1 | 19454 | 49 |
PTPRG |
3.226e-02 | -3.43 | KCNJ3 (potassium inwardly rectifying channel subfamily J member 3) | protein interactions | 3760 | 13 | 1 | 19454 | 49 |
KCNJ3 |
3.226e-02 | -3.43 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 49 |
NFIA |
3.226e-02 | -3.43 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 49 |
APOE |
3.226e-02 | -3.43 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 49 |
RIMS2 |
3.226e-02 | -3.43 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 49 |
NRXN1 |
3.241e-02 | -3.43 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 49 |
RALYL,RUNX1T1 |
3.243e-02 | -3.43 | large_intestine-rectum-adenoma | COSMIC cancer mutations | large_intestine-rectum-adenoma | 99 | 2 | 16828 | 48 |
RELN,CNTN4 |
3.253e-02 | -3.43 | ZDHHC17 (zinc finger DHHC-type palmitoyltransferase 17) | protein interactions | 23390 | 277 | 3 | 19454 | 49 |
SYT1,SLC1A3,NRG1 |
3.298e-02 | -3.41 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 5 | 19454 | 49 |
RIMS2,SLC1A3,PTPRG,ANK2,DTNA |
3.323e-02 | -3.40 | human chr7q21.11 | chromosome location | human chr7q21.11 | 18 | 1 | 26134 | 49 |
CACNA2D1 |
3.323e-02 | -3.40 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 49 |
CADPS2 |
3.335e-02 | -3.40 | regulation of cation channel activity | biological process | GO:2001257 | 116 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
3.347e-02 | -3.40 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 49 |
PCDH9,NRG1 |
3.349e-02 | -3.40 | endometrium-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-endometrioid_carcinoma | 15680 | 48 | 16828 | 48 |
NRXN3,DTNA,UNC5C,LSAMP,GPC6,CNTN4,PTPRG,GLCE,CACNA2D1,EPHA5,CNTNAP2,LINGO2,GRIK2,ANK2,CNTN5,GRIA4,TLL1,FSTL5,EBF1,MYT1L,SYT1,GRID2,CADPS2,CDH18,KIF21A,ZNF385B,APOE,RIMS1,RELN,ST18,NFIA,PCDH9,CHN2,SLC1A3,NRXN1,NPAS3,RALYL,RUNX1T1,NRG1,SLC35F3,KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,TRPM3,NRG3,RIMS2 |
3.355e-02 | -3.39 | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 633 | 5 | 16828 | 48 |
CDH18,KIF21A,NRXN3,TLL1,UNC5C |
3.373e-02 | -3.39 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 49 |
CDH18,PCDH9 |
3.407e-02 | -3.38 | interneuron migration | biological process | GO:1904936 | 14 | 1 | 18204 | 45 |
RELN |
3.407e-02 | -3.38 | regulation of NMDA receptor activity | biological process | GO:2000310 | 14 | 1 | 18204 | 45 |
RELN |
3.407e-02 | -3.38 | regulation of long-term synaptic depression | biological process | GO:1900452 | 14 | 1 | 18204 | 45 |
GRID2 |
3.407e-02 | -3.38 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 45 |
APOE |
3.407e-02 | -3.38 | layer formation in cerebral cortex | biological process | GO:0021819 | 14 | 1 | 18204 | 45 |
RELN |
3.407e-02 | -3.38 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 45 |
APOE |
3.407e-02 | -3.38 | ventricular trabecula myocardium morphogenesis | biological process | GO:0003222 | 14 | 1 | 18204 | 45 |
NRG1 |
3.407e-02 | -3.38 | bundle of His cell to Purkinje myocyte communication | biological process | GO:0086069 | 14 | 1 | 18204 | 45 |
CACNA2D1 |
3.407e-02 | -3.38 | dendrite self-avoidance | biological process | GO:0070593 | 14 | 1 | 18204 | 45 |
CNTN4 |
3.407e-02 | -3.38 | interleukin-6-mediated signaling pathway | biological process | GO:0070102 | 14 | 1 | 18204 | 45 |
ST18 |
3.422e-02 | -3.37 | transmembrane transport | biological process | GO:0055085 | 1264 | 7 | 18204 | 45 |
GRIK2,SLC1A3,GRID2,CACNA2D1,TRPM3,KCNJ3,GRIA4 |
3.426e-02 | -3.37 | calcium channel activity | molecular function | GO:0005262 | 117 | 2 | 18094 | 45 |
CACNA2D1,TRPM3 |
3.427e-02 | -3.37 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 1 | 18094 | 45 |
SLC1A3 |
3.440e-02 | -3.37 | Death Domain, Fas | gene3d domains | 1.10.533.10 | 96 | 2 | 14470 | 44 |
ANK2,UNC5C |
3.441e-02 | -3.37 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 13 | 18204 | 45 |
ANK2,CST3,GRID2,CACNA2D1,KCNJ3,LINGO2,RIMS1,RIMS2,NRXN1,APOE,GRIK2,RELN,PTPRG |
3.441e-02 | -3.37 | negative regulation of epithelial cell migration | biological process | GO:0010633 | 118 | 2 | 18204 | 45 |
PTPRG,APOE |
3.441e-02 | -3.37 | positive regulation of calcium ion transport | biological process | GO:0051928 | 118 | 2 | 18204 | 45 |
ANK2,CACNA2D1 |
3.446e-02 | -3.37 | Ionotropic activity of Kainate Receptors | REACTOME pathways | R-HSA-451306 | 12 | 1 | 10285 | 30 |
GRIK2 |
3.446e-02 | -3.37 | Activation of Ca-permeable Kainate Receptor | REACTOME pathways | R-HSA-451308 | 12 | 1 | 10285 | 30 |
GRIK2 |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC6 |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC6 |
3.452e-02 | -3.37 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 2 | 7161 | 22 |
GRIA4,KCNJ3 |
3.452e-02 | -3.37 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 2 | 7161 | 22 |
GRIA4,KCNJ3 |
3.453e-02 | -3.37 | endometrioid_carcinoma | COSMIC cancer mutations | endometrioid_carcinoma | 15690 | 48 | 16828 | 48 |
PTPRG,GLCE,EPHA5,CACNA2D1,DTNA,NRXN3,LSAMP,UNC5C,CNTN4,GPC6,EBF1,FSTL5,TLL1,GRIA4,MYT1L,LINGO2,CNTNAP2,CNTN5,ANK2,GRIK2,ST18,NFIA,PCDH9,NRXN1,NPAS3,CHN2,SLC1A3,GRID2,KIF21A,CDH18,CADPS2,SYT1,RELN,APOE,ZNF385B,RIMS1,RIMS2,TRPM3,NRG3,NRG1,RUNX1T1,RALYL,SLC35F3,STXBP5L,LRRTM4,CST3,KCNJ3,ZNF385D |
3.461e-02 | -3.36 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 48 |
SYT1 |
3.470e-02 | -3.36 | CSF3 (colony stimulating factor 3) | protein interactions | 1440 | 14 | 1 | 19454 | 49 |
PTPRG |
3.470e-02 | -3.36 | CHGA (chromogranin A) | protein interactions | 1113 | 14 | 1 | 19454 | 49 |
SYT1 |
3.470e-02 | -3.36 | C9 (complement C9) | protein interactions | 735 | 14 | 1 | 19454 | 49 |
APOE |
3.470e-02 | -3.36 | GRID2 (glutamate ionotropic receptor delta type subunit 2) | protein interactions | 2895 | 14 | 1 | 19454 | 49 |
GRIK2 |
3.470e-02 | -3.36 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 49 |
APOE |
3.470e-02 | -3.36 | OTUD7A (OTU deubiquitinase 7A) | protein interactions | 161725 | 14 | 1 | 19454 | 49 |
ANK2 |
3.470e-02 | -3.36 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 49 |
CST3 |
3.474e-02 | -3.36 | endometrium | COSMIC cancer mutations | endometrium | 15692 | 48 | 16828 | 48 |
SYT1,CADPS2,CDH18,KIF21A,GRID2,RIMS1,ZNF385B,APOE,RELN,PCDH9,NFIA,ST18,SLC1A3,CHN2,NPAS3,NRXN1,SLC35F3,RALYL,RUNX1T1,NRG1,ZNF385D,KCNJ3,CST3,LRRTM4,STXBP5L,NRG3,TRPM3,RIMS2,UNC5C,LSAMP,NRXN3,DTNA,GPC6,CNTN4,GLCE,PTPRG,CACNA2D1,EPHA5,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,GRIA4,TLL1,EBF1,FSTL5,MYT1L |
3.475e-02 | -3.36 | Visual phototransduction | REACTOME pathways | R-HSA-2187338 | 101 | 2 | 10285 | 30 |
GPC6,APOE |
3.510e-02 | -3.35 | cellular component assembly | biological process | GO:0022607 | 2472 | 11 | 18204 | 45 |
CNTN5,TRPM3,NRG1,APOE,CDH18,NRG3,SYT1,ANK2,GRID2,RIMS1,NRXN1 |
3.531e-02 | -3.34 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 47 |
PCDH9,CDH18 |
3.558e-02 | -3.34 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 3 | 19454 | 49 |
PTPRG,DTNA,EPHA5 |
3.563e-02 | -3.33 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 4 | 18204 | 45 |
APOE,SLC1A3,GRIK2,ANK2 |
3.565e-02 | -3.33 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 2 | 19454 | 49 |
CACNA2D1,APOE |
3.567e-02 | -3.33 | OCLN (occludin) | protein interactions | 100506658 | 495 | 4 | 19454 | 49 |
PTPRG,ANK2,DTNA,CCSER1 |
3.572e-02 | -3.33 | skin-sole-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-sole-malignant_melanoma-acral_lentiginous | 254 | 3 | 16828 | 48 |
CDH18,ST18,CNTNAP2 |
3.620e-02 | -3.32 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 49 |
APOE,PCDH9 |
3.636e-02 | -3.31 | EphA2_TM | pfam domains | PF14575 | 14 | 1 | 17795 | 47 |
EPHA5 |
3.636e-02 | -3.31 | Ephrin_lbd | pfam domains | PF01404 | 14 | 1 | 17795 | 47 |
EPHA5 |
3.642e-02 | -3.31 | Tyr_kinase_rcpt_V_CS | interpro domains | IPR001426 | 14 | 1 | 18521 | 49 |
EPHA5 |
3.642e-02 | -3.31 | Tyr_kinase_ephrin_rcpt | interpro domains | IPR016257 | 14 | 1 | 18521 | 49 |
EPHA5 |
3.642e-02 | -3.31 | Eph_TM | interpro domains | IPR027936 | 14 | 1 | 18521 | 49 |
EPHA5 |
3.642e-02 | -3.31 | Ephrin_rcpt_lig-bd_dom | interpro domains | IPR001090 | 14 | 1 | 18521 | 49 |
EPHA5 |
3.646e-02 | -3.31 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 45 |
APOE |
3.646e-02 | -3.31 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 45 |
APOE |
3.646e-02 | -3.31 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 45 |
NFIA |
3.646e-02 | -3.31 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 45 |
ANK2 |
3.646e-02 | -3.31 | dense core granule localization | biological process | GO:0032253 | 15 | 1 | 18204 | 45 |
CADPS2 |
3.646e-02 | -3.31 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 45 |
APOE |
3.646e-02 | -3.31 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 45 |
NFIA |
3.660e-02 | -3.31 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 49 |
CDH18,PCDH9 |
3.668e-02 | -3.31 | voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization | molecular function | GO:0086008 | 15 | 1 | 18094 | 45 |
KCNJ3 |
3.668e-02 | -3.31 | transmembrane-ephrin receptor activity | molecular function | GO:0005005 | 15 | 1 | 18094 | 45 |
EPHA5 |
3.669e-02 | -3.31 | vesicle-mediated transport | biological process | GO:0016192 | 1283 | 7 | 18204 | 45 |
RIMS2,CADPS2,STXBP5L,ANK2,RIMS1,SYT1,APOE |
3.697e-02 | -3.30 | potassium channel activity | molecular function | GO:0005267 | 122 | 2 | 18094 | 45 |
GRIK2,KCNJ3 |
3.704e-02 | -3.30 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 48 |
APOE |
3.704e-02 | -3.30 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 48 |
CNTNAP2 |
3.714e-02 | -3.29 | Sgo1 (shugoshin 1) | protein interactions | 72415 | 15 | 1 | 19454 | 49 |
RIMS1 |
3.714e-02 | -3.29 | EBF1 (EBF transcription factor 1) | protein interactions | 1879 | 15 | 1 | 19454 | 49 |
EBF1 |
3.714e-02 | -3.29 | DEFB123 (defensin beta 123) | protein interactions | 245936 | 15 | 1 | 19454 | 49 |
CACNA2D1 |
3.714e-02 | -3.29 | BSN (bassoon presynaptic cytomatrix protein) | protein interactions | 8927 | 15 | 1 | 19454 | 49 |
RIMS1 |
3.714e-02 | -3.29 | TMEM181 (transmembrane protein 181) | protein interactions | 57583 | 15 | 1 | 19454 | 49 |
NRG1 |
3.728e-02 | -3.29 | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | REACTOME pathways | R-HSA-112308 | 13 | 1 | 10285 | 30 |
CACNA2D1 |
3.728e-02 | -3.29 | Downregulation of ERBB2:ERBB3 signaling | REACTOME pathways | R-HSA-1358803 | 13 | 1 | 10285 | 30 |
NRG1 |
3.778e-02 | -3.28 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 49 |
PCDH9,CDH18 |
3.782e-02 | -3.27 | regulation of cellular component biogenesis | biological process | GO:0044087 | 1016 | 6 | 18204 | 45 |
NRXN1,NRG1,APOE,CNTNAP2,GRID2,LINGO2 |
3.787e-02 | -3.27 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 4 | 18204 | 45 |
APOE,SLC1A3,GRIK2,ANK2 |
3.788e-02 | -3.27 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 49 |
EPHA5,DTNA |
3.822e-02 | -3.26 | cerebral cortex development | biological process | GO:0021987 | 125 | 2 | 18204 | 45 |
RELN,CNTNAP2 |
3.822e-02 | -3.26 | mammary gland development | biological process | GO:0030879 | 125 | 2 | 18204 | 45 |
NRG3,NRG1 |
3.822e-02 | -3.26 | memory | biological process | GO:0007613 | 125 | 2 | 18204 | 45 |
RELN,APOE |
3.864e-02 | -3.25 | protein tyrosine kinase binding | molecular function | GO:1990782 | 125 | 2 | 18094 | 45 |
NRG3,NRG1 |
3.866e-02 | -3.25 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 49 |
TLL1 |
3.866e-02 | -3.25 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 49 |
NRG3 |
3.870e-02 | -3.25 | V_SNARE | prosite domains | PS50892 | 12 | 1 | 12186 | 40 |
STXBP5L |
3.876e-02 | -3.25 | H2BC9 (H2B clustered histone 9) | protein interactions | 8345 | 297 | 3 | 19454 | 49 |
ZNF385B,ST18,NRG1 |
3.884e-02 | -3.25 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 47 | 16828 | 48 |
MYT1L,GRIA4,TLL1,EBF1,FSTL5,ANK2,GRIK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,GLCE,PTPRG,GPC6,CNTN4,UNC5C,LSAMP,NRXN3,DTNA,NRG3,TRPM3,RIMS2,ZNF385D,KCNJ3,LRRTM4,STXBP5L,SLC35F3,RALYL,NRG1,RUNX1T1,SLC1A3,CHN2,NPAS3,NRXN1,PCDH9,ST18,NFIA,RIMS1,ZNF385B,APOE,RELN,SYT1,CDH18,CADPS2,KIF21A,GRID2 |
3.884e-02 | -3.25 | regulation of postsynaptic specialization assembly | biological process | GO:0099150 | 16 | 1 | 18204 | 45 |
GRID2 |
3.884e-02 | -3.25 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 45 |
SLC1A3 |
3.884e-02 | -3.25 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 45 |
APOE |
3.884e-02 | -3.25 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 45 |
APOE |
3.884e-02 | -3.25 | regulation of short-term neuronal synaptic plasticity | biological process | GO:0048172 | 16 | 1 | 18204 | 45 |
GRIK2 |
3.884e-02 | -3.25 | glutamatergic neuron differentiation | biological process | GO:1905962 | 16 | 1 | 18204 | 45 |
GRID2 |
3.884e-02 | -3.25 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 45 |
APOE |
3.898e-02 | -3.24 | cellular component organization | biological process | GO:0016043 | 5636 | 20 | 18204 | 45 |
CST3,GRID2,ANK2,SYT1,CNTN4,NRG3,NRXN3,RIMS1,EPHA5,NFIA,NRXN1,CNTN5,APOE,NRG1,TRPM3,RELN,CDH18,CNTNAP2,UNC5C,TLL1 |
3.934e-02 | -3.24 | negative regulation of neuron projection development | biological process | GO:0010977 | 127 | 2 | 18204 | 45 |
APOE,PTPRG |
3.934e-02 | -3.24 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 2 | 18204 | 45 |
CDH18,ANK2 |
3.948e-02 | -3.23 | cell-cell junction | cellular component | GO:0005911 | 513 | 4 | 19108 | 48 |
CDH18,PCDH9,CNTNAP2,ANK2 |
3.956e-02 | -3.23 | RBM18 (RNA binding motif protein 18) | protein interactions | 92400 | 16 | 1 | 19454 | 49 |
SYT1 |
3.956e-02 | -3.23 | NEUROG1 (neurogenin 1) | protein interactions | 4762 | 16 | 1 | 19454 | 49 |
RUNX1T1 |
3.956e-02 | -3.23 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 49 |
CDH18 |
3.956e-02 | -3.23 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | HOXB2 (homeobox B2) | protein interactions | 3212 | 16 | 1 | 19454 | 49 |
RUNX1T1 |
3.956e-02 | -3.23 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 49 |
APOE |
3.972e-02 | -3.23 | monoatomic cation transport | biological process | GO:0006812 | 766 | 5 | 18204 | 45 |
ANK2,CACNA2D1,SLC1A3,TRPM3,KCNJ3 |
3.974e-02 | -3.23 | regulation of small GTPase mediated signal transduction | biological process | GO:0051056 | 306 | 3 | 18204 | 45 |
RELN,APOE,CHN2 |
3.985e-02 | -3.22 | animal organ development | biological process | GO:0048513 | 2846 | 12 | 18204 | 45 |
ANK2,GRID2,CNTN4,NRG3,EPHA5,NFIA,CNTN5,NRG1,PCDH9,RELN,CNTNAP2,UNC5C |
4.036e-02 | -3.21 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 48 | 16828 | 48 |
TLL1,GRIA4,EBF1,FSTL5,MYT1L,CNTNAP2,LINGO2,ANK2,GRIK2,CNTN5,GLCE,PTPRG,CACNA2D1,EPHA5,LSAMP,UNC5C,DTNA,NRXN3,GPC6,CNTN4,NRG3,TRPM3,RIMS2,SLC35F3,NRG1,RUNX1T1,RALYL,ZNF385D,KCNJ3,LRRTM4,CST3,STXBP5L,PCDH9,ST18,NFIA,SLC1A3,CHN2,NPAS3,NRXN1,SYT1,KIF21A,CADPS2,CDH18,GRID2,RIMS1,APOE,ZNF385B,RELN |
4.046e-02 | -3.21 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 1 | 26134 | 49 |
LSAMP |
4.081e-02 | -3.20 | enzyme regulator activity | molecular function | GO:0030234 | 1305 | 7 | 18094 | 45 |
APOE,CST3,STXBP5L,NRG3,RIMS1,NRG1,CHN2 |
4.111e-02 | -3.19 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 48 |
SYT1,GRIK2 |
4.122e-02 | -3.19 | regulation of postsynaptic density organization | biological process | GO:1905874 | 17 | 1 | 18204 | 45 |
GRID2 |
4.122e-02 | -3.19 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 45 |
NFIA |
4.122e-02 | -3.19 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 45 |
NFIA |
4.122e-02 | -3.19 | regulation of excitatory synapse assembly | biological process | GO:1904889 | 17 | 1 | 18204 | 45 |
GRID2 |
4.122e-02 | -3.19 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | negative regulation of smooth muscle cell apoptotic process | biological process | GO:0034392 | 17 | 1 | 18204 | 45 |
GRIA4 |
4.122e-02 | -3.19 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | ganglion development | biological process | GO:0061548 | 17 | 1 | 18204 | 45 |
UNC5C |
4.122e-02 | -3.19 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | positive regulation of neurotransmitter secretion | biological process | GO:0001956 | 17 | 1 | 18204 | 45 |
SYT1 |
4.122e-02 | -3.19 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 1 | 18204 | 45 |
APOE |
4.122e-02 | -3.19 | heparin metabolic process | biological process | GO:0030202 | 17 | 1 | 18204 | 45 |
GLCE |
4.123e-02 | -3.19 | sole | COSMIC cancer mutations | sole | 269 | 3 | 16828 | 48 |
CDH18,ST18,CNTNAP2 |
4.124e-02 | -3.19 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 47 |
RIMS2,RIMS1 |
4.132e-02 | -3.19 | EIF2B2 (eukaryotic translation initiation factor 2B subunit beta) | protein interactions | 8892 | 128 | 2 | 19454 | 49 |
SYT1,PCDH9 |
4.132e-02 | -3.19 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 49 |
NRXN1,SYT1 |
4.132e-02 | -3.19 | FARP1 (FERM, ARH/RhoGEF and pleckstrin domain protein 1) | protein interactions | 10160 | 128 | 2 | 19454 | 49 |
PTPRG,ANK2 |
4.145e-02 | -3.18 | IRK | pfam domains | PF01007 | 16 | 1 | 17795 | 47 |
KCNJ3 |
4.145e-02 | -3.18 | IRK_C | pfam domains | PF17655 | 16 | 1 | 17795 | 47 |
KCNJ3 |
4.147e-02 | -3.18 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 45 |
PTPRG |
4.147e-02 | -3.18 | ephrin receptor activity | molecular function | GO:0005003 | 17 | 1 | 18094 | 45 |
EPHA5 |
4.147e-02 | -3.18 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 45 |
PTPRG |
4.147e-02 | -3.18 | ligand-gated sodium channel activity | molecular function | GO:0015280 | 17 | 1 | 18094 | 45 |
GRIK2 |
4.152e-02 | -3.18 | K_chnl_inward-rec_Kir_cyto | interpro domains | IPR013518 | 16 | 1 | 18521 | 49 |
KCNJ3 |
4.152e-02 | -3.18 | IRK_C | interpro domains | IPR041647 | 16 | 1 | 18521 | 49 |
KCNJ3 |
4.152e-02 | -3.18 | K_chnl_inward-rec_Kir | interpro domains | IPR016449 | 16 | 1 | 18521 | 49 |
KCNJ3 |
4.152e-02 | -3.18 | Kir_TM | interpro domains | IPR040445 | 16 | 1 | 18521 | 49 |
KCNJ3 |
4.164e-02 | -3.18 | Nifedipine Action Pathway | SMPDB pathways | SMP0000379 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Amlodipine Action Pathway | SMPDB pathways | SMP0000376 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Metoprolol Action Pathway | SMPDB pathways | SMP0000302 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Levobunolol Action Pathway | SMPDB pathways | SMP0000666 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Fosphenytoin (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000326 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Isoprenaline Action Pathway | SMPDB pathways | SMP0000663 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Quinidine Action Pathway | SMPDB pathways | SMP0000323 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Esmolol Action Pathway | SMPDB pathways | SMP0000301 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Practolol Action Pathway | SMPDB pathways | SMP0000669 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Sotalol Action Pathway | SMPDB pathways | SMP0000660 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Mexiletine Action Pathway | SMPDB pathways | SMP0000329 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Bopindolol Action Pathway | SMPDB pathways | SMP0000657 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Dobutamine Action Pathway | SMPDB pathways | SMP0000662 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Epinephrine Action Pathway | SMPDB pathways | SMP0000661 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Carteolol Action Pathway | SMPDB pathways | SMP0000658 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Acebutolol Action Pathway | SMPDB pathways | SMP0000296 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Nadolol Action Pathway | SMPDB pathways | SMP0000303 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Bisoprolol Action Pathway | SMPDB pathways | SMP0000300 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Diltiazem Action Pathway | SMPDB pathways | SMP0000359 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Betaxolol Action Pathway | SMPDB pathways | SMP0000299 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Pindolol Action Pathway | SMPDB pathways | SMP0000306 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Timolol Action Pathway | SMPDB pathways | SMP0000659 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Disopyramide Action Pathway | SMPDB pathways | SMP0000325 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Atenolol Action Pathway | SMPDB pathways | SMP0000298 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Amiodarone Action Pathway | SMPDB pathways | SMP0000665 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Nimodipine Action Pathway | SMPDB pathways | SMP0000380 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Propranolol Action Pathway | SMPDB pathways | SMP0000307 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Verapamil Action Pathway | SMPDB pathways | SMP0000375 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Procainamide (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000324 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Arbutamine Action Pathway | SMPDB pathways | SMP0000664 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Alprenolol Action Pathway | SMPDB pathways | SMP0000297 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Tocainide Action Pathway | SMPDB pathways | SMP0000330 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Felodipine Action Pathway | SMPDB pathways | SMP0000377 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Penbutolol Action Pathway | SMPDB pathways | SMP0000305 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Ibutilide Action Pathway | SMPDB pathways | SMP0000332 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Nitrendipine Action Pathway | SMPDB pathways | SMP0000382 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Bevantolol Action Pathway | SMPDB pathways | SMP0000668 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Nebivolol Action Pathway | SMPDB pathways | SMP0000366 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Flecainide Action Pathway | SMPDB pathways | SMP0000331 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Oxprenolol Action Pathway | SMPDB pathways | SMP0000304 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Muscle/Heart Contraction | SMPDB pathways | SMP0000588 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Isradipine Action Pathway | SMPDB pathways | SMP0000378 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Metipranolol Action Pathway | SMPDB pathways | SMP0000667 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Bupranolol Action Pathway | SMPDB pathways | SMP0000670 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.164e-02 | -3.18 | Nisoldipine Action Pathway | SMPDB pathways | SMP0000381 | 57 | 1 | 1369 | 1 |
KCNJ3 |
4.176e-02 | -3.18 | ephrin a2 ectodomain | gene3d domains | 2.60.40.1770 | 14 | 1 | 14470 | 44 |
EPHA5 |
4.179e-02 | -3.18 | cytoplasmic region | cellular component | GO:0099568 | 307 | 3 | 19108 | 48 |
RIMS1,RIMS2,GRIK2 |
4.190e-02 | -3.17 | EIF2B4 (eukaryotic translation initiation factor 2B subunit delta) | protein interactions | 8890 | 129 | 2 | 19454 | 49 |
PCDH9,SYT1 |
4.198e-02 | -3.17 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 49 |
NRXN3 |
4.198e-02 | -3.17 | CNTN2 (contactin 2) | protein interactions | 6900 | 17 | 1 | 19454 | 49 |
CNTNAP2 |
4.198e-02 | -3.17 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 49 |
APOE |
4.198e-02 | -3.17 | EPB42 (erythrocyte membrane protein band 4.2) | protein interactions | 2038 | 17 | 1 | 19454 | 49 |
ANK2 |
4.198e-02 | -3.17 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 49 |
DTNA |
4.226e-02 | -3.16 | human chr2p25.3 | chromosome location | human chr2p25.3 | 23 | 1 | 26134 | 49 |
MYT1L |
4.237e-02 | -3.16 | Carvedilol Action Pathway | SMPDB pathways | SMP0000367 | 58 | 1 | 1369 | 1 |
KCNJ3 |
4.237e-02 | -3.16 | Labetalol Action Pathway | SMPDB pathways | SMP0000368 | 58 | 1 | 1369 | 1 |
KCNJ3 |
4.264e-02 | -3.15 | protein kinase activator activity | molecular function | GO:0030295 | 132 | 2 | 18094 | 45 |
NRG1,NRG3 |
4.277e-02 | -3.15 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 3 | 19454 | 49 |
DTNA,NRXN1,NRXN3 |
4.310e-02 | -3.14 | Lidocaine (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000328 | 59 | 1 | 1369 | 1 |
KCNJ3 |
4.359e-02 | -3.13 | ectopic germ cell programmed cell death | biological process | GO:0035234 | 18 | 1 | 18204 | 45 |
UNC5C |
4.359e-02 | -3.13 | spinal cord patterning | biological process | GO:0021511 | 18 | 1 | 18204 | 45 |
RELN |
4.359e-02 | -3.13 | positive regulation of dendritic spine morphogenesis | biological process | GO:0061003 | 18 | 1 | 18204 | 45 |
RELN |
4.359e-02 | -3.13 | positive regulation of neuron migration | biological process | GO:2001224 | 18 | 1 | 18204 | 45 |
RELN |
4.359e-02 | -3.13 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 45 |
APOE |
4.359e-02 | -3.13 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 45 |
CST3 |
4.359e-02 | -3.13 | secretory granule localization | biological process | GO:0032252 | 18 | 1 | 18204 | 45 |
CADPS2 |
4.385e-02 | -3.13 | racemase and epimerase activity | molecular function | GO:0016854 | 18 | 1 | 18094 | 45 |
GLCE |
4.385e-02 | -3.13 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 1 | 18094 | 45 |
APOE |
4.385e-02 | -3.13 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 1 | 18094 | 45 |
SLC1A3 |
4.398e-02 | -3.12 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 47 |
DTNA |
4.398e-02 | -3.12 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 47 |
PTPRG |
4.398e-02 | -3.12 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 47 |
CST3 |
4.399e-02 | -3.12 | Lipid digestion, mobilization, and transport | REACTOME pathways | R-HSA-73923 | 115 | 2 | 10285 | 30 |
RELN,APOE |
4.406e-02 | -3.12 | Synaptotagmin | interpro domains | IPR001565 | 17 | 1 | 18521 | 49 |
SYT1 |
4.406e-02 | -3.12 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 49 |
CST3 |
4.406e-02 | -3.12 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 49 |
PTPRG |
4.406e-02 | -3.12 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 49 |
PTPRG |
4.406e-02 | -3.12 | human chr3p24.3 | chromosome location | human chr3p24.3 | 24 | 1 | 26134 | 49 |
ZNF385D |
4.427e-02 | -3.12 | PTPRS (protein tyrosine phosphatase receptor type S) | protein interactions | 5802 | 133 | 2 | 19454 | 49 |
LRRTM4,GPC6 |
4.428e-02 | -3.12 | costamere | cellular component | GO:0043034 | 18 | 1 | 19108 | 48 |
ANK2 |
4.440e-02 | -3.11 | Ccdc77 (coiled-coil domain containing 77) | protein interactions | 67200 | 18 | 1 | 19454 | 49 |
CACNA2D1 |
4.440e-02 | -3.11 | RELN (reelin) | protein interactions | 5649 | 18 | 1 | 19454 | 49 |
RELN |
4.440e-02 | -3.11 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 49 |
APOE |
4.440e-02 | -3.11 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 2 | 18094 | 45 |
GRIK2,KCNJ3 |
4.487e-02 | -3.10 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 49 |
ANK2,SYT1 |
4.487e-02 | -3.10 | ARL4C (ADP ribosylation factor like GTPase 4C) | protein interactions | 10123 | 134 | 2 | 19454 | 49 |
PCDH9,UNC5C |
4.500e-02 | -3.10 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 2 | 18094 | 45 |
TRPM3,CACNA2D1 |
4.501e-02 | -3.10 | EPH_LBD | prosite domains | PS51550 | 14 | 1 | 12186 | 40 |
EPHA5 |
4.501e-02 | -3.10 | RECEPTOR_TYR_KIN_V_2 | prosite domains | PS00791 | 14 | 1 | 12186 | 40 |
EPHA5 |
4.501e-02 | -3.10 | RECEPTOR_TYR_KIN_V_1 | prosite domains | PS00790 | 14 | 1 | 12186 | 40 |
EPHA5 |
4.510e-02 | -3.10 | cell recognition | biological process | GO:0008037 | 137 | 2 | 18204 | 45 |
CNTNAP2,CNTN4 |
4.511e-02 | -3.10 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 20 | 18204 | 45 |
RIMS2,LINGO2,RIMS1,NPAS3,NFIA,NRXN1,CACNA2D1,GRID2,ANK2,SYT1,RELN,CADPS2,GRIK2,SLC1A3,UNC5C,CNTNAP2,GLCE,NRG1,APOE,ST18 |
4.523e-02 | -3.10 | postsynaptic density | cellular component | GO:0014069 | 317 | 3 | 19108 | 48 |
GRID2,GRIK2,GRIA4 |
4.556e-02 | -3.09 | LGALS1 (galectin 1) | protein interactions | 3956 | 317 | 3 | 19454 | 49 |
LINGO2,PTPRG,PCDH9 |
4.585e-02 | -3.08 | ErbB receptor signaling network | Pathway Interaction DB | erbb_network_pathway | 13 | 1 | 2226 | 8 |
NRG3 |
4.596e-02 | -3.08 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 38 |
NFIA |
4.596e-02 | -3.08 | regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | biological process | GO:1902514 | 19 | 1 | 18204 | 45 |
CACNA2D1 |
4.596e-02 | -3.08 | presynapse assembly | biological process | GO:0099054 | 19 | 1 | 18204 | 45 |
CNTN5 |
4.596e-02 | -3.08 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 45 |
APOE |
4.596e-02 | -3.08 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 1 | 18204 | 45 |
APOE |
4.608e-02 | -3.08 | NIBAN2 (niban apoptosis regulator 2) | protein interactions | 64855 | 136 | 2 | 19454 | 49 |
EPHA5,PTPRG |
4.619e-02 | -3.07 | protease binding | molecular function | GO:0002020 | 138 | 2 | 18094 | 45 |
CNTNAP2,CST3 |
4.622e-02 | -3.07 | signal transduction | biological process | GO:0007165 | 4637 | 17 | 18204 | 45 |
PTPRG,UNC5C,RELN,GRIK2,APOE,GRIA4,NRG1,ST18,CHN2,NFIA,ZNF385B,RIMS2,EPHA5,DTNA,ANK2,GRID2,NRG3 |
4.623e-02 | -3.07 | syntaxin-1 binding | molecular function | GO:0017075 | 19 | 1 | 18094 | 45 |
SYT1 |
4.629e-02 | -3.07 | positive regulation of cation transmembrane transport | biological process | GO:1904064 | 139 | 2 | 18204 | 45 |
CACNA2D1,ANK2 |
4.629e-02 | -3.07 | TSP1REPEAT | prints domains | PR01705 | 13 | 1 | 5227 | 19 |
UNC5C |
4.681e-02 | -3.06 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.681e-02 | -3.06 | RAB26 (RAB26, member RAS oncogene family) | protein interactions | 25837 | 19 | 1 | 19454 | 49 |
RIMS1 |
4.681e-02 | -3.06 | Cep76 (centrosomal protein 76) | protein interactions | 225659 | 19 | 1 | 19454 | 49 |
CACNA2D1 |
4.681e-02 | -3.06 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 49 |
TRPM3 |
4.681e-02 | -3.06 | CACNA1B (calcium voltage-gated channel subunit alpha1 B) | protein interactions | 774 | 19 | 1 | 19454 | 49 |
RIMS1 |
4.681e-02 | -3.06 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | CCL19 (C-C motif chemokine ligand 19) | protein interactions | 6363 | 19 | 1 | 19454 | 49 |
CACNA2D1 |
4.696e-02 | -3.06 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 44 |
CDH18,PCDH9 |
4.706e-02 | -3.06 | clathrin-coated vesicle membrane | cellular component | GO:0030665 | 138 | 2 | 19108 | 48 |
SYT1,APOE |
4.740e-02 | -3.05 | kinase activator activity | molecular function | GO:0019209 | 140 | 2 | 18094 | 45 |
NRG3,NRG1 |
4.742e-02 | -3.05 | central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 48 |
CNTNAP2 |
4.742e-02 | -3.05 | diencephalon | COSMIC cancer mutations | diencephalon | 17 | 1 | 16828 | 48 |
CNTNAP2 |
4.758e-02 | -3.05 | G protein-activated inward rectifier potassium channel 1 | gene3d domains | 2.60.40.1400 | 16 | 1 | 14470 | 44 |
KCNJ3 |
4.765e-02 | -3.04 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 49 |
DTNA |
4.792e-02 | -3.04 | PTPRA (protein tyrosine phosphatase receptor type A) | protein interactions | 5786 | 139 | 2 | 19454 | 49 |
UNC5C,PTPRG |
4.802e-02 | -3.04 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 48 | 16828 | 48 |
MYT1L,GRIA4,TLL1,FSTL5,EBF1,GRIK2,ANK2,CNTN5,CNTNAP2,LINGO2,CACNA2D1,EPHA5,PTPRG,GLCE,GPC6,CNTN4,NRXN3,DTNA,UNC5C,LSAMP,TRPM3,NRG3,RIMS2,KCNJ3,ZNF385D,STXBP5L,CST3,LRRTM4,RALYL,RUNX1T1,NRG1,SLC35F3,CHN2,SLC1A3,NRXN1,NPAS3,ST18,NFIA,PCDH9,ZNF385B,APOE,RIMS1,RELN,SYT1,GRID2,CDH18,CADPS2,KIF21A |
4.832e-02 | -3.03 | positive regulation of potassium ion transmembrane transporter activity | biological process | GO:1901018 | 20 | 1 | 18204 | 45 |
ANK2 |
4.832e-02 | -3.03 | axonal fasciculation | biological process | GO:0007413 | 20 | 1 | 18204 | 45 |
CNTN4 |
4.832e-02 | -3.03 | membrane repolarization during cardiac muscle cell action potential | biological process | GO:0086013 | 20 | 1 | 18204 | 45 |
KCNJ3 |
4.832e-02 | -3.03 | nitric oxide mediated signal transduction | biological process | GO:0007263 | 20 | 1 | 18204 | 45 |
APOE |
4.832e-02 | -3.03 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 1 | 18204 | 45 |
SLC1A3 |
4.832e-02 | -3.03 | cardiac muscle cell membrane repolarization | biological process | GO:0099622 | 20 | 1 | 18204 | 45 |
KCNJ3 |
4.832e-02 | -3.03 | neuron projection fasciculation | biological process | GO:0106030 | 20 | 1 | 18204 | 45 |
CNTN4 |
4.848e-02 | -3.03 | Trafficking of GluR2-containing AMPA receptors | REACTOME pathways | R-HSA-416993 | 17 | 1 | 10285 | 30 |
GRIA4 |
4.848e-02 | -3.03 | Unblocking of NMDA receptor, glutamate binding and activation | REACTOME pathways | R-HSA-438066 | 17 | 1 | 10285 | 30 |
GRIA4 |
4.853e-02 | -3.03 | EFNB2 (ephrin B2) | protein interactions | 1948 | 140 | 2 | 19454 | 49 |
EPHA5,RELN |
4.900e-02 | -3.02 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 4 | 16828 | 48 |
GRIA4,PCDH9,LSAMP,CNTN5 |
4.900e-02 | -3.02 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 4 | 16828 | 48 |
CNTN5,GRIA4,PCDH9,LSAMP |
4.903e-02 | -3.02 | PDZ_6 | pfam domains | PF17820 | 19 | 1 | 17795 | 47 |
RIMS2 |
4.903e-02 | -3.02 | PAS | pfam domains | PF00989 | 19 | 1 | 17795 | 47 |
NPAS3 |
4.903e-02 | -3.02 | zf-MYND | pfam domains | PF01753 | 19 | 1 | 17795 | 47 |
RUNX1T1 |
4.908e-02 | -3.01 | triglyceride-rich plasma lipoprotein particle | cellular component | GO:0034385 | 20 | 1 | 19108 | 48 |
APOE |
4.908e-02 | -3.01 | very-low-density lipoprotein particle | cellular component | GO:0034361 | 20 | 1 | 19108 | 48 |
APOE |
4.911e-02 | -3.01 | PDZ_6 | interpro domains | IPR041489 | 19 | 1 | 18521 | 49 |
RIMS2 |
4.911e-02 | -3.01 | PAS_fold | interpro domains | IPR013767 | 19 | 1 | 18521 | 49 |
NPAS3 |
4.911e-02 | -3.01 | Znf_ZZ | interpro domains | IPR000433 | 19 | 1 | 18521 | 49 |
DTNA |
4.911e-02 | -3.01 | Znf_ZZ_sf | interpro domains | IPR043145 | 19 | 1 | 18521 | 49 |
DTNA |
4.921e-02 | -3.01 | NTN1 (netrin 1) | protein interactions | 9423 | 20 | 1 | 19454 | 49 |
UNC5C |
4.921e-02 | -3.01 | MLC1 (modulator of VRAC current 1) | protein interactions | 23209 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | KCNJ5 (potassium inwardly rectifying channel subfamily J member 5) | protein interactions | 3762 | 20 | 1 | 19454 | 49 |
KCNJ3 |
4.921e-02 | -3.01 | SAXO5 (stabilizer of axonemal microtubules 5) | protein interactions | 374877 | 20 | 1 | 19454 | 49 |
CADPS2 |
4.921e-02 | -3.01 | GALNT5 (polypeptide N-acetylgalactosaminyltransferase 5) | protein interactions | 11227 | 20 | 1 | 19454 | 49 |
NRG1 |
4.921e-02 | -3.01 | ADRA1D (adrenoceptor alpha 1D) | protein interactions | 146 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | CCDC197 (coiled-coil domain containing 197) | protein interactions | 256369 | 20 | 1 | 19454 | 49 |
RUNX1T1 |
4.923e-02 | -3.01 | voltage-gated monoatomic cation channel activity | molecular function | GO:0022843 | 143 | 2 | 18094 | 45 |
CACNA2D1,KCNJ3 |
4.943e-02 | -3.01 | human chr2p12 | chromosome location | human chr2p12 | 27 | 1 | 26134 | 49 |
LRRTM4 |
4.961e-02 | -3.00 | CADHERIN_1 | prosite domains | PS00232 | 109 | 2 | 12186 | 40 |
CDH18,PCDH9 |
4.965e-02 | -3.00 | protein transport | biological process | GO:0015031 | 1086 | 6 | 18204 | 45 |
STXBP5L,CADPS2,ANK2,RIMS2,RIMS1,APOE |